<SEC-DOCUMENT>0001654954-24-014335.txt : 20241114
<SEC-HEADER>0001654954-24-014335.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114090624
ACCESSION NUMBER:		0001654954-24-014335
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954078884
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15543
		FILM NUMBER:		241457632

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptn_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ptn="http://ptn.com/20240930"><head><title>ptn_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-07-01to2024-09-30" id="ixv-6618">0000911216</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-07-01to2024-09-30" format="ixt:booleanfalse" id="ixv-6619">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2024-07-01to2024-09-30" id="ixv-6620">--06-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2024-07-01to2024-09-30" id="ixv-6621">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2024-07-01to2024-09-30" id="ixv-6622">2024</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-6623">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-6624">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-6625">4030</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" unitRef="USDPShares" decimals="INF" id="ixv-6626">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" unitRef="USDPShares" decimals="INF" id="ixv-6627">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-6628">300000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-6629">19548167</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-6630">17926640</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-6631">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-6632">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-6633">4030</ix:nonFraction><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2023-07-01to2023-09-30" unitRef="Shares" decimals="0" id="ixv-6634">279700</ix:nonFraction><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2024-07-01to2024-09-30" unitRef="USD" decimals="0" id="ixv-6635">7781844</ix:nonFraction><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-10-04to2023-10-31" unitRef="USD" decimals="0" id="ixv-6636">9109117</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptn-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-07-01to2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-04to2023-10-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-07-01to2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_OneToThreeYearsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_CurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2017-11-01to2017-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-09-01to2017-09-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_ContigentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-11-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2024-07-01to2024-09-30" id="ixv-7188">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-7189">&#9746;</ix:nonNumeric></p></td><td style="vertical-align:top;"><strong>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2024-07-01to2024-09-30" format="ixt:datemonthdayyearen" id="ixv-7190">September 30, 2024</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">or</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-7191">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from ___________ to __________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission file number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2024-07-01to2024-09-30" id="ixv-7192">001-15543</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg17.jpg" alt="ptn_10qimg17.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2024-07-01to2024-09-30" id="ixv-7193">PALATIN TECHNOLOGIES, INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:stateprovnameen" id="ixv-7194">Delaware</ix:nonNumeric></strong></p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2024-07-01to2024-09-30" id="ixv-7195">95-4078884</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(State or other jurisdiction of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">incorporation or organization)</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr><tr style="height:15px"><td style="width:40%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:40%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2024-07-01to2024-09-30" id="ixv-7196">4B Cedar Brook Drive</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2024-07-01to2024-09-30" id="ixv-7197">Cranbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:stateprovnameen" id="ixv-7198">New Jersey</ix:nonNumeric></strong></p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:40%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2024-07-01to2024-09-30" id="ixv-7199">08512</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Address of principal executive offices)</p></td><td style="width:18%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2024-07-01to2024-09-30" id="ixv-7200">609</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2024-07-01to2024-09-30" id="ixv-7201">495&#8209;2200</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trading Symbol</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Name of Each Exchange </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>on Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2024-07-01to2024-09-30" id="ixv-7202">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2024-07-01to2024-09-30" id="ixv-7203">PTN</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:exchnameen" id="ixv-7204">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2024-07-01to2024-09-30" id="ixv-7205">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2024-07-01to2024-09-30" id="ixv-7206">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160; No&#160;&#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;">Large accelerated filer</td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:entityfilercategoryen" id="ixv-7207">Non-accelerated filer</ix:nonNumeric></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-7208">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Emerging growth company</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-7209">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-7210">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date (November 13, 2024): <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-11-13" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-7211">19,548,167</ix:nonFraction></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC</strong>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">Table of Contents</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td></tr><tr style="height:15px"><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#P1">PART I &#8211; FINANCIAL INFORMATION</a></strong></p></td><td/></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P1I1">Item 1. Financial Statements (Unaudited)</a></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"><a href="#BS">Consolidated Balance Sheets as of September 30, 2024 and June 30, 2024</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"><a href="#SO">Consolidated Statements of Operations for the Three Months Ended September 30, 2024 and 2023</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"><a href="#SE">Consolidated Statements of Changes in Stockholders&#8217; Deficiency for the Three Months Ended September 30, 2024 and 2023</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"><a href="#CF">Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2024 and 2023</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"><a href="#NOTES">Notes to Consolidated Financial Statements</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">9</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#P1I2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">20</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P1I3">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P1I4">Item 4. Controls and Procedures</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#P2">PART II &#8211; OTHER INFORMATION</a></strong></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I1">Item 1. Legal Proceedings</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I1A">Item 1A. Risk Factors</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I1A">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I3">Item 3. Defaults Upon Senior Securities</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I4">Item 4. Mine Safety Disclosures</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I5">Item 5. Other Information</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#P2I6">Item 6. Exhibits</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">26</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#SIG">Signatures</a></strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Special Note Regarding Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;Palatin&#8221; mean Palatin Technologies, Inc. and its subsidiary. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Statements in this Quarterly Report, as well as oral statements that may be made by us or by our officers, directors, or employees acting on our behalf, that are not historical facts constitute &#8220;forward-looking statements,&#8221; which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The forward-looking statements in this Quarterly Report do not constitute guarantees of future performance. Investors are cautioned that statements that are not strictly historical facts contained in this Quarterly Report, including, without limitation, the following are forward looking statements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">whether Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;), which acquired our product Vyleesi&#174; (the trade name for bremelanotide for treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sales to generate significant milestone payments under our purchase agreement with Cosette;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024; a co-formulation of bremelanotide with a phosphodiesterase type 5 inhibitor (PDE5i) for treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy, scheduled to start a pharmacokinetic study in the first quarter of calendar year 2025; PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed a first&#160;Phase 3 clinical trial with top line results announced&#160;from the Phase 3 clinical trial in the first quarter of calendar year 2024; PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials in the third quarter of calendar year 2022; and a proof-of-concept melanocortin agonist clinical trial for diabetic nephropathy, which entered a Phase 2 clinical in the fourth quarter of calendar year 2022;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">estimates of our expenses, future revenue and capital requirements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to achieve profitability;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to advance product candidates into, and successfully complete, clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing or likelihood of regulatory filings and approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment of inflammatory and autoimmune related diseases and disorders, including ocular indications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to compete with other products and technologies treating the same or similar indications as our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the ability of our third-party collaborators to timely carry out their duties under their agreements with us;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to recognize the potential value of our licensing arrangements with third parties;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the potential to achieve revenues from the sale of our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain adequate reimbursement from private insurers and other healthcare payers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all;</td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the performance and retention of our management team, senior staff professionals, other employees, and third-party contractors and consultants;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology in the United States and throughout the world;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our compliance with federal and state laws and regulations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing and costs associated with obtaining regulatory approval for our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of fluctuations in foreign exchange rates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of any geopolitical instability, economic uncertainty, financial markets volatility, or capital markets disruption resulting from the ongoing Russia-Ukraine and Israel-Hamas military conflicts, and any resulting effects on our revenue, financial condition, or results of operations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of legislative or regulatory healthcare reforms in the United States;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to adapt to changes in global economic conditions as well as competing products and technologies; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to remain listed on the NYSE American stock exchange.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Such forward-looking statements involve risks, uncertainties and other factors that could cause our actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Our future operating results are subject to risks and uncertainties and are dependent upon many factors, including, without limitation, the risks identified under the caption &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report, and any of those made in our other reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Except as required by law, we do not intend, and undertake no obligation, to publicly update forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="P1"><strong>PART I</strong> <strong>&#8211; FINANCIAL INFORMATION</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="P1I1"><strong>Item 1. Financial Statements.</strong> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="BS">Consolidated Balance Sheets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(unaudited)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September&#160;30,&#160;2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June&#160;30,&#160;2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>ASSETS</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">Current assets:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,384,214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,527,396</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">228,435</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_296" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">242,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_299" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,612,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_298" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,769,668</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property and equipment, net</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">307,571</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_300" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">388,361</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Right-of-use assets - operating leases</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">438,123</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">527,321</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_304" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_305" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_307" name="us-gaap:Assets" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,415,259</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_306" name="us-gaap:Assets" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>LIABILITIES AND STOCKHOLDERS DEFICIENCY</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Current liabilities:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,949,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,101,929</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,573,292</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,185,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Short-term operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">319,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">380,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Short-term finance lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,527</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,001,350</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">944,150</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_319" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,861,717</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,657,681</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Long-term operating lease liabilities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_321" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">132,447</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">163,782</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other long-term liabilities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_325" name="us-gaap:OtherLongTermDebt" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,106,700</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_324" name="us-gaap:OtherLongTermDebt" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,032,300</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_329" name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,100,864</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_328" name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,853,763</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Commitments and contingencies (Note 12)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stockholders deficiency:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Preferred stock of $0.01 par value authorized <ix:nonFraction id="fid_350" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,000,000</ix:nonFraction> shares: shares issued and outstanding designated as follows:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:left;">Series A Convertible: authorized <ix:nonFraction id="fid_351" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares as of September 30, 2024: issued and outstanding <ix:nonFraction id="fid_362" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares as of September 30, 2024 and June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_336" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_337" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Common stock of $<ix:nonFraction id="fid_349" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value authorized <ix:nonFraction id="fid_356" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">300,000,000</ix:nonFraction> shares:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 30px; text-align:left;">issued and outstanding <ix:nonFraction id="fid_359" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">19,548,167</ix:nonFraction> shares as of September 30, 2024 and <ix:nonFraction id="fid_358" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,926,640</ix:nonFraction> shares as of June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_339" name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">195,481</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">179,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_341" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,709,073</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_340" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,475,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_343" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">449,590,199</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_342" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">441,766,550</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total stockholders deficiency</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_345" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,685,605</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_344" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">111,497</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total liabilities and stockholders deficiency</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_347" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,415,259</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_346" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SO">Consolidated Statements of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(unaudited)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three&#160;Months&#160;Ended&#160;September&#160;30</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">REVENUES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Product revenue, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2010" name="ptn:ProductRevenueNet" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2011" name="ptn:ProductRevenueNet" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,105,977</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">OPERATING EXPENSES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2013" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,743,754</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2014" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,014,630</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2015" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,020,931</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2016" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,200,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2017" name="us-gaap:OperatingExpenses" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,764,685</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2018" name="us-gaap:OperatingExpenses" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,214,874</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Loss from operations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2019" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,764,685</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2020" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,108,897</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">OTHER (EXPENSE) INCOME</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Investment income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2022" name="us-gaap:InvestmentIncomeNet" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">78,576</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2023" name="us-gaap:InvestmentIncomeNet" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">71,630</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Foreign currency transaction (loss) gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2024" name="ptn:ForeignCurrencyTransactionLossGain" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">131,600</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2025" name="ptn:ForeignCurrencyTransactionLossGain" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2026" name="us-gaap:InterestExpense" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,940</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2027" name="us-gaap:InterestExpense" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,882</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Change in fair value of warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2028" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2029" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">682,400</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Total other (expense) income, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2030" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">58,964</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2031" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">902,898</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">NET LOSS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2032" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,823,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2033" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,205,999</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Basic and diluted net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2034" name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.39</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2035" name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.43</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2036" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">19,845,106</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2037" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,170,699</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="SE"><strong>Consolidated Statements of Changes in Stockholders Deficiency</strong>&#160;</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(unaudited)&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Three Months Ended September 30, 2024</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><strong>&#160;</strong></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders' (Deficiency) Equity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contigently</strong></p></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Redeemable</strong></p></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px; BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance June 30, 2024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2219" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2217" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2220" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2218" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,926,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2221" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">179,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2222" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,475,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2223" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">441,766,550</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2224" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">111,497</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2257" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2227" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2226" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">232,941</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2229" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,329</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2230" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">346,694</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2228" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2232" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">349,023</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2231" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2235" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2234" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">54,691</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2237" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">547</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2238" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">98,935</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2236" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2240" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">99,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Shares released from abeyance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2239" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2243" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2242" name="ptn:SharesReleasedFromAbeyanceShares" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,443,277</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2245" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,433</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2246" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">14,433</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2244" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2247" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2248" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px; BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2249" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2250" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2251" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2253" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,823,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2254" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,823,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance September 30, 2024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2252" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px; BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2255" name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2258" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2256" name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">19,548,167</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2259" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">195,481</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2260" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,709,073</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2261" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">449,590,199</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2262" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,685,605</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Three Months Ended September 30, 2023</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders' (Deficiency) Equity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contigently</strong></p></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Redeemable</strong></td><td style="BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px; BORDER-LEFT: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance June 30, 2023</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2311" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2263" name="us-gaap:SharesIssued" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2266" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2264" name="us-gaap:SharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,656,714</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2267" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">116,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2268" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">409,933,959</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2269" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">412,030,437</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2270" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,979,871</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2316" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2274" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2272" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">98,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2275" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">984</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2276" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">389,352</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2277" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2278" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">390,336</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;">Withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2282" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2285" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2280" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">25,467</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2283" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">255</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2284" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">56,146</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2290" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2286" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">56,401</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Sale of common stock, net of costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2293" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2296" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2288" name="ptn:SaleOfCommonStockNetOfCostsShares" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,027</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2291" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,170</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2292" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">529,199</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2297" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2294" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">531,369</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2298" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px; BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2312" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2313" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2314" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2299" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,205,999</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2300" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,205,999</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance September 30, 2023</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2315" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_ptn_ContigentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px; BORDER-LEFT: #000000 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2301" name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2304" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2302" name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,946,646</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2305" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">119,466</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2306" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">410,796,364</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2307" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">417,236,436</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2308" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,320,566</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="CF"><strong>Consolidated Statements of Cash Flows</strong>&#160;</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(unaudited)&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:10%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2164" name="us-gaap:ProfitLoss" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,823,649</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:10%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2165" name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,205,999</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Depreciation and amortization</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2167" name="us-gaap:DepreciationAndAmortization" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,790</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2168" name="us-gaap:DepreciationAndAmortization" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">87,357</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Decrease in right-of-use asset</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2169" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">89,198</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2170" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">88,563</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Unrealized foreign currency transaction loss (gain)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2171" name="ptn:UnrealizedForeignCurrencyTransactionLossGain" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">131,600</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2172" name="ptn:UnrealizedForeignCurrencyTransactionLossGain" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">159,750</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Stock-based compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2173" name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">349,023</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2174" name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">390,336</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Change in fair value of liability classified warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2175" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2176" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">682,400</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Changes in operating assets and liabilities:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Accounts receivable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2178" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2179" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,567,260</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Prepaid expenses and other assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2180" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,837</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2181" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">563,548</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Inventories</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2182" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2183" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,072,251</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Accounts payable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2184" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">152,901</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2185" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,033,887</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Accrued expenses</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2186" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">388,246</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2187" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">641,212</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Operating lease liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2188" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">92,357</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2189" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">90,382</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">Net cash used in operating activities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2190" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,016,213</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2191" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">5,906,393</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Maturity of marketable securities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2193" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2194" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,992,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:left;">Net cash provided by investing activities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2195" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2196" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,992,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Payment of withholding taxes related to restricted stock units</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2198" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,482</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2199" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,401</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Proceeds from the sale of common stock and warrants, net</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2200" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2201" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">531,369</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Payment of finance lease obligations</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2202" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">27,487</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2203" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,074</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Net cash (used in) provided by financing activities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2309" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">126,969</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2310" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">448,894</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">NET DECREASE IN CASH AND CASH EQUIVALENTS</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2206" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,143,182</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2207" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,464,609</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">CASH AND CASH EQUIVALENTS, beginning of period</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2208" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,527,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2209" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,989,582</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">CASH AND CASH EQUIVALENTS, end of period</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2210" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,384,214</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2211" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,524,973</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">SUPPLEMENTAL CASH FLOW INFORMATION:</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash paid for interest</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2213" name="us-gaap:InterestPaidNet" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,940</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2214" name="us-gaap:InterestPaidNet" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,882</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="NOTES">Notes to Consolidated Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1937" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_663ba5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women.&#160;As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, and a co-formulation of bremelanotide with a phosphodiesterase type 5 inhibitor (&#8220;PDE5i&#8221;) for treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of September 30, 2024 of $<ix:nonFraction id="fid_1444" name="ptn:RetainedEarningAccumulatedDeficit" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">449,590,199</ix:nonFraction> and a net loss for the three months ended September 30, 2024, of $<ix:nonFraction id="fid_1445" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,823,649</ix:nonFraction>. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of September 30, 2024, the Company&#8217;s cash and cash equivalents were $<ix:nonFraction id="fid_1447" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,384,214</ix:nonFraction> and current liabilities were $<ix:nonFraction id="fid_1448" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,861,717</ix:nonFraction>. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40,&#160;<em>Presentation of Financial Statements&#160;&#8212;&#160;Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_663ba5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on our available cash and cash equivalents as of September 30, 2024, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company may be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the first half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $<ix:nonFraction id="fid_2162" name="ptn:SalesBasedMilestonePayments" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,000,000</ix:nonFraction> on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and accounts receivable. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1945" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three months ended September 30, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1938" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_4ec9fe"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1953" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1989" name="ptn:RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revision of Previously Issued Financial Statements</em> - The Company has revised certain prior period amounts on the consolidated financial statements to correct a misstatement with respect to improperly classifying warrants as equity instead of as a warrant liability that is adjusted to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of ASC 815-40, <em>Contracts in Entity&#8217;s Own Equity</em>. As of September 30, 2023, The Company recorded an adjustment to record a liability for the warrants of $<ix:nonFraction id="fid_29" name="us-gaap:MarketRiskBenefitLiabilityAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,168,144</ix:nonFraction> million , adjusted contingently redeemable warrants for $<ix:nonFraction id="fid_30" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction>, decreased additional paid-in capital for $<ix:nonFraction id="fid_31" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,619,090</ix:nonFraction> and increased accumulated deficit for $<ix:nonFraction id="fid_32" name="us-gaap:CumulativeEarningsDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,187,546</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also recorded a gain of $682,400 as a result in the change in fair value of the warrant liabilities for the three months ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has assessed the impact of improperly classifying the warrants within equity rather than as a warranty liability that is adjusted through charges or credits to the income statement to reflect changes in the fair value of the warrants, and determined the impact is not material, quantitatively or qualitatively, to any prior period impacted. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_4ec9fe" continuedAt="cont_2549d7"><ix:nonNumeric id="fid_1954" name="us-gaap:UseOfEstimates" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em>&#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1955" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $<ix:nonFraction id="fid_282" name="ptn:MoneyMarketAccountsAndTreasuryBills" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,974,575</ix:nonFraction> and $<ix:nonFraction id="fid_2040" name="ptn:MoneyMarketAccountsAndTreasuryBills" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction> in a money market account at September 30, 2024 and June 30, 2024, respectively. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1957" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1958" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1961" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1962" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1963" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_c102e8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_2549d7" continuedAt="cont_fe9484"><ix:continuation id="cont_c102e8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1964" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_59679d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligation were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three months ended September 30, 2023 were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1971" name="ptn:ScheduleOfSalesTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" name="ptn:RevenuesGross" contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,587,150</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Product sales allowances and accruals</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_605" name="ptn:ProductSalesAllowancesAndAccruals" contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,481,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Net sales</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_264" name="us-gaap:Revenues" contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,105,977</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_fe9484"><ix:continuation id="cont_59679d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1965" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1966" name="ptn:AccruedLiabilitiesPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1967" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1968" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1969" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended September 30, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three ended September 30, 2024 and 2023 were <ix:nonFraction id="fid_287" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,105,938</ix:nonFraction> and <ix:nonFraction id="fid_1415" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,519,682</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are <ix:nonFraction id="fid_1416" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">279,700</ix:nonFraction> vested restricted stock units that had not been issued as of September 30, 2024, and 2023, respectively, due to a provision in the restricted stock unit agreements to delay delivery.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1970" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1939" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(4) NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update&#160;(&#8220;ASU&#8221;) 2023-07,&#160;Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1940" name="ptn:AssetPurchaseAgreementTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $<ix:nonFraction id="fid_1450" name="us-gaap:AccountsReceivablePurchase" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">171,000,000</ix:nonFraction>, consisting of an upfront purchase price of $<ix:nonFraction id="fid_1452" name="us-gaap:SupplementalDeferredPurchasePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,500,000</ix:nonFraction>, $<ix:nonFraction id="fid_1449" name="us-gaap:PaymentsForPurchaseOfOtherAssets1" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction> payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $<ix:nonFraction id="fid_1451" name="ptn:PaymentsToSalesBasedMilestonePayments" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,000,000</ix:nonFraction>. As of September 30, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1988" name="ptn:ManufacturingSupplyAgreementsTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1941" name="ptn:AgreementWithFosunTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $<ix:nonFraction id="fid_1618" name="us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,500,000</ix:nonFraction> in October 2017, which consisted of an upfront payment of $<ix:nonFraction id="fid_1619" name="us-gaap:PaymentsForRestructuring" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,000,000</ix:nonFraction> less $<ix:nonFraction id="fid_1626" name="ptn:UpfrontPaymentOfLess" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,000</ix:nonFraction> that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1942" name="ptn:AgreementWithKwangdongTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $<ix:nonFraction id="fid_631" name="us-gaap:OfficersCompensation" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">417,500</ix:nonFraction> in December 2017, consisting of an upfront payment of $<ix:nonFraction id="fid_633" name="us-gaap:PaymentsForRestructuring" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,000</ix:nonFraction>, less $<ix:nonFraction id="fid_634" name="ptn:taxexpenses" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">82,500</ix:nonFraction>, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $<ix:nonFraction id="fid_636" name="us-gaap:PaymentsToAcquireReceivables" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,000,000</ix:nonFraction> milestone payment based on the first commercial sale in Korea.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1943" name="us-gaap:OtherCurrentAssetsTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1972" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" name="ptn:PrepaidClinicalStudyCosts" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">39,823</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_575" name="ptn:PrepaidClinicalStudyCosts" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,926</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_638" name="ptn:PrepaidInsurancePremiums" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">43,956</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_577" name="ptn:PrepaidInsurancePremiums" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">71,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_640" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">144,656</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_581" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">147,248</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_641" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">228,435</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_583" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">242,271</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1944" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1973" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Carrying Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted&#160;prices&#160;in <br/>active markets<br/>(Level 1)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant unobservable&#160;inputs<br/>(Level 3)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">September 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1460" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,974,575</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1471" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,974,575</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1461" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1466" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">June 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2042" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2041" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2043" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2044" name="ptn:CarryingValueDuringTheYear" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1948" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(11) ACCRUED EXPENSES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1981" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September&#160;30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_661" name="ptn:CostClinicalStudy" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,761,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_660" name="ptn:CostClinicalStudy" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,509,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_663" name="ptn:OtherResearchRelatedExpenses" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,965</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_662" name="ptn:OtherResearchRelatedExpenses" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">65,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_665" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">187,238</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_664" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">284,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_667" name="ptn:PersonalCost" contextRef="AsOf2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_666" name="ptn:PersonalCost" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,771,694</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_669" name="ptn:AccruedSellingExpenses" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">324,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_668" name="ptn:AccruedSellingExpenses" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">351,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_671" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">139,731</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_670" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">201,883</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_673" name="ptn:TotaAcrruedLiabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,573,292</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_672" name="ptn:TotaAcrruedLiabilities" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,185,046</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1949" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_9d7e22"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_9d7e22"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of September 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1982" name="ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,661,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_866" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2024-09-30_ptn_CurrentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,554,700</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2024-09-30_ptn_OneToThreeYearsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,106,700</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2024, the Company has $<ix:nonFraction id="fid_870" name="ptn:OtherLiabilitiesCurrents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,001,350</ix:nonFraction> and $<ix:nonFraction id="fid_872" name="ptn:AccruedOtherLongTermLiabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,106,700</ix:nonFraction> accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $<ix:nonFraction id="fid_869" name="ptn:OtherLiabilitiesCurrents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">944,150</ix:nonFraction> and $<ix:nonFraction id="fid_871" name="ptn:AccruedOtherLongTermLiabilities" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,032,300</ix:nonFraction> was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1950" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true" continuedAt="cont_a97243"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211;&#160;As of September 30, 2024, <ix:nonFraction id="fid_1653" name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $<ix:nonFraction id="fid_1676" name="us-gaap:CashAvailableForDistributions" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100</ix:nonFraction> divided by the Series A Conversion Price. As of September 30, 2024, the Series A Conversion Price was $<ix:nonFraction id="fid_1664" name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">75.45</ix:nonFraction>, and each share of Series A Convertible Preferred Stock is convertible into approximately <ix:nonFraction id="fid_1665" name="us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare" contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.33</ix:nonFraction> shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $<ix:nonFraction id="fid_1666" name="us-gaap:CashAvailableForDistributions" contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100</ix:nonFraction> per share, or $<ix:nonFraction id="fid_1663" name="ptn:AggregateValue" contextRef="From2024-07-01to2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">403,000</ix:nonFraction> in the aggregate as of September 30, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $<ix:nonFraction id="fid_1667" name="ptn:CashAvailableForDistributionsAdditional" contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100</ix:nonFraction> per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Financing Transactions &#8211; </em>On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), <ix:nonNumeric id="fid_1651" name="ptn:DescriptionOfSecuritiesPurchaseAgreement" contextRef="From2024-02-01to2024-02-29">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_1636" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.46</ix:nonFraction> per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a97243" continuedAt="cont_bd72a8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to <ix:nonFraction id="fid_2061" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">91,575</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $<ix:nonFraction id="fid_2062" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.825</ix:nonFraction> per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $<ix:nonFraction id="fid_1678" name="ptn:GrossProceeds" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,000,006</ix:nonFraction>, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $<ix:nonFraction id="fid_1635" name="us-gaap:CostsAndExpenses" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,224,056</ix:nonFraction>. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), an aggregate of (i<ix:nonNumeric id="fid_2065" name="ptn:DescriptionOfSecuritiesPurchaseAgreement" contextRef="From2023-10-01to2023-10-20">) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_1637" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-20" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.12</ix:nonFraction> per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $<ix:nonFraction id="fid_1640" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-10-20" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction> per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase <ix:nonFraction id="fid_2069" name="ptn:PurchaseOfWarrantShares" contextRef="From2024-07-01to2024-09-30_ptn_TwentyTwentyThreeEquityDistributionAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,033,491</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $<ix:nonFraction id="fid_1679" name="us-gaap:CostsAndExpenses" contextRef="From2023-10-01to2023-10-20" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,573,948</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounting for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 12, 2023, the Company entered into a new equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. <ix:nonNumeric id="fid_2071" name="ptn:DescriptionOfSecuritiesPurchaseAgreement" contextRef="From2023-04-01to2023-04-12">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission</ix:nonNumeric>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_bd72a8" continuedAt="cont_552052"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2105" name="ptn:ScheduleOfEquityDistributionAgreementTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Gross proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1518" name="ptn:EquityGrossProceedsShares" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,027</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1516" name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">547,803</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2048" name="ptn:EquityNetProceedsShares" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">721,061</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2058" name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,744,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Fees</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1522" name="us-gaap:ProceedsFromFeesReceived" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,434</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2054" name="us-gaap:ProceedsFromFeesReceived" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,336</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Expenses</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1526" name="ptn:EquityExpensesProceeds" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2050" name="ptn:EquityExpensesProceeds" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">126,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Net proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1528" name="ptn:EquityNetProceedsShares" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,027</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1530" name="ptn:EquityNetProceedsProceeds" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">531,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2060" name="ptn:EquityGrossProceedsShares" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">721,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2046" name="ptn:EquityNetProceedsProceeds" contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,565,406</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three months ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Warrants</em> - On June 20, 2024, the Company entered into a letter agreement (the &#8220;Inducement Letter&#8221;) with a holder (the &#8220;Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, the Exercising Holder agreed to exercise, for cash, Existing Warrants to purchase, in the aggregate, <ix:nonFraction id="fid_1685" name="ptn:WarrantsToPurchaseShares" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,233,277</ix:nonFraction> shares of common stock in exchange for the Company&#8217;s agreement to <ix:nonNumeric id="fid_2078" name="ptn:DescriptionOfExistingHolderPurchaseOfWarrants" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember">(i) lower the exercise price to $<ix:nonFraction id="fid_2076" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-20_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.88</ix:nonFraction> per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of <ix:nonFraction id="fid_2077" name="ptn:PurchaseOfWarrantOfCommonStockSeriesA" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,849,915</ix:nonFraction> warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $<ix:nonFraction id="fid_1687" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,078,561</ix:nonFraction> from the exercise of the Existing Warrants by the Exercising Holder (the &#8220;Warrant Inducement&#8221;)</ix:nonNumeric>. As part of the agreement, <ix:nonFraction id="fid_2080" name="ptn:ExercisingHolderReleasedShares" contextRef="From2024-07-01to2024-09-30_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,443,277</ix:nonFraction> shares of common stock were held in abeyance on behalf of the Exercising Holder.&#160;During the three months ended September 30, 2024, at the request of the Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of September 30, 2024, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2106" name="ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:39%;"/><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares of Common</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;"/></tr><tr style="height:15px"><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Share</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td>May 2022 Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1531" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">66,666</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1534" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">12.50</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1537" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember">May 11, 2026</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td>October 2022 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1533" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">90,909</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1536" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.88</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1539" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">October 31, 2027</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td>October 2023 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1542" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">943,396</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1541" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.12</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1540" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember">April 24, 2029</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td>October 2023 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1545" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">117,925</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1544" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.65</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1543" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">October 20, 2028</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td>January 2024 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1548" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,831,503</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1547" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.46</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1546" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">February 1, 2028</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td>January 2024 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1551" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">91,575</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1550" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.83</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1549" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">February 1, 2028</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td>June 2024 Series A Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1532" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,727,273</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1535" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.88</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1538" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember">June 24, 2029</ix:nonNumeric></p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td>June 2024 Series B Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_1554" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,122,642</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ <ix:nonFraction id="fid_1553" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.88</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1552" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">June 24, 2029</ix:nonNumeric></p></td><td>*</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="mso-ignore: colspan;" colspan="3">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Options &#8211;</em> For the three months ended September 30, 2024, and 2023, the Company recorded stock-based compensation related to stock options of $<ix:nonFraction id="fid_2081" name="ptn:StockBasedCompensationToStockOptions" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">177,734</ix:nonFraction> and $<ix:nonFraction id="fid_2083" name="ptn:StockBasedCompensationToStockOptions" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">205,317</ix:nonFraction>. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_552052"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of stock option activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2107" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Term in Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1555" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,263,440</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1558" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.11</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1566" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:duryear">8.2</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1559" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1560" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1561" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1586" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">14,338</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">7.92</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1588" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,249,102</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1563" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.12</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1567" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:duryear">8.0</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1571" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Exercisable at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1590" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">927,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1564" name="ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">10.81</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1568" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:duryear">6.4</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1572" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected to vest at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1591" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,321,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1565" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.83</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1569" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="From2024-07-01to2024-09-30" format="ixt-sec:duryear">9.1</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1570" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding options in the table above are <ix:nonFraction id="fid_2084" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">418,945</ix:nonFraction> and <ix:nonFraction id="fid_2085" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">88,911</ix:nonFraction> unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2086" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">95,167</ix:nonFraction>, <ix:nonFraction id="fid_2089" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-07-01to2022-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">60,566</ix:nonFraction>, <ix:nonFraction id="fid_2090" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">238,838</ix:nonFraction> and <ix:nonFraction id="fid_2092" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-07-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">264,945</ix:nonFraction>, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation related to restricted stock units of $<ix:nonFraction id="fid_2093" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">171,289</ix:nonFraction> and $<ix:nonFraction id="fid_2094" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">185,019</ix:nonFraction>, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of restricted stock unit activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2109" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="From2024-07-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1603" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,374,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1610" name="ptn:RestrictedStockVestedInPeriod" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">232,941</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1616" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,726</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1613" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,139,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2095" name="ptn:NumberOfOutstandingSharesOfRestrictedStockUnits" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">279,700</ix:nonFraction> vested shares that have not been issued as of September 30, 2024, due to a provision in the restricted stock unit agreements to delay delivery. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2096" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">274,549</ix:nonFraction> and <ix:nonFraction id="fid_2097" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" contextRef="From2023-07-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">59,842</ix:nonFraction> unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2099" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">22,343</ix:nonFraction>, <ix:nonFraction id="fid_2100" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2021-07-01to2022-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">40,707</ix:nonFraction>, <ix:nonFraction id="fid_2101" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">152,432</ix:nonFraction> and <ix:nonFraction id="fid_2098" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2023-07-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">184,443</ix:nonFraction> restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the vesting of restricted share units during the three months ended September 30, 2024, the Company withheld <ix:nonFraction id="fid_2104" name="ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares" contextRef="From2024-07-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,691</ix:nonFraction> shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="P1I2"><strong>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements filed as part of this report and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2024.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>The following discussion and analysis contain forward-looking statements within the meaning of the federal securities laws. You are urged to carefully review our description and examples of forward-looking statements included earlier in this Quarterly Report immediately prior to Part I, under the heading &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Forward-looking statements are subject to risk that could cause actual results to differ materially from those expressed in the forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and other factors that may affect our business and operating results, including those made in this Quarterly Report and our Annual Report on Form 10-K for the year ended June 30, 2024, as well as any of those made in our other reports filed with the SEC. You are cautioned not to place undue reliance on the forward-looking statements included herein, which speak only as of the date of this document. We do not intend, and undertake no obligation, to publish revised forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our significant accounting policies, which are described in the notes to our consolidated financial statements included in this report and in our Annual Report on Form 10-K for the year ended June 30, 2024, have not changed during the three months ended September 30, 2024. We believe that our accounting policies and estimates relating to the carrying value of inventory, revenue recognition, accrued expenses, purchase commitment liabilities, warrants and stock-based compensation are the most critical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Our Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor (&#8220;MCr&#8221;) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 and was being marketed in the United States by AMAG Pharmaceuticals, Inc. (&#8220;AMAG&#8221;) for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women pursuant to a license agreement between them for Vyleesi for North America, which was entered into on January 8, 2017 (the &#8220;AMAG License Agreement&#8221;). The AMAG License Agreement was terminated effective July 24, 2020, and we commenced marketing Vyleesi in North America. As disclosed in Note 5 to the Consolidated Financial Statements, effective December 19, 2023, Cosette acquired all rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, and treatment of erectile dysfunction, including a co-formulation of bremelanotide with a phosphodiesterase type 5 inhibitor (&#8220;PDE5i&#8221;) for treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy, scheduled to start a pharmacokinetic study in the first quarter of calendar year 2025; and secondarily on ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed Phase 3 clinical trials and announced top line results from the first Phase 3 clinical trial in the first quarter of calendar year 2024; ulcerative colitis, including PL8177, an oral peptide formulation, which entered Phase 2 ulcerative colitis clinical trials in the third quarter of calendar year 2022; and a proof-of-concept melanocortin agonist clinical trial for diabetic nephropathy, which entered a Phase 2 clinical in the fourth quarter of calendar year 2022. We are actively engaged in discussions with potential partners and licensees that have the financial and operational resources to progress our products for ocular conditions through development, approval and commercialization. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Pipeline Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following chart illustrates the status of our drug development programs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><img src="ptn_10qimg15.jpg" alt="ptn_10qimg15.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Our Strategy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Key elements of our business strategy include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Maintaining a team to create, develop and commercialize MCr products addressing unmet medical needs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Entering into strategic alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale, and distribution of product candidates that we are developing;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Partially funding our product development programs with the cash flow generated from the sale of Vyleesi to Cosette and existing license agreements, as well as any future research, collaboration, or license agreements; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Completing development and seeking regulatory approval of certain of our other product candidates.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Corporate Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We were incorporated under the laws of the State of Delaware on November 21, 1986 and commenced operations in the biopharmaceutical area in 1996. Our corporate offices are located at 4B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, New Jersey 08512, and our telephone number is (609) 495-2200. We maintain an Internet site, where among other things, we make available free of charge on and through this website our Forms 3, 4 and 5, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) and Section 16 of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained in it or connected to it are not incorporated into this Quarterly Report on Form 10-Q. The reference to our website is an inactive textual reference only. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (<em>www.sec.gov</em>).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Results of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Three Months Ended September 30, 2024, Compared to the Three Months Ended September 30, 2023:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenues &#8211; </em>For the three months ended September 30, 2024 and 2023, we recognized $0 and $2,105,977 in product revenue, net of allowances, respectively. The decrease in net revenue is a result of the sale of Vyleesi&#8217;s worldwide rights to Cosette.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development</em> &#8211; Research and development expenses were $5,743,754 and $5,014,630 for the three months ended September 30, 2024 and 2023, respectively. The increase for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023, was related to the overall increase in spending on our MCr programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Research and development expenses related to our MCr programs and other preclinical programs were $4,081,037 and $3,459,587 for the three months ended September 30, 2024 and 2023, respectively. The increase was primarily related to an increase in spending on our MCr programs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The amounts of project spending above exclude general research and development spending, which was $1,662,717 and $1,672,427 for the three months ended September 30, 2024 and 2024, respectively. The decrease is primarily attributable to a decrease in compensation-related expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cumulative spending from inception to September 30, 2024, was approximately $311,900,000 on our Vyleesi program and approximately $239,700,000 on all our other programs (which include PL3994, melanocortin receptor agonists, other discovery programs and terminated programs). Due to various risk factors described in our Annual Report on Form 10-K for the year ended June 30, 2024, under &#8220;Risk Factors,&#8221; including the difficulty in currently estimating the costs and timing of future Phase 1 clinical trials and larger-scale Phase 2 and Phase 3 clinical trials for any product under development, we cannot predict with reasonable certainty when, if ever, a program will advance to the next stage of development or be successfully completed, or when, if ever, related net cash inflows will be generated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Selling, General and Administrative</em> &#8211; Selling, general and administrative expenses, which consist mainly of compensation and related costs, were $2,020,931 and $3,200,244 for the three months ended September 30, 2024 and 2023, respectively. The decrease is a result of the elimination of selling expenses relating to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Other (Expense) Income &#8211; </em>Total other (expense) income, net was ($58,964) and $902,898 for the three months ended September 30, 2024 and 2023, respectively. For the three months ended September 30, 2024, we recognized foreign currency loss of $131,600 and $5,940 of interest expense offset by investment income of $78,576.&#160;For the three months ended September 30, 2023, we recognized an increase in the fair value of warrant liabilities of $682,400, foreign currency gain of $159,750 and investment income of $71,630 offset by $10,882 of interest expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since inception, we have generally incurred net operating losses, primarily related to spending on our research and development programs. We have financed our net operating losses primarily through debt and equity financings and amounts received under collaborative and license agreements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our product candidates are at various stages of development and will require significant further research, development, and testing and some may never be successfully developed or commercialized. We may experience uncertainties, delays, difficulties, and expenses commonly experienced by early-stage biopharmaceutical companies, which may include unanticipated problems and additional costs relating to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the development and testing of products in animals and humans;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product approval or clearance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">good manufacturing practices (&#8220;GMP&#8221;) compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">intellectual property rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product introduction;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">marketing, sales, and competition; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">obtaining sufficient capital.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Failure to enter into or successfully perform under collaboration agreements and obtain timely regulatory approval for our product candidates and indications would impact our ability to generate revenues and could make it more difficult to attract investment capital for funding our operations. Any of these possibilities could materially and adversely affect our operations and require us to curtail or cease certain programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended September 30, 2024, net cash used in operating activities was $7,016,213 compared to $5,906,393 for the three months ended September 30, 2023. The increase in cash used in operations for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, was primarily related to an increase in the net loss during the period and working capital changes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended September 30, 2023, net cash provided by investing activities was $2,992,890 related to the maturity of marketable securities.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the three months ended September 30, 2024, net cash used in financing activities was $126,969, which consisted of $99,482 for payment of withholding taxes related to restricted stock units and $27,487 for payment of finance lease obligations. During the three months ended September 30, 2023, net cash provided by financing activities was $448,894, which consisted of proceeds from the sale of common stock of $531,369, offset by $56,401 for payment of withholding taxes related to restricted stock units and $26,074 for payment of finance lease obligations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have incurred cumulative negative cash flows from operations since our inception, and have expended substantial funds to advance our planned product development efforts. Continued operations are dependent upon our ability to complete equity or debt financing activities and to enter into additional licensing or collaboration arrangements. As of September 30, 2024, our cash and cash equivalents were $2,384,214, and our current liabilities were $9,861,717. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our obligations include short-term lease obligations in an aggregate amount of $338,047 in current liabilities as of September 30, 2024, $132,447 in long-term lease liabilities, inventory purchase commitments in an aggregate amount of $2,108,050 which consists of $1,001,350 in current liabilities as of September 30, 2024, and $1,106,700 in other long-term liabilities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There have been no material changes outside the ordinary course of business to our contractual obligations and commitments, as disclosed in our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We intend to utilize existing capital resources for general corporate purposes and working capital requirements, including preclinical and clinical development of our MC1r and MC4r programs, and development of other portfolio products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As a result of our sale of worldwide rights to Vyleesi pursuant to the Purchase Agreement, we currently do not have a recurring source of revenue. Based on our available cash and cash equivalents as of September 30, 2024, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for one year from the date our consolidated financial statements are issued. We are evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm our business, results of operations, and future prospects. If we are not able to secure adequate additional funding in future periods, we would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. We may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If we are unable to raise capital when needed or enter into a strategic transaction, then we may be required to cease operations, which could cause our stockholders to lose all or part of their investment. Based on our current operating and development plans, we expect that our existing cash and cash equivalents as of the date of this filing will be sufficient to enable the Company to fund its operations into the first half of the calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We will need additional funding to complete required clinical trials for our product candidates and development programs and, if those clinical trials are successful (which we cannot predict), to complete submission of required regulatory applications to the FDA. However, current economic conditions may negatively impact our operations, including possible effects on our financial condition, ability to access the capital markets on attractive terms or at all, liquidity, operations, suppliers, industry, and workforce. We will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2025 and beyond.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P1I3">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not required to be provided by smaller reporting companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="P1I4"><strong>Item 4. Controls and Procedures</strong><strong>.</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective due to the previously-reported material weakness in our controls over financial reporting related to the accounting for complex financial instruments. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, Company management believes that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the period presented. We will continue to improve these processes to ensure that the nuances of such significant or non-routine transactions are effectively evaluated in the context of the appropriate accounting standards. There were no other changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="P2">PART II &#8211; OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I1">Item 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business. We are not currently a party to any claim or legal proceeding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I1A">Item 1A. Risk Factors.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs, and our management&#8217;s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties facing our business. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Other than set forth below, there have been no material changes to our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We are currently not in compliance with the continued listing standards of the NYSE American. Our failure to resume compliance with the continued listing standards or make continued progress toward compliance consistent with a plan of compliance that we submitted to NYSE Regulation may result in the delisting of our common stock.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are currently not in compliance with the continued listing standards of the NYSE American. If we fail to regain compliance with the NYSE American listing standards, our common stock could be de-listed from the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our common stock is listed on the NYSE American, a national securities exchange, under the symbol &#8220;PTN&#8221;. As a result, we are subject to NYSE American&#8217;s listing standards, which generally mandate that we meet certain requirements relating to stockholders&#8217; equity, market capitalization, aggregate market value of publicly held shares and distribution requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 4, 2024, the Company received a letter from the staff of NYSE American LLC (the &#8220;NYSE American&#8221;) stating that the Company&#8217;s stockholders&#8217; equity as reported in its Annual Report on Form 10-K for the year ended June 30, 2024 was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(iii) requires a listed company to have stockholders&#8217; equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 10, 2023, the Company received a notice from the staff of NYSE American that the Company was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders&#8217; equity $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, and Section 1003(a)(ii) requires a listed company to have stockholders&#8217; equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company remains subject to the procedures and requirements of Section 1009 of the Company Guide, and previously submitted a plan (the &#8220;Plan&#8221;) of actions it has taken or will take to regain compliance with the continued listing standards by April 10, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The NYSE American accepted the Plan and granted a Plan period through April 10, 2025 to regain compliance with the continued listing standards, which now includes continued listing standards under Section 1003(a)(iii). The Company will be able to continue its listing during the Plan period and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan until it has regained compliance. If the Company is not in compliance with the continued listing standards by that date or if the Company does not make progress consistent with the Plan during the plan period, the Exchange may commence delisting procedures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There can be no assurance that the Company will be able to meet milestones set forth in the Plan between now and April 10, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If we fail to regain compliance with the continued listing requirements of the NYSE American, the NYSE American may take steps to de-list our common stock. If the NYSE American de-lists our securities for trading on its exchange, we could face significant material adverse consequences, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a limited availability of market quotations for our securities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">reduced liquidity with respect to our securities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a determination that our shares of common stock are &#8220;penny stock&#8221; which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a limited amount of news and analyst coverage for our company; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a decreased ability to issue additional securities or obtain additional financing in the future.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Such a de-listing would likely have a negative effect on the price of our common stock and would impair our investors&#8217; ability to sell or purchase our common stock when investors wish to do so.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Shares of our common stock are considered to be covered securities because they are listed on the NYSE American. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed on the NYSE American, our common stock would not be deemed covered securities and we would be subject to regulation in each state in which we offer our securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Item 2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As disclosed in the table below, 54,691 shares of common stock were withheld during the three months ended September 30, 2024, at the direction of the employees and as permitted under the 2011 Stock Incentive Plan in order to pay the minimum amount of tax liability owed by the employees from the vesting of previously issued restricted stock units:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fiscal Month Period</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Number of Shares Purchased <sup style="vertical-align:super">(1)</sup></strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Price per Share</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maximum <br/>Number of Shares that May Yet be Purchased Under Announced Plans or Programs</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">July 1, 2024 through July 31, 2024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,691</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">August 1, 2024 through August 31, 2024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">September 1, 2024 through September 30, 2024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">54,691</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><sup style="vertical-align:super">(1)</sup> Consists solely of 54,691 shares that were withheld to satisfy tax withholding amounts due from employees upon the vesting of previously issued restricted stock units.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I3">Item 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I4">Item 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I5">Item 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2I6">Item 6.&#160;Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Exhibits filed or furnished with this report:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exhibit Number</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filed Herewith</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:15%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing Date</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SEC File No.</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">Amended and Restated Bylaws of Palatin Technologies, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 17, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 27, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">3.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">August 31, 2022</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-15543</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex34.htm">3.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex34.htm">Certificate of Decrease of Series A Convertible Preferred Stock.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">May 16, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex311.htm">31.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex311.htm">Certification of Chief Executive Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex312.htm">31.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex312.htm">Certification of Chief Financial Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex321.htm">32.1</a></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex322.htm">32.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.INS</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Instance Document (the instance document does not appear on the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.PRE</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">104</p></td><td colspan="6" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">*In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certification furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline"><span id="SIG" class="atag" style="display:inline">SIGNATURES</span></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:50%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:35%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Palatin Technologies, Inc.</strong></p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">(Registrant)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">/s/ Carl Spana</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Date: November 14, 2024</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Carl Spana, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">President and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Chief Executive Officer (Principal</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Executive Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">/s/ Stephen T. Wills</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Date: November 14, 2024</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stephen T. Wills, CPA, MST</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Executive Vice President, Chief Financial Officer and Chief Operating Officer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">(Principal Financial and Accounting Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ptn_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Chief Executive Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Carl Spana, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: November 14, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Carl Spana</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Carl Spana, President and Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ptn_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Chief Financial Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Stephen T. Wills, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: November 14, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ptn_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Principal Executive Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Carl Spana, President and Chief Executive Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dated: November 14, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="margin:0px">/s/ Carl Spana</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="margin:0px">Carl Spana, President and Chief Executive Officer (Principal Executive Officer) </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ptn_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Principal Financial Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dated: November 14, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:38%;vertical-align:top;"> <p style="margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:38%;vertical-align:top;"> <p style="margin:0px">Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ptn-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/13/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ptn="http://ptn.com/20240930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ptn.com/20240930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://ptn.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" id="ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited">
        <link:definition>000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>000008 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" id="NewAndRecentlyAdoptedAccountingPronouncements">
        <link:definition>000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreement" id="AssetPurchaseAgreement">
        <link:definition>000011 - Disclosure - ASSET PURCHASE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" id="ManufacturingSupplyAgreementsForVyleesi">
        <link:definition>000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosun" id="AgreementWithFosun">
        <link:definition>000013 - Disclosure - AGREEMENT WITH FOSUN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdong" id="AgreementWithKwangdong">
        <link:definition>000014 - Disclosure - AGREEMENT WITH KWANGDONG</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000016 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>000017 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiency" id="StockholdersDeficiency">
        <link:definition>000019 - Disclosure - STOCKHOLDERS DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>000024 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyTables" id="StockholdersDeficiencyTables">
        <link:definition>000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
        <link:definition>000027 - Disclosure - ORGANIZATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" id="AssetPurchaseAgreementDetailsNarrative">
        <link:definition>000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" id="AgreementWithFosunDetailsNarrative">
        <link:definition>000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" id="AgreementWithKwangdongDetailsNarrative">
        <link:definition>000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <link:definition>000035 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" id="StockholdersDeficiencyDetails">
        <link:definition>000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" id="StockholdersDeficiencyDetails1">
        <link:definition>000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" id="StockholdersDeficiencyDetails2">
        <link:definition>000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" id="StockholdersDeficiencyDetails3">
        <link:definition>000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" id="StockholdersDeficiencyDetailsNarrative">
        <link:definition>000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <element id="ptn_ProductRevenueNet" name="ProductRevenueNet" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ForeignCurrencyTransactionLossGain" name="ForeignCurrencyTransactionLossGain" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" name="WithholdingTaxesRelatedToRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" name="WithholdingTaxesRelatedToRestrictedStockUnitsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsShares" name="SaleOfCommonStockNetOfCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsAmount" name="SaleOfCommonStockNetOfCostsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceShares" name="SharesReleasedFromAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceAmount" name="SharesReleasedFromAbeyanceAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnrealizedForeignCurrencyTransactionLossGain" name="UnrealizedForeignCurrencyTransactionLossGain" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" name="ChangeInFairValueOfLiabilityClassifiedWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementTextBlock" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsTextBlock" name="ManufacturingSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunTextBlock" name="AgreementWithFosunTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongTextBlock" name="AgreementWithKwangdongTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" name="RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfSalesTableTextBlock" name="ScheduleOfSalesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" name="ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" name="ScheduleOfEquityDistributionAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" name="ScheduleOfStockPurchaseWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RetainedEarningAccumulatedDeficit" name="RetainedEarningAccumulatedDeficit" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SalesBasedMilestonePayments" name="SalesBasedMilestonePayments" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevenuesGross" name="RevenuesGross" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ProductSalesAllowancesAndAccruals" name="ProductSalesAllowancesAndAccruals" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_MoneyMarketAccountsAndTreasuryBills" name="MoneyMarketAccountsAndTreasuryBills" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PaymentsToSalesBasedMilestonePayments" name="PaymentsToSalesBasedMilestonePayments" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UpfrontPaymentOfLess" name="UpfrontPaymentOfLess" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_taxexpenses" name="taxexpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidClinicalStudyCosts" name="PrepaidClinicalStudyCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidInsurancePremiums" name="PrepaidInsurancePremiums" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CarryingValueDuringTheYear" name="CarryingValueDuringTheYear" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CostClinicalStudy" name="CostClinicalStudy" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OtherResearchRelatedExpenses" name="OtherResearchRelatedExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PersonalCost" name="PersonalCost" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedSellingExpenses" name="AccruedSellingExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_TotaAcrruedLiabilities" name="TotaAcrruedLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OtherLiabilitiesCurrents" name="OtherLiabilitiesCurrents" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedOtherLongTermLiabilities" name="AccruedOtherLongTermLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityGrossProceedsShares" name="EquityGrossProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityFeesShares" name="EquityFeesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesShares" name="EquityExpensesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesProceeds" name="EquityExpensesProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsShares" name="EquityNetProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsProceeds" name="EquityNetProceedsProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesOfCommonStock" name="SharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisePricePerShareWarrantsOutstanding" name="ExercisePricePerShareWarrantsOutstanding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_LatestTerminationDate" name="LatestTerminationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" name="shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RestrictedStockVestedInPeriod" name="RestrictedStockVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantShares" name="PurchaseOfWarrantShares" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockBasedCompensationToStockOptions" name="StockBasedCompensationToStockOptions" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGranted" name="UnvestedPerformanceBasedStockOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" name="StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" name="NumberOfOutstandingSharesOfRestrictedStockUnits" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" name="UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" name="StockIssuedDuringPeriodValueRestrictedStockUnitshares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_GrossProceeds" name="GrossProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantOfCommonStockSeriesA" name="PurchaseOfWarrantOfCommonStockSeriesA" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfSecuritiesPurchaseAgreement" name="DescriptionOfSecuritiesPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AggregateValue" name="AggregateValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CashAvailableForDistributionsAdditional" name="CashAvailableForDistributionsAdditional" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" name="DescriptionOfExistingHolderPurchaseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisingHolderReleasedShares" name="ExercisingHolderReleasedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantsToPurchaseShares" name="WarrantsToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OrganizationAbstract" name="OrganizationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementAbstract" name="AssetPurchaseAgreementAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" name="ManufacturingSupplyAgreementsForVyleesiabstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunAbstract" name="AgreementWithFosunAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongAbstract" name="AgreementWithKwangdongAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" name="StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStocksMember" id="ptn_SeriesAConvertiblePreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CurrentMember" id="ptn_CurrentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OneToThreeYearsMember" id="ptn_OneToThreeYearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MayTwoThousandTwentyTwoWarrantsMember" id="ptn_MayTwoThousandTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwoThousandTwentyFourSerisAWarrantsMember" id="ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" id="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoZeroTwoThreePrivateWarrantsMember" id="ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" id="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPrivateWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwoThousandTwentyFourSerisBWarrantsMember" id="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwentyTwentyThreeEquityDistributionAgreementMember" id="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleSeriesAPreferredStocksMember" id="ptn_ConvertibleSeriesAPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CumulativeFromInceptionMember" id="ptn_CumulativeFromInceptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyFourPlacementAgentWarrantsMember" id="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStockMember" id="ptn_SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ContigentlyRedeemableWarrantsMember" id="ptn_ContigentlyRedeemableWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockWarrantsMember" id="ptn_StockWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>ptn-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/13/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_e85f03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_e85f03" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_f1024e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_f1024e" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_ef7d3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_ef7d3e" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_0c9eb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_0c9eb3" xml:lang="en-US">Statement Class Of Stock Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStocksMember" xlink:to="ptn_SeriesAConvertiblePreferredStocksMember_lbl_9637c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember_lbl_9637c5" xml:lang="en-US">Series A Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1b3fca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1b3fca" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_1314e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_1314e6" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_b74f4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_b74f4d" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_4" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_5a7594" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_5a7594" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_306f25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_306f25" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_202245" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_202245" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_af55b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_af55b5" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_8" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_dff1e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_dff1e0" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_078cf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_078cf4" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_5e5b80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_5e5b80" xml:lang="en-US">Short-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_92abc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_92abc5" xml:lang="en-US">Short-term finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_f3a81a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_f3a81a" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_f9585e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_f9585e" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_14" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_09550d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_09550d" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_3ff03e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl_3ff03e" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_f156eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_f156eb" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_17" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_ea2e2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_ea2e2d" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_1bbd47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_1bbd47" xml:lang="en-US">Stockholders' deficiency:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_3badce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_3badce" xml:lang="en-US">Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of September 30, 2024: issued and outstanding 4,030 shares as of September 30, 2024 and June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_0084ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_0084ba" xml:lang="en-US">Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 19,548,167 shares as of September 30, 2024 and 17,926,640 shares as of June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_c2aaaa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_c2aaaa" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f812a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f812a3" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_901ea2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_901ea2" xml:lang="en-US">Total stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_24" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_66a049" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_66a049" xml:lang="en-US">Total liabilities and stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_25" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_b839f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_b839f7" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_921e66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_921e66" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_d74f23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_d74f23" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_fc9e91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_fc9e91" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_632639" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_632639" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_897b00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_897b00" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_1e5c73" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_1e5c73" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_3265e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_3265e6" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_5c61ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_5c61ef" xml:lang="en-US">Consolidated Statements of Operations (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl_31f736" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl_31f736" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductRevenueNet" xlink:label="ptn_ProductRevenueNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProductRevenueNet" xlink:to="ptn_ProductRevenueNet_lbl_461fbc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProductRevenueNet_lbl_461fbc" xml:lang="en-US">Product revenue, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_6c62aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_6c62aa" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_edc755" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_edc755" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_532c7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_532c7d" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_7e593d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_7e593d" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_7" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_78544a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_78544a" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_8" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_bd9b05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_bd9b05" xml:lang="en-US">OTHER (EXPENSE) INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl_154955" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl_154955" xml:lang="en-US">Investment income</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="ptn_ForeignCurrencyTransactionLossGain" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ForeignCurrencyTransactionLossGain" xlink:to="ptn_ForeignCurrencyTransactionLossGain_lbl_44615d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ForeignCurrencyTransactionLossGain_lbl_44615d" xml:lang="en-US">Foreign currency transaction (loss) gain</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_866ad2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_866ad2" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_12" xml:lang="en-US">[Interest Expense, Operating and Nonoperating]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_357d0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_357d0f" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_6d5796" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_6d5796" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_14" xml:lang="en-US">[Other Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_913f0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_913f0f" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_15" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_fe8463" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_fe8463" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_deb54f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_deb54f" xml:lang="en-US">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_54c79f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_54c79f" xml:lang="en-US">Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_1fa99c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_1fa99c" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="ptn_SeriesAConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStockMember" xlink:to="ptn_SeriesAConvertiblePreferredStockMember_lbl_e0f253" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStockMember_lbl_e0f253" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_0b9034" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_0b9034" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ContigentlyRedeemableWarrantsMember" xlink:label="ptn_ContigentlyRedeemableWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ContigentlyRedeemableWarrantsMember" xlink:to="ptn_ContigentlyRedeemableWarrantsMember_lbl_60feca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ContigentlyRedeemableWarrantsMember_lbl_60feca" xml:lang="en-US">Contigently Redeemable Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_5673e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_5673e9" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_3853b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_3853b0" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_7f55d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_7f55d6" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_460d11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_460d11" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_4c4fb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_4c4fb0" xml:lang="en-US">Stock-based compensation, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_af2acd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_af2acd" xml:lang="en-US">Stock-based compensation, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_aee9af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_aee9af" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_18ba47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_18ba47" xml:lang="en-US">Withholding taxes related to restricted stock units, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsShares" xlink:to="ptn_SaleOfCommonStockNetOfCostsShares_lbl_4a42f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares_lbl_4a42f1" xml:lang="en-US">Sale of common stock, net of costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsAmount" xlink:to="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_5ecf79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_5ecf79" xml:lang="en-US">Sale of common stock, net of costs, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_1ab4e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_1ab4e5" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="ptn_SharesReleasedFromAbeyanceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceShares" xlink:to="ptn_SharesReleasedFromAbeyanceShares_lbl_5365dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceShares_lbl_5365dc" xml:lang="en-US">Shares released from abeyance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="ptn_SharesReleasedFromAbeyanceAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceAmount" xlink:to="ptn_SharesReleasedFromAbeyanceAmount_lbl_9b2423" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceAmount_lbl_9b2423" xml:lang="en-US">Shares released from abeyance, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_b0ad0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_b0ad0f" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_506370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_506370" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_f8f866" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_f8f866" xml:lang="en-US">Consolidated Statements of Cash Flows (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_a06e09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_a06e09" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_38760c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_38760c" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_3" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e5f043" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e5f043" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_fc78d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_fc78d7" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_f2eb46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_f2eb46" xml:lang="en-US">Decrease in right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="ptn_UnrealizedForeignCurrencyTransactionLossGain" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:to="ptn_UnrealizedForeignCurrencyTransactionLossGain_lbl_ca8fe3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnrealizedForeignCurrencyTransactionLossGain_lbl_ca8fe3" xml:lang="en-US">Unrealized foreign currency transaction loss (gain)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_e449c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_e449c7" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_ad5048" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_ad5048" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_813c4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_813c4c" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_f879a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_f879a1" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_8487b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_8487b1" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_3a2388" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_3a2388" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_9641df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_9641df" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_e6ca08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_e6ca08" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_ba1779" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_ba1779" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_0cdd0c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_0cdd0c" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_3b5f81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_3b5f81" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_234790" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_234790" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2895c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2895c4" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_20" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_8fb102" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_8fb102" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_c7c188" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_c7c188" xml:lang="en-US">Payment of withholding taxes related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_22" xml:lang="en-US">[Payment, Tax Withholding, Share-Based Payment Arrangement]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_aca7c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_aca7c9" xml:lang="en-US">Proceeds from the sale of common stock and warrants, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_ae7d14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_ae7d14" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_24" xml:lang="en-US">[Finance Lease, Principal Payments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_371f93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_371f93" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_25" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_8f5cba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_8f5cba" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_26" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_ad5b1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_ad5b1b" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_09842b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_09842b" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_15267e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_15267e" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_abf719" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_abf719" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OrganizationAbstract" xlink:label="ptn_OrganizationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OrganizationAbstract" xlink:to="ptn_OrganizationAbstract_lbl_9a3149" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OrganizationAbstract_lbl_9a3149" xml:lang="en-US">ORGANIZATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_54d169" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_54d169" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_BasisOfPresentationAbstract" xlink:label="ptn_BasisOfPresentationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_BasisOfPresentationAbstract" xlink:to="ptn_BasisOfPresentationAbstract_lbl_301e49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_BasisOfPresentationAbstract_lbl_301e49" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_610fbe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_610fbe" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_764f23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_764f23" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_3690f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_3690f5" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_1f2498" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_1f2498" xml:lang="en-US">NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_040d97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_040d97" xml:lang="en-US">NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="ptn_AssetPurchaseAgreementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementAbstract" xlink:to="ptn_AssetPurchaseAgreementAbstract_lbl_6c1a7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementAbstract_lbl_6c1a7c" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_c8757d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_c8757d" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="ptn_AssetPurchaseAgreementTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xml:lang="en-US">[ASSET PURCHASE AGREEMENT]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:to="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_d4056f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_d4056f" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_8b2337" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_8b2337" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xml:lang="en-US">[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithFosunAbstract" xlink:label="ptn_AgreementWithFosunAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunAbstract" xlink:to="ptn_AgreementWithFosunAbstract_lbl_11e17f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunAbstract_lbl_11e17f" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_8c0047" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_8c0047" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="ptn_AgreementWithFosunTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH FOSUN]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="ptn_AgreementWithKwangdongAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongAbstract" xlink:to="ptn_AgreementWithKwangdongAbstract_lbl_fb3543" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongAbstract_lbl_fb3543" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_4a97bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_4a97bb" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="ptn_AgreementWithKwangdongTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH KWANGDONG]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_4c7c70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_4c7c70" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_4dd50c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_4dd50c" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_fc68e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_fc68e7" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_a4e9a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_a4e9a7" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl_64a8f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl_64a8f9" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_1860b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_1860b2" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_12af99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_12af99" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:to="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_14a46a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_14a46a" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_57ddf3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_57ddf3" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_00491b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_00491b" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:label="ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:to="ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl_53d559" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl_53d559" xml:lang="en-US">Revision of Previously Issued Financial Statements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_20f05d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_20f05d" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_9a8be8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_9a8be8" xml:lang="en-US">Cash, Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_630615" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_630615" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_946cf0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_946cf0" xml:lang="en-US">Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_bab51e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_bab51e" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_8d73eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_8d73eb" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_f3f6c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_f3f6c0" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_933b6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_933b6c" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_00edfc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_00edfc" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedLiabilitiesPolicyTextBlock" xlink:to="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_e2f6a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_e2f6a7" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_297c74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_297c74" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_17f035" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_17f035" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_bbf40e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_bbf40e" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_e9016a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_e9016a" xml:lang="en-US">Translation of foreign currencies</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="ptn_ScheduleOfSalesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfSalesTableTextBlock" xlink:to="ptn_ScheduleOfSalesTableTextBlock_lbl_97f54c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfSalesTableTextBlock_lbl_97f54c" xml:lang="en-US">Schedule of sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_23b3c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_23b3c3" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_e2e308" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_e2e308" xml:lang="en-US">Schedule of fair value asset measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_4b9328" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_4b9328" xml:lang="en-US">Schdule of Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:to="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_ec57f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_ec57f4" xml:lang="en-US">Schedule of inventory purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:to="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_ffa73e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_ffa73e" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:to="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_095269" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_095269" xml:lang="en-US">Outstanding Stock Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_3d7b39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_3d7b39" xml:lang="en-US">Option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_2c086b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_2c086b" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RetainedEarningAccumulatedDeficit" xlink:to="ptn_RetainedEarningAccumulatedDeficit_lbl_182957" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_RetainedEarningAccumulatedDeficit_lbl_182957" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RetainedEarningAccumulatedDeficit" xlink:label="ptn_RetainedEarningAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RetainedEarningAccumulatedDeficit" xlink:to="ptn_RetainedEarningAccumulatedDeficit_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RetainedEarningAccumulatedDeficit_lbl_2" xml:lang="en-US">[Accumulated deficit]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_0d867a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_0d867a" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SalesBasedMilestonePayments" xlink:label="ptn_SalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SalesBasedMilestonePayments" xlink:to="ptn_SalesBasedMilestonePayments_lbl_503f6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SalesBasedMilestonePayments_lbl_503f6a" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_068d12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_068d12" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_5" xml:lang="en-US">[Cash and Cash Equivalents, at Carrying Value]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_d3758a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_d3758a" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_cffbf7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_cffbf7" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl_96623f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl_96623f" xml:lang="en-US">Product Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RevenuesGross" xlink:label="ptn_RevenuesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevenuesGross" xlink:to="ptn_RevenuesGross_lbl_4aa095" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevenuesGross_lbl_4aa095" xml:lang="en-US">Gross product sales</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="ptn_ProductSalesAllowancesAndAccruals" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProductSalesAllowancesAndAccruals" xlink:to="ptn_ProductSalesAllowancesAndAccruals_lbl_2fc7fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProductSalesAllowancesAndAccruals_lbl_2fc7fb" xml:lang="en-US">Product sales allowances and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_86efc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_86efc5" xml:lang="en-US">Net sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_011cfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_011cfb" xml:lang="en-US">Potential number of common shares excluded from diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketRiskBenefitLiabilityAmount" xlink:label="us-gaap_MarketRiskBenefitLiabilityAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketRiskBenefitLiabilityAmount" xlink:to="us-gaap_MarketRiskBenefitLiabilityAmount_lbl_0a9a01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketRiskBenefitLiabilityAmount_lbl_0a9a01" xml:lang="en-US">Liability for the warrants amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl_bceb40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl_bceb40" xml:lang="en-US">Contingently redeemable warrants amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_07e3c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_07e3c5" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl_5" xml:lang="en-US">[Additional Paid in Capital, Common Stock]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="us-gaap_CumulativeEarningsDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl_f81df8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl_f81df8" xml:lang="en-US">Increased accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_a286ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_a286ba" xml:lang="en-US">Weighted average vested restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_MoneyMarketAccountsAndTreasuryBills" xlink:label="ptn_MoneyMarketAccountsAndTreasuryBills" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_MoneyMarketAccountsAndTreasuryBills" xlink:to="ptn_MoneyMarketAccountsAndTreasuryBills_lbl_563250" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_MoneyMarketAccountsAndTreasuryBills_lbl_563250" xml:lang="en-US">Money market account and treasury bills</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_3a9c16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_3a9c16" xml:lang="en-US">Payable the settlement of certain purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="us-gaap_AccountsReceivablePurchase" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivablePurchase" xlink:to="us-gaap_AccountsReceivablePurchase_lbl_9da05c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivablePurchase_lbl_9da05c" xml:lang="en-US">Acounts receiveble</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_6d8b99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_6d8b99" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xml:lang="en-US">[Sales-based milestone payments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl_3c554f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl_3c554f" xml:lang="en-US">Upfront purchase price amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl_0f31d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl_0f31d3" xml:lang="en-US">Gain of the sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_c747a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_c747a5" xml:lang="en-US">Company License Agreement Recievables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_abf702" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl_abf702" xml:lang="en-US">Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UpfrontPaymentOfLess" xlink:label="ptn_UpfrontPaymentOfLess" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UpfrontPaymentOfLess" xlink:to="ptn_UpfrontPaymentOfLess_lbl_42c6ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UpfrontPaymentOfLess_lbl_42c6ea" xml:lang="en-US">Upfront payment of less</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl_b35dac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl_b35dac" xml:lang="en-US">Recievable under company agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_1c61c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl_1c61c7" xml:lang="en-US">Upfront payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_taxexpenses" xlink:label="ptn_taxexpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_taxexpenses" xlink:to="ptn_taxexpenses_lbl_dffbb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_taxexpenses_lbl_dffbb4" xml:lang="en-US">Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="us-gaap_PaymentsToAcquireReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireReceivables" xlink:to="us-gaap_PaymentsToAcquireReceivables_lbl_924c4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireReceivables_lbl_924c4a" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="ptn_PrepaidClinicalStudyCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidClinicalStudyCosts" xlink:to="ptn_PrepaidClinicalStudyCosts_lbl_2af97e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidClinicalStudyCosts_lbl_2af97e" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PrepaidInsurancePremiums" xlink:label="ptn_PrepaidInsurancePremiums" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidInsurancePremiums" xlink:to="ptn_PrepaidInsurancePremiums_lbl_af4f54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidInsurancePremiums_lbl_af4f54" xml:lang="en-US">Insurance premiums</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl_2f6a61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl_2f6a61" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl_3faae3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl_3faae3" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_1b4e8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_1b4e8f" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl_3ad4f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl_3ad4f8" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl_cf7511" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl_cf7511" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl_2eb678" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl_2eb678" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CarryingValueDuringTheYear" xlink:label="ptn_CarryingValueDuringTheYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CarryingValueDuringTheYear" xlink:to="ptn_CarryingValueDuringTheYear_lbl_1b98b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CarryingValueDuringTheYear_lbl_1b98b5" xml:lang="en-US">Carrying Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CostClinicalStudy" xlink:to="ptn_CostClinicalStudy_lbl_372eda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_CostClinicalStudy_lbl_372eda" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CostClinicalStudy" xlink:label="ptn_CostClinicalStudy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CostClinicalStudy" xlink:to="ptn_CostClinicalStudy_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CostClinicalStudy_lbl_2" xml:lang="en-US">[Clinical / regulatory costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OtherResearchRelatedExpenses" xlink:label="ptn_OtherResearchRelatedExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OtherResearchRelatedExpenses" xlink:to="ptn_OtherResearchRelatedExpenses_lbl_11810a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OtherResearchRelatedExpenses_lbl_11810a" xml:lang="en-US">Other research related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl_de42bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl_de42bf" xml:lang="en-US">Professional services</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PersonalCost" xlink:label="ptn_PersonalCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PersonalCost" xlink:to="ptn_PersonalCost_lbl_a1cf08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PersonalCost_lbl_a1cf08" xml:lang="en-US">Personal cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedSellingExpenses" xlink:label="ptn_AccruedSellingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedSellingExpenses" xlink:to="ptn_AccruedSellingExpenses_lbl_7bb157" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedSellingExpenses_lbl_7bb157" xml:lang="en-US">Selling expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_15ff3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_15ff3b" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xml:lang="en-US">[Other Accrued Liabilities, Current]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TotaAcrruedLiabilities" xlink:to="ptn_TotaAcrruedLiabilities_lbl_9055b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_TotaAcrruedLiabilities_lbl_9055b0" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TotaAcrruedLiabilities" xlink:label="ptn_TotaAcrruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TotaAcrruedLiabilities" xlink:to="ptn_TotaAcrruedLiabilities_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TotaAcrruedLiabilities_lbl_8" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_670a7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_670a7c" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CurrentMember" xlink:label="ptn_CurrentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CurrentMember" xlink:to="ptn_CurrentMember_lbl_6621a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CurrentMember_lbl_6621a8" xml:lang="en-US">Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OneToThreeYearsMember" xlink:label="ptn_OneToThreeYearsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OneToThreeYearsMember" xlink:to="ptn_OneToThreeYearsMember_lbl_e1152f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OneToThreeYearsMember_lbl_e1152f" xml:lang="en-US">1 - 3 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl_c864b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl_c864b0" xml:lang="en-US">Inventory purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OtherLiabilitiesCurrents" xlink:label="ptn_OtherLiabilitiesCurrents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OtherLiabilitiesCurrents" xlink:to="ptn_OtherLiabilitiesCurrents_lbl_dbefef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OtherLiabilitiesCurrents_lbl_dbefef" xml:lang="en-US">Other Liabilities Current</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedOtherLongTermLiabilities" xlink:label="ptn_AccruedOtherLongTermLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedOtherLongTermLiabilities" xlink:to="ptn_AccruedOtherLongTermLiabilities_lbl_297184" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedOtherLongTermLiabilities_lbl_297184" xml:lang="en-US">Accrued Other long-term Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CumulativeFromInceptionMember" xlink:label="ptn_CumulativeFromInceptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CumulativeFromInceptionMember" xlink:to="ptn_CumulativeFromInceptionMember_lbl_594440" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CumulativeFromInceptionMember_lbl_594440" xml:lang="en-US">Cumulative From Inception</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityGrossProceedsShares" xlink:label="ptn_EquityGrossProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityGrossProceedsShares" xlink:to="ptn_EquityGrossProceedsShares_lbl_ca92c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityGrossProceedsShares_lbl_ca92c0" xml:lang="en-US">Equity Gross proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl_a89e66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl_a89e66" xml:lang="en-US">Equity Gross proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityFeesShares" xlink:label="ptn_EquityFeesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityFeesShares" xlink:to="ptn_EquityFeesShares_lbl_d1be7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityFeesShares_lbl_d1be7b" xml:lang="en-US">Equity Fees, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_770cf5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_770cf5" xml:lang="en-US">Equity Fees, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_5" xml:lang="en-US">[Proceeds from Fees Received]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesShares" xlink:label="ptn_EquityExpensesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesShares" xlink:to="ptn_EquityExpensesShares_lbl_6662cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesShares_lbl_6662cb" xml:lang="en-US">Equity Expenses, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_a4c5f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_EquityExpensesProceeds_lbl_a4c5f7" xml:lang="en-US">Equity Expenses, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesProceeds" xlink:label="ptn_EquityExpensesProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesProceeds_lbl_7" xml:lang="en-US">[Equity Expenses, Proceeds]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsShares" xlink:label="ptn_EquityNetProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsShares" xlink:to="ptn_EquityNetProceedsShares_lbl_596f1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsShares_lbl_596f1e" xml:lang="en-US">Equity Net proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsProceeds" xlink:label="ptn_EquityNetProceedsProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsProceeds" xlink:to="ptn_EquityNetProceedsProceeds_lbl_629aaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsProceeds_lbl_629aaf" xml:lang="en-US">Equity Net proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:to="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_d8cb1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_d8cb1f" xml:lang="en-US">May 2022 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" xlink:label="ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" xlink:to="ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember_lbl_7f4bba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember_lbl_7f4bba" xml:lang="en-US">June 2024 Seris A Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:to="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_fdb974" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_fdb974" xml:lang="en-US">October 2022 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" xlink:label="ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" xlink:to="ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember_lbl_77e469" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember_lbl_77e469" xml:lang="en-US">October 2023 Private Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:to="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_8be542" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_8be542" xml:lang="en-US">October 2023 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_a3b28f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_a3b28f" xml:lang="en-US">January 2024 Private Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_a90ffe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_a90ffe" xml:lang="en-US">January 2024 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:to="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_76f64b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_76f64b" xml:lang="en-US">June 2024 Seris B Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesOfCommonStock" xlink:label="ptn_SharesOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_63a9e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesOfCommonStock_lbl_63a9e7" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisePricePerShareWarrantsOutstanding" xlink:to="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_000f9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_000f9a" xml:lang="en-US">Exercise Price per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_LatestTerminationDate" xlink:label="ptn_LatestTerminationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_LatestTerminationDate" xlink:to="ptn_LatestTerminationDate_lbl_075727" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_LatestTerminationDate_lbl_075727" xml:lang="en-US">Latest Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_c40051" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_c40051" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_890c0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_890c0d" xml:lang="en-US">Number of Options Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_b402ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_b402ff" xml:lang="en-US">Number of Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xml:lang="en-US">[Number of Options Forfeited]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_1a5e61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_1a5e61" xml:lang="en-US">Number of Options Exercied</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xml:lang="en-US">[Number of Options Exercied]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_50b1d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_50b1d1" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_ba5b0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_ba5b0f" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_96f19e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_96f19e" xml:lang="en-US">Number of Options Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_c63758" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_c63758" xml:lang="en-US">Number of Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_6a69ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_6a69ac" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_547344" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_547344" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_a42e9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_a42e9c" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_bc2453" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_bc2453" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_e28aa0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_e28aa0" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_690ce3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_690ce3" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:to="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_259212" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_259212" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_007675" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_007675" xml:lang="en-US">Weighted Average Exercise Price Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_b25514" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_b25514" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_3a37cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_3a37cb" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_b4ff53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_b4ff53" xml:lang="en-US">Weighted Average Remaining Term in Years Options exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_651be0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_651be0" xml:lang="en-US">Weighted Average Remaining Term in Years Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_2a0eeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_2a0eeb" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_f99caf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_f99caf" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_f8e246" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_f8e246" xml:lang="en-US">Aggregate Intrinsic Value Options Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_bf5039" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_bf5039" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xml:lang="en-US">[Outstanding at beginning of year]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_8584da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_8584da" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_404823" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_404823" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="ptn_RestrictedStockVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RestrictedStockVestedInPeriod" xlink:to="ptn_RestrictedStockVestedInPeriod_lbl_76295b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RestrictedStockVestedInPeriod_lbl_76295b" xml:lang="en-US">Vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6da0fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6da0fb" xml:lang="en-US">Expirations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_1c25a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_1c25a6" xml:lang="en-US">Outstanding at ending of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_5329c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_5329c3" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_fb1a42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_fb1a42" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:to="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_d117fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_d117fe" xml:lang="en-US">2023 Equity Distribution Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConvertibleSeriesAPreferredStocksMember" xlink:to="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_102b5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_102b5d" xml:lang="en-US">Convertible Series A Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:to="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_fcebd5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_fcebd5" xml:lang="en-US">2024 Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockWarrantsMember" xlink:label="ptn_StockWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockWarrantsMember" xlink:to="ptn_StockWarrantsMember_lbl_c5a3f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockWarrantsMember_lbl_c5a3f2" xml:lang="en-US">Stock Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_e4d7a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_SharesOfCommonStock_lbl_e4d7a4" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantShares" xlink:label="ptn_PurchaseOfWarrantShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantShares" xlink:to="ptn_PurchaseOfWarrantShares_lbl_0a1812" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantShares_lbl_0a1812" xml:lang="en-US">Purchase of warrant shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="ptn_StockBasedCompensationToStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockBasedCompensationToStockOptions" xlink:to="ptn_StockBasedCompensationToStockOptions_lbl_acb586" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockBasedCompensationToStockOptions_lbl_acb586" xml:lang="en-US">Stock-based compensation to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_5c4e16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_5c4e16" xml:lang="en-US">Unvested performance-based stock options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_41864f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_41864f" xml:lang="en-US">Number of shares outstanding granted</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:to="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_e24f93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_e24f93" xml:lang="en-US">Stock-based compensation related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:to="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_cc0844" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_cc0844" xml:lang="en-US">Number of outstanding shares of restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_4e4402" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_4e4402" xml:lang="en-US">Unvested performance-based stock options granted estricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_91a35c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_91a35c" xml:lang="en-US">Restricted stock units number of shares outstanding granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_2741b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_2741b6" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_11" xml:lang="en-US">[Withholding taxes related to restricted stock units, shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_11a1be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_11a1be" xml:lang="en-US">Fees and expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_GrossProceeds" xlink:label="ptn_GrossProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GrossProceeds" xlink:to="ptn_GrossProceeds_lbl_4e5a1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_GrossProceeds_lbl_4e5a1e" xml:lang="en-US">Gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_c4d64d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_c4d64d" xml:lang="en-US">Exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl_a21351" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl_a21351" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:to="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_1423d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_1423d8" xml:lang="en-US">Purchase of warrant of common stock series A</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:to="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_76ee0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_76ee0f" xml:lang="en-US">Description of securities purchase agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_2027cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_2027cb" xml:lang="en-US">Convertible preferred stock were outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AggregateValue" xlink:label="ptn_AggregateValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AggregateValue" xlink:to="ptn_AggregateValue_lbl_c718c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AggregateValue_lbl_c718c0" xml:lang="en-US">Aggregate value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl_666d69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl_666d69" xml:lang="en-US">Conversion price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:to="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_f82756" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_f82756" xml:lang="en-US">Convertible shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="us-gaap_CashAvailableForDistributions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAvailableForDistributions" xlink:to="us-gaap_CashAvailableForDistributions_lbl_5991de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAvailableForDistributions_lbl_5991de" xml:lang="en-US">Distributable value of dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="ptn_CashAvailableForDistributionsAdditional" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CashAvailableForDistributionsAdditional" xlink:to="ptn_CashAvailableForDistributionsAdditional_lbl_eb7931" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CashAvailableForDistributionsAdditional_lbl_eb7931" xml:lang="en-US">Distributable value of dividend additional</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:to="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_86e970" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_86e970" xml:lang="en-US">Description of existing holder purchase of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="ptn_ExercisingHolderReleasedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisingHolderReleasedShares" xlink:to="ptn_ExercisingHolderReleasedShares_lbl_be6049" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisingHolderReleasedShares_lbl_be6049" xml:lang="en-US">Exercising holder released shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WarrantsToPurchaseShares" xlink:label="ptn_WarrantsToPurchaseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantsToPurchaseShares" xlink:to="ptn_WarrantsToPurchaseShares_lbl_ff6ee3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantsToPurchaseShares_lbl_ff6ee3" xml:lang="en-US">Warrants to purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_7e9006" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_7e9006" xml:lang="en-US">Gross proceeds from exercise of Existing Warrants</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptn-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/13/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:href="ptn-20240930.xsd#NewAndRecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20240930.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20240930.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20240930.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20240930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20240930.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20240930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20240930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductRevenueNet" xlink:label="loc_ptnProductRevenueNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_ptnProductRevenueNet" xlink:type="arc" weight="1" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="loc_ptnForeignCurrencyTransactionLossGain" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_ptnForeignCurrencyTransactionLossGain" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="loc_ptnUnrealizedForeignCurrencyTransactionLossGain" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnUnrealizedForeignCurrencyTransactionLossGain" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:title="000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000024 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000027 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000035 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ptn-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/13/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:href="ptn-20240930.xsd#NewAndRecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20240930.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20240930.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20240930.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20240930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20240930.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20240930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20240930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_3e0c07" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_429b36" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3e0c07" xlink:to="loc_us-gaapStatementTable_429b36" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5d638a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_429b36" xlink:to="loc_us-gaapStatementLineItems_5d638a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_b30397" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_429b36" xlink:to="loc_us-gaapStatementClassOfStockAxis_b30397" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_aaeb0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_b30397" xlink:to="loc_us-gaapClassOfStockDomain_aaeb0d" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_1a9e0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_aaeb0d" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_1a9e0a" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20949d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20949d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_06817b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_06817b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70faa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapAssetsCurrent_70faa5" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_b609c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_b609c5" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_4c7bee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_4c7bee" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_39a38e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOtherAssetsNoncurrent_39a38e" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_c663cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapAssets_c663cb" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_06b7c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapAccountsPayableCurrent_06b7c1" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_b0af9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_b0af9f" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_9065d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_9065d5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_2e40a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_2e40a0" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_f15f44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_f15f44" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_d8829f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapLiabilitiesCurrent_d8829f" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_c4ae12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_c4ae12" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_a2a270" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapOtherLongTermDebt_a2a270" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_408721" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapLiabilities_408721" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7ff683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5d638a" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7ff683" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7ff683" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_3583eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapPreferredStockValue_3583eb" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_154e6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapCommonStockValue_154e6d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_be50e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapAdditionalPaidInCapital_be50e4" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_56ee85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_56ee85" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_b9340a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapStockholdersEquity_b9340a" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_a8c74e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_b05791" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_a8c74e" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_a1aadf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2775e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_a1aadf" xlink:to="loc_us-gaapStatementTable_2775e5" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5b03d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2775e5" xlink:to="loc_us-gaapStatementLineItems_5b03d1" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_5f6a65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2775e5" xlink:to="loc_us-gaapStatementClassOfStockAxis_5f6a65" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_a6d6d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_5f6a65" xlink:to="loc_us-gaapClassOfStockDomain_a6d6d6" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_a8ef25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_a6d6d6" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_a8ef25" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_fe22c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_fe22c5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_c07f71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_c07f71" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_b6f96c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_b6f96c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_689827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapCommonStockSharesAuthorized_689827" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_e460f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapCommonStockSharesIssued_e460f0" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_4e5781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapCommonStockSharesOutstanding_4e5781" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_0088d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapPreferredStockSharesIssued_0088d6" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_c21642" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5b03d1" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_c21642" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_cabaee" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_aa9ba8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_cabaee" xlink:to="loc_us-gaapRevenuesAbstract_aa9ba8" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductRevenueNet" xlink:label="loc_ptnProductRevenueNet_37bdf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_aa9ba8" xlink:to="loc_ptnProductRevenueNet_37bdf6" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_c7732f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_aa9ba8" xlink:to="loc_us-gaapOperatingExpensesAbstract_c7732f" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_969a94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_c7732f" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_969a94" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_ff3682" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_c7732f" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_ff3682" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_a0bf74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_c7732f" xlink:to="loc_us-gaapOperatingExpenses_a0bf74" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_0f5ac1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_c7732f" xlink:to="loc_us-gaapOperatingIncomeLoss_0f5ac1" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_c7732f" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet_428886" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapInvestmentIncomeNet_428886" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="loc_ptnForeignCurrencyTransactionLossGain_45f5d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_ptnForeignCurrencyTransactionLossGain_45f5d2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_596252" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapInterestExpense_596252" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_17c617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_17c617" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_4f5ba9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_4f5ba9" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_f2225d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapNetIncomeLoss_f2225d" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_438159" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapEarningsPerShareBasic_438159" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_1067eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_4f73d5" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_1067eb" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_63b016" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a50c7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_63b016" xlink:to="loc_us-gaapStatementTable_a50c7b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1eefa7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a50c7b" xlink:to="loc_us-gaapStatementLineItems_1eefa7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_25efbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a50c7b" xlink:to="loc_us-gaapStatementEquityComponentsAxis_25efbe" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_92190e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_25efbe" xlink:to="loc_us-gaapEquityComponentDomain_92190e" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember_a0b8d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_92190e" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember_a0b8d9" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_4ebe13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_92190e" xlink:to="loc_us-gaapCommonStockMember_4ebe13" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ContigentlyRedeemableWarrantsMember" xlink:label="loc_ptnContigentlyRedeemableWarrantsMember_6a78d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_92190e" xlink:to="loc_ptnContigentlyRedeemableWarrantsMember_6a78d9" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_0a5004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_92190e" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_0a5004" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_78b1ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_92190e" xlink:to="loc_us-gaapRetainedEarningsMember_78b1ee" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_c635fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapSharesIssued_c635fb" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_72876f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapStockholdersEquity_72876f" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_601fda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_601fda" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_d91e68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_d91e68" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_fdfe55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_fdfe55" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_501ccb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_501ccb" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares_e3b50f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares_e3b50f" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount_f002e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount_f002e5" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_6ab12e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapNetIncomeLoss_6ab12e" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares_84450c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares_84450c" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount_91a151" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount_91a151" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_bbf901" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapSharesIssued_bbf901" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_1186e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1eefa7" xlink:to="loc_us-gaapStockholdersEquity_1186e6" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_b0185e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_a3a5f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_b0185e" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_a3a5f6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_94b2db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_a3a5f6" xlink:to="loc_us-gaapProfitLoss_94b2db" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_a3a5f6" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_6fdbb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_us-gaapDepreciationAndAmortization_6fdbb6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_857897" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_857897" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="loc_ptnUnrealizedForeignCurrencyTransactionLossGain_1275e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_ptnUnrealizedForeignCurrencyTransactionLossGain_1275e0" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_9cfa85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_us-gaapShareBasedCompensation_9cfa85" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_133a60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_133a60" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96d530" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_1767d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_1767d7" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d41b45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d41b45" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_d3a8aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_d3a8aa" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_f7563e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_f7563e" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_6d9b1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_6d9b1e" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_9bf57f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_9bf57f" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_373d7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_373d7c" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_464ead" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_b2024a" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_464ead" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_e17d3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_464ead" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_e17d3b" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_d1d7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_464ead" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_d1d7ac" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_464ead" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_9f9a56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_9f9a56" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_8af9d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_8af9d9" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_39bcd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_39bcd7" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9da0dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9da0dc" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_afb944" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_afb944" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51035f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51035f" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33f34a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33f34a" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_691656" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_9e621b" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_691656" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_0f4eb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_691656" xlink:to="loc_us-gaapInterestPaidNet_0f4eb0" order="29" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_1d7046" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b709c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_1d7046" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b709c6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_BasisOfPresentationAbstract" xlink:label="loc_ptnBasisOfPresentationAbstract_a989f2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8bd2ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnBasisOfPresentationAbstract_a989f2" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8bd2ee" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_762b7c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_40c772" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_762b7c" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_40c772" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:title="000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_1d1f8f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b9ad6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_1d1f8f" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b9ad6a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_e67d8f" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="loc_ptnAssetPurchaseAgreementTextBlock_03a66e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_e67d8f" xlink:to="loc_ptnAssetPurchaseAgreementTextBlock_03a66e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_7c98b3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="loc_ptnManufacturingSupplyAgreementsTextBlock_5c91d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_7c98b3" xlink:to="loc_ptnManufacturingSupplyAgreementsTextBlock_5c91d8" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_3a7430" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="loc_ptnAgreementWithFosunTextBlock_6eccfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_3a7430" xlink:to="loc_ptnAgreementWithFosunTextBlock_6eccfc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_d87b58" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="loc_ptnAgreementWithKwangdongTextBlock_7f2d9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_d87b58" xlink:to="loc_ptnAgreementWithKwangdongTextBlock_7f2d9d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_3efd3f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock_aa61e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_3efd3f" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock_aa61e1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_3ebc31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_d9689d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_3ebc31" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_d9689d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_1cdddf" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_c7ee22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1cdddf" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_c7ee22" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_42537f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_cbad24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_42537f" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_cbad24" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e71e71" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_60745e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e71e71" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_60745e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_57a594" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_e8ab4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_e8ab4e" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:label="loc_ptnRevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_a28118" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_ptnRevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_a28118" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_3d56a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapUseOfEstimates_3d56a5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_1d19be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_1d19be" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_038c40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_038c40" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_105bda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_105bda" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_0bce04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_0bce04" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9b9b71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9b9b71" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_409199" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_409199" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_60d2c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_60d2c9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_e846d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_e846d1" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_ptnAccruedLiabilitiesPolicyTextBlock_991e1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_ptnAccruedLiabilitiesPolicyTextBlock_991e1f" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_2ecdbf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_2ecdbf" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_ea2007" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_ea2007" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_231d40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_231d40" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_154a84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_57a594" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_154a84" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_0a7609" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="loc_ptnScheduleOfSalesTableTextBlock_78644e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0a7609" xlink:to="loc_ptnScheduleOfSalesTableTextBlock_78644e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_97cb6b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_925c76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_97cb6b" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_925c76" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_f377e8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_996e6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_f377e8" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_996e6c" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000024 - Disclosure - ACCRUED EXPENSES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_768abb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_67a23e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_768abb" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_67a23e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c5b8a7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_886efa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c5b8a7" xlink:to="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_886efa" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_514bca" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_67facf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_514bca" xlink:to="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_67facf" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_0fa58f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_514bca" xlink:to="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_0fa58f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6efa71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_514bca" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6efa71" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_15a187" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_514bca" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_15a187" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000027 - Disclosure - ORGANIZATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_37c68f" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RetainedEarningAccumulatedDeficit" xlink:label="loc_ptnRetainedEarningAccumulatedDeficit_95f914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_37c68f" xlink:to="loc_ptnRetainedEarningAccumulatedDeficit_95f914" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_25f7cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_37c68f" xlink:to="loc_us-gaapNetIncomeLoss_25f7cc" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SalesBasedMilestonePayments" xlink:label="loc_ptnSalesBasedMilestonePayments_ba2449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_37c68f" xlink:to="loc_ptnSalesBasedMilestonePayments_ba2449" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_5e9989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_37c68f" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_5e9989" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_4a49ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_37c68f" xlink:to="loc_us-gaapLiabilitiesCurrent_4a49ca" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_a21b07" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7b56be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_a21b07" xlink:to="loc_us-gaapStatementTable_7b56be" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_fdbd8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b56be" xlink:to="loc_us-gaapStatementLineItems_fdbd8f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_ded59f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b56be" xlink:to="loc_srtProductOrServiceAxis_ded59f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_af3482" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_ded59f" xlink:to="loc_srtProductsAndServicesDomain_af3482" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_56cdf1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_af3482" xlink:to="loc_us-gaapProductMember_56cdf1" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross_bc3a3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdbd8f" xlink:to="loc_ptnRevenuesGross_bc3a3d" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals_305795" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdbd8f" xlink:to="loc_ptnProductSalesAllowancesAndAccruals_305795" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_29a9b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdbd8f" xlink:to="loc_us-gaapRevenues_29a9b9" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_0317ed" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_afc5d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_afc5d2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketRiskBenefitLiabilityAmount" xlink:label="loc_us-gaapMarketRiskBenefitLiabilityAmount_317dc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapMarketRiskBenefitLiabilityAmount_317dc5" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_486dc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_486dc9" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_85c6a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_85c6a2" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CumulativeEarningsDeficit" xlink:label="loc_us-gaapCumulativeEarningsDeficit_072fcc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapCumulativeEarningsDeficit_072fcc" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_2275a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_2275a7" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_MoneyMarketAccountsAndTreasuryBills" xlink:label="loc_ptnMoneyMarketAccountsAndTreasuryBills_91db6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_0317ed" xlink:to="loc_ptnMoneyMarketAccountsAndTreasuryBills_91db6d" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_096f9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" xlink:to="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_096f9f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="loc_us-gaapAccountsReceivablePurchase_3c7929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" xlink:to="loc_us-gaapAccountsReceivablePurchase_3c7929" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="loc_ptnPaymentsToSalesBasedMilestonePayments_6345ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" xlink:to="loc_ptnPaymentsToSalesBasedMilestonePayments_6345ed" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="loc_us-gaapSupplementalDeferredPurchasePrice_b4b506" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" xlink:to="loc_us-gaapSupplementalDeferredPurchasePrice_b4b506" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1_da73b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_cc82a7" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1_da73b0" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_9c3c16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_042b9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_9c3c16" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_042b9a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_03401b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_9c3c16" xlink:to="loc_us-gaapPaymentsForRestructuring_03401b" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UpfrontPaymentOfLess" xlink:label="loc_ptnUpfrontPaymentOfLess_247ed5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_9c3c16" xlink:to="loc_ptnUpfrontPaymentOfLess_247ed5" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_1c907a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_bbb065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_1c907a" xlink:to="loc_us-gaapOfficersCompensation_bbb065" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_f07912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_1c907a" xlink:to="loc_us-gaapPaymentsForRestructuring_f07912" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_taxexpenses" xlink:label="loc_ptntaxexpenses_487078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_1c907a" xlink:to="loc_ptntaxexpenses_487078" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaapPaymentsToAcquireReceivables_db50a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_1c907a" xlink:to="loc_us-gaapPaymentsToAcquireReceivables_db50a0" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_68568a" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="loc_ptnPrepaidClinicalStudyCosts_cfc0ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_68568a" xlink:to="loc_ptnPrepaidClinicalStudyCosts_cfc0ac" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PrepaidInsurancePremiums" xlink:label="loc_ptnPrepaidInsurancePremiums_e0f489" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_68568a" xlink:to="loc_ptnPrepaidInsurancePremiums_e0f489" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_a29271" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_68568a" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_a29271" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_bb0e3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_68568a" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_bb0e3c" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_19d57a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_6192d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_19d57a" xlink:to="loc_us-gaapStatementTable_6192d9" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7d02ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6192d9" xlink:to="loc_us-gaapStatementLineItems_7d02ce" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_17152f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6192d9" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_17152f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_79927a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_17152f" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_79927a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0cbb7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_79927a" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0cbb7b" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_8e8c06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_79927a" xlink:to="loc_us-gaapFairValueInputsLevel2Member_8e8c06" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_5ed626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_79927a" xlink:to="loc_us-gaapFairValueInputsLevel3Member_5ed626" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CarryingValueDuringTheYear" xlink:label="loc_ptnCarryingValueDuringTheYear_608b30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7d02ce" xlink:to="loc_ptnCarryingValueDuringTheYear_608b30" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000035 - Disclosure - ACCRUED EXPENSES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CostClinicalStudy" xlink:label="loc_ptnCostClinicalStudy_74308b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_ptnCostClinicalStudy_74308b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OtherResearchRelatedExpenses" xlink:label="loc_ptnOtherResearchRelatedExpenses_fdd783" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_ptnOtherResearchRelatedExpenses_fdd783" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent_56ec31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent_56ec31" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PersonalCost" xlink:label="loc_ptnPersonalCost_7ba790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_ptnPersonalCost_7ba790" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedSellingExpenses" xlink:label="loc_ptnAccruedSellingExpenses_ac14a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_ptnAccruedSellingExpenses_ac14a1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_8eca6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_8eca6b" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TotaAcrruedLiabilities" xlink:label="loc_ptnTotaAcrruedLiabilities_fe2af7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_1fba7d" xlink:to="loc_ptnTotaAcrruedLiabilities_fe2af7" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_2ad53c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0053d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_2ad53c" xlink:to="loc_us-gaapStatementTable_0053d7" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_cf3a70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0053d7" xlink:to="loc_us-gaapStatementLineItems_cf3a70" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_9daecf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0053d7" xlink:to="loc_us-gaapPlanNameAxis_9daecf" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_8c1d4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_9daecf" xlink:to="loc_us-gaapPlanNameDomain_8c1d4b" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember_0566d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_8c1d4b" xlink:to="loc_ptnCurrentMember_0566d0" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember_b1733b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_8c1d4b" xlink:to="loc_ptnOneToThreeYearsMember_b1733b" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases_9f9f3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_cf3a70" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases_9f9f3b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c4af18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OtherLiabilitiesCurrents" xlink:label="loc_ptnOtherLiabilitiesCurrents_1bd3ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c4af18" xlink:to="loc_ptnOtherLiabilitiesCurrents_1bd3ee" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AccruedOtherLongTermLiabilities" xlink:label="loc_ptnAccruedOtherLongTermLiabilities_d7cff6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c4af18" xlink:to="loc_ptnAccruedOtherLongTermLiabilities_d7cff6" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_c011cc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f6f2dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_c011cc" xlink:to="loc_us-gaapStatementTable_f6f2dd" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8559d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f6f2dd" xlink:to="loc_us-gaapStatementLineItems_8559d5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_dcf1c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f6f2dd" xlink:to="loc_us-gaapPlanNameAxis_dcf1c0" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_c2ba9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_dcf1c0" xlink:to="loc_us-gaapPlanNameDomain_c2ba9f" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember_7cc515" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_c2ba9f" xlink:to="loc_ptnCumulativeFromInceptionMember_7cc515" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares_30a1e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityGrossProceedsShares_30a1e9" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_ff89e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_us-gaapProceedsFromOtherEquity_ff89e9" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares_aa7755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityFeesShares_aa7755" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_cade77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_us-gaapProceedsFromFeesReceived_cade77" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares_ec5a07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityExpensesShares_ec5a07" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds_4f10c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityExpensesProceeds_4f10c8" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares_8ea785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityNetProceedsShares_8ea785" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds_94daae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8559d5" xlink:to="loc_ptnEquityNetProceedsProceeds_94daae" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_941161" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_d00e84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_941161" xlink:to="loc_us-gaapStatementTable_d00e84" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_563ff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d00e84" xlink:to="loc_us-gaapStatementLineItems_563ff5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_2f668a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_d00e84" xlink:to="loc_us-gaapPlanNameAxis_2f668a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_0d98cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_2f668a" xlink:to="loc_us-gaapPlanNameDomain_0d98cf" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_b047cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_b047cc" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisAWarrantsMember_d7789b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisAWarrantsMember_d7789b" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_d1cc3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_d1cc3b" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePrivateWarrantsMember_b3aca4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnOctoberTwoZeroTwoThreePrivateWarrantsMember_b3aca4" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_43678f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_43678f" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_295686" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_295686" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_9b91f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_9b91f2" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_0e7b62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_0d98cf" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_0e7b62" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_fb08b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_563ff5" xlink:to="loc_ptnSharesOfCommonStock_fb08b3" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding_a9ae13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_563ff5" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding_a9ae13" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate_261f3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_563ff5" xlink:to="loc_ptnLatestTerminationDate_261f3c" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_f109b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_f109b4" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_00cf42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_00cf42" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_95abd1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_95abd1" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_de0f18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_de0f18" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_8a8aeb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_8a8aeb" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_a4c25f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_a4c25f" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_710b77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_710b77" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_913ec3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_913ec3" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_63e9ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_63e9ea" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb5ba9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb5ba9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5c4ed2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5c4ed2" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_95ebfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_95ebfe" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9c71ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9c71ef" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_4caa19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_4caa19" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_58af8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_58af8e" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_fa2418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_fa2418" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b532ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b532ae" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fa26fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fa26fb" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d4a476" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d4a476" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39baf4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_39baf4" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_8eec27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_8eec27" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_da54a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_da54a7" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_b8a3cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_9d97b7" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_b8a3cc" order="23" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_a7757e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_a7757e" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_bcc2b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_bcc2b9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_87818c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_87818c" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="loc_ptnRestrictedStockVestedInPeriod_3ec8dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_ptnRestrictedStockVestedInPeriod_3ec8dd" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_3c79d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_3c79d8" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_0b98f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_81056b" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_0b98f5" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_049ce7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f9fd81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_049ce7" xlink:to="loc_us-gaapStatementTable_f9fd81" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b32754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9fd81" xlink:to="loc_us-gaapStatementLineItems_b32754" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_a6ac95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9fd81" xlink:to="loc_us-gaapAwardTypeAxis_a6ac95" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56b7bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_a6ac95" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56b7bf" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_a6fd9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9fd81" xlink:to="loc_us-gaapStatementClassOfStockAxis_a6fd9c" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_49043d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_a6fd9c" xlink:to="loc_us-gaapClassOfStockDomain_49043d" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_c88dec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9fd81" xlink:to="loc_us-gaapPlanNameAxis_c88dec" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_d6506c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_c88dec" xlink:to="loc_us-gaapPlanNameDomain_d6506c" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_fb6dca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f9fd81" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_fb6dca" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_4bc54a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_fb6dca" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_4bc54a" order="60" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_b7d37f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56b7bf" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_b7d37f" order="61" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember_839b8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_49043d" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember_839b8c" order="62" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_ad5c49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_d6506c" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_ad5c49" order="63" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember_c4f3e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_4bc54a" xlink:to="loc_ptnStockWarrantsMember_c4f3e7" order="64" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_25a0f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnSharesOfCommonStock_25a0f8" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares_713fd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnPurchaseOfWarrantShares_713fd8" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="loc_ptnStockBasedCompensationToStockOptions_76db19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnStockBasedCompensationToStockOptions_76db19" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_ecb683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_ecb683" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_97cdb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_97cdb8" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_37112c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_37112c" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_df499f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_df499f" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_957923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_957923" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_0cfc35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_0cfc35" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_fa8de1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_fa8de1" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_6005dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapCostsAndExpenses_6005dd" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_GrossProceeds" xlink:label="loc_ptnGrossProceeds_4542ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnGrossProceeds_4542ad" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c0c977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c0c977" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_1893c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapSharesIssuedPricePerShare_1893c4" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_7372cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_7372cc" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_573785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_573785" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_caf860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_caf860" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue_d6a363" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnAggregateValue_d6a363" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_b8ee53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_b8ee53" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_43d7a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_43d7a3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions_b67043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapCashAvailableForDistributions_b67043" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="loc_ptnCashAvailableForDistributionsAdditional_b1345e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnCashAvailableForDistributionsAdditional_b1345e" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_2c1983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_2c1983" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares_75d769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnExercisingHolderReleasedShares_75d769" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares_497486" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_ptnWarrantsToPurchaseShares_497486" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_0f0624" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b32754" xlink:to="loc_us-gaapProceedsFromWarrantExercises_0f0624" order="26" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ptn-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/13/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20240930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20240930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:href="ptn-20240930.xsd#NewAndRecentlyAdoptedAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20240930.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20240930.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20240930.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20240930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20240930.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20240930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20240930.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20240930.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20240930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20240930.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLongTermDebt" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" order="24" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ContigentlyRedeemableWarrantsMember" xlink:label="loc_ptnContigentlyRedeemableWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnContigentlyRedeemableWarrantsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements" xlink:title="000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000024 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000027 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnRevenuesGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnProductSalesAllowancesAndAccruals" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CarryingValueDuringTheYear" xlink:label="loc_ptnCarryingValueDuringTheYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnCarryingValueDuringTheYear" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000035 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCurrentMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOneToThreeYearsMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCumulativeFromInceptionMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityGrossProceedsShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityFeesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesProceeds" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsProceeds" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisAWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisAWarrantsMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePrivateWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoZeroTwoThreePrivateWarrantsMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnLatestTerminationDate" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ptnStockWarrantsMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="loc_ptnStockBasedCompensationToStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockBasedCompensationToStockOptions" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_GrossProceeds" xlink:label="loc_ptnGrossProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnGrossProceeds" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnAggregateValue" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAvailableForDistributions" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="loc_ptnCashAvailableForDistributionsAdditional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnCashAvailableForDistributionsAdditional" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisingHolderReleasedShares" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20240930.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantsToPurchaseShares" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" order="26" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptn_10qimg17.jpg
<TEXT>
begin 644 ptn_10qimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  ^ 0<# 2(  A$! Q$!_\0
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M/]\Y;\B*RPF$JRFJD=+=R:-&;:DCUKP2T?P_^U_VY>PZ?I=POF;KF41A7'<
M\G(XX]!6Y9?%C2_$6N?V+X+T^ZURX',EP%\FV@7^\[MSCV"DGM7SEX)^'/B3
MXE:RUY<3SIIRO_I&HW!+ECW5,_>;]!WKZV\+^%-&\'Z-'I.BVBP6Z\LQY>1N
M[.W<U>-A1IR;;YIOMHEZE5XPB][L\^_:%W_\*C/F8W_;8-VWIGGI6)X/NOC,
MO@715T?3?#KZ<+2/[,\\D@D,>WY2V#C.*WOVB/\ DE#?]?T']:[#X;?\DO\
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L3Z5ZG%'Y<2QYSM4+GZ5,OW:!6DZM245&3NH[%.4FDF]A]%%%00%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptn_10qimg15.jpg
<TEXT>
begin 644 ptn_10qimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %@ FX# 2(  A$! Q$!_\0
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MV#)!RV[L *(QC*33",4WJ>KZ[\2-!T/7+G0VAU*_U:UA2X>SL+)YY/*;/SC
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M$> TR?\ +/D$8)R2#@&JWB30+AO'_P .IM+TO.FZ5-=^:8D CM4-L43CL,X
MQ63--JG@_P"*?B;6KCPWJFKZ9KEO:M!<:9!]H>&2%&1HG4'(!R&!Z<G.*=HO
M5!:+.BD^)/AG_A'-,UZSGN-0BU24V]G;6L+/<3RC.Z,1\$,NUMV[&W!S5*W^
M*WA=M#U76;Q-1TRTTFZCL[M[VS>/RI78+MQWVY&<= 0>]>8WFD^)M'/A1H;&
M>U\0:GKNIZU'8V1B>YM8Y$;Y?WA$14!U\S)'+ *<U;GL6U;P9X@\/:?IFL7/
MB:/7;"_U>'48XA*Y>:-O, B8Q^6(X^ #P%Y]SDCN7RQ/35^(FF?V-;ZA#H/B
M*4W$KQP6RZ7+YT@0 F3:1PA# AF(SGUIS?$_PE%X17Q1=7<]KI_VL6$OG6[K
M);S[]A21,94@]:R_B.WB:+6="CM(];/AMUF_M!M 0-=^;A?*!_B$9^?)7G.,
MD"N(L_"?B;_A I;5]#U%9Y/&L&HK#=R+-/\ 9O.B;S'8$AL $DY/0^E-1BTF
MR5&+1W4?Q<\+M=7-B+#7!JT>UDTHZ9*+N>,@D2)'C)3 /S'&.AP<"M%_B5X:
M_P"$5TWQ-:R7-[:ZG*+>SM[:W9[B>;YLQB/J&&ULYQC::KII-\/CU+K'V.3^
MSSX<2U%U@;#+]I9MF?7'-<58>'_L?PV2P\3^&=?ED&O7UW;R:0I^U6),\C1S
MKM8, 5;L#][D8-%HL+1/7-%U:'6--BU"&WN[59"P,-Y;M#*A!((96Y'(^A[5
MNFN'^',GB>3PE&?%37!NQ/*(&NT5+EK8.?*,RI\HD*XSC^>:[BLWH[&;T8M%
M%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 4Y)EC&6D %/^T6__/9/SKR_XM,T;:1Y<C)S+G:Q'9:X!K.\
M;R8TO-US)"+AHB[*(HB,[F<_+TQGZBN"KBG"3@HWL>UALOC7IQJ2GRWOT['T
M7]I7_GLOYTGVA?\ GLOYU\]+H>O,#^YD&#@AK@ ]2.F[N1@>M1-I.N+#]H\N
M0IM#86X!;& >F<YPP./0UG]<E_(SI_LNGM[1?<?17VA?^>R_G1]H_P"FR_\
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MBZ3?ZG?6$*Q7&JSBXNGWD^9($" \GCY5 XK6^T0_\_"_]]5\Q^=/_P ]Y?\
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M_P ]Y?\ OLU7]I:6Y?Q*_P!7Y[<_X'U!]IA_YZ)^=-^U0_\ /5?SKYA\Z?\
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MSY91C&3C)(P,'M71P_&KP[;:193:]9SV]Y<VLMT8[-1.@".X"#Y@VXK&2,@
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MQ_\ /-?RK9U6./\ X1[PY^[7_CWG[?\ 3P]:7_"O/'G_ $)VL?\ @*U:FI>
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MHDT<>3Y:2*ZR1LKAV*H%(/S,6!&T<Y%26_@/6&\76GAG4+4:?>W:AH]\9E#
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M91YO><;>H7/.O+C_ .>:_E1Y<?\ SS7\JZO_ (5YX\_Z$[6/_ 5J1OA[XZ4
MMX/U903@9MF&3Z5V<V'_ )D5='*^7'_SS7\J/+C_ .>:_E75_P#"N_'G_0G:
MQ_X"M2?\*\\>;@O_  A^KAB"0/LS9(_R11S8?NOO"Z.5\N/_ )YK^5'EQ_\
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MPTCK7_0JV'_@3)_A1_PTCK7_ $*MA_X$R?X4?5J_\H>SD?2-%?-W_#2.M?\
M0JV'_@3)_A1_PTCK7_0JV'_@3)_A3^JXC^4/9R/I>'[[?2IZ^8T_:2UI#D>%
M; ?]O,G^%._X:5U[_H5K'_P)D_PK/ZI6_E%[.1]-45\R_P##2NO?]"M8_P#@
M3)_A1_PTKKW_ $*UC_X$R?X4OJE;^4?LY'TU17S+_P -*Z]_T*UC_P"!,G^%
M'_#2NO?]"M8_^!,G^%'U2M_*'LY'TU4<W^J_&OFG_AI77O\ H5K'_P "9/\
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MNP8UX-4(/AWXBNO OA+P_=6NB8TC59+RZ#R,W[M;@RQ+:R*I:-<[>, [4"\
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M5'_"H_B5_P!"C=_]_(O_ (JOLCS8_P"]^AH\V/\ O?H:]+^T*W9&GM6?&_\
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M_A4?Q*_Z%&[_ ._D7_Q5?9'FQ_WOT-'FQ_WOT-']HUNR#VK/C?\ X5'\2O\
MH4;O_OY%_P#%4?\ "H_B5_T*-W_W\B_^*K[(\V/^]^AH\V/^]^AH_M&MV0>U
M9\;_ /"H_B5_T*-W_P!_(O\ XJE_X5#\2_\ H4;K_O[%_P#%U]D"6/</F[^A
MJWY\7]_]#2>9UNR#VK/F'X9_"#Q7:^-]/UOQ)ILFFV6FRBX5-RO)/(/N@!2<
M 'DD^F.]?3_VY<?\>MQ_W[I//B_O_H://B_O_H:\ZM6E7ES3,I2<MQWVY?\
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MVL^%-1T>&ZA@DOH3#&\C +EOSS],'-<C=>!];AUB>XT-M.MKA%3[-J+?NYD
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MX'^-'GM_SZ7/_? _QJU]HM_^>\?_ 'T*/M%O_P ]X_\ OH47 J^>W_/I<_\
M? _QH\]O^?2Y_P"^!_C5K[1;_P#/>/\ [Z%'VBW_ .>\?_?0HN!5\]O^?2Y_
M[X'^-1RRR,F!:7&<_P!T?XU>^T6__/>/_OH4?:+?_GO'_P!]"BX&9F;_ )\[
MC_OD?XT9F_Y\[C_OD?XUI_:+?_GO'_WT*/M%O_SWC_[Z%/F8[F9F;_GSN/\
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MB]=KJ&&?QJ?S(_[WZ&J\TB>9][MZ&FAHK_9;/_GSM_\ ORO^%'V6S_Y\[?\
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MS(_[WZ&CS(_[WZ&@!]%,\R/^]^AH\R/^]^AH ?13/,C_ +WZ&CS(_P"]^AH
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M7]Z7_O\ /_C5.'4]/5CFY X_NM_A4W]JZ=_S]+_WRW^%2R2;[+%_>E_[_/\
MXT?98O[TO_?Y_P#&H?[5T[_GZ7_OEO\ "C^U=._Y^E_[Y;_"@";[+%_>E_[_
M #_XT?98O[TO_?Y_\:A_M73O^?I?^^6_PH_M73O^?I?^^6_PH F^RQ?WI?\
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M_P */[5T[_GZ7_OEO\*1)-]EB_O2_P#?Y_\ &C[+%_>E_P"_S_XU#_:NG?\
M/TO_ 'RW^%']JZ=_S]+_ -\M_A0!-]EB_O2_]_G_ ,:/LL7]Z7_O\_\ C4/]
MJZ=_S]+_ -\M_A1_:NG?\_2_]\M_A0 QH5W']Y-_W^?_ !I/)7_GI-_W^?\
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MX4?VKIW_ #]+_P!\M_A3 NT52_M73O\ GZ7_ +Y;_"C^U=._Y^E_[Y;_  H
MNT52_M73O^?I?^^6_P */[5T[_GZ7_OEO\* +M%4O[5T[_GZ7_OEO\*/[5T[
M_GZ7_OEO\* +M%4O[5T[_GZ7_OEO\*/[5T[_ )^E_P"^6_PH NT52_M73O\
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M_5Q_WT/\*3^S4_Y^KC_OH?X57,409-&34_\ 9J?\_5Q_WT/\*/[-3_GZN/\
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MVLCYC_X9Q\29Y\2:6!_UREKVSX?^#K?P#X9&DV;"[FED,US<R$J9I" .!C@
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MYB?WJ/,3^]19 6/MMS_SQB_[[/\ A1]MN?\ GC%_WV?\*K^8G]ZCS$_O460
M/,>8S3,"Y&T!>BCT'^-6[R.22SFCBF,$CQLJR*,E"1@-^'6JGF)_>K0DFCVK
M\WZ&DP/&-(\$_$71-,T?3]%72M($*1PZE-!?.QO722%FNSF+)=TCE0J3G]YR
MQIU]X%^*W]@"&R\>71OOL]E&[&\.6<!S=,I*8!+F,J?[J%<#//L1D0=6Q^!I
M/.B_OBD2>17G@/XBS:I#=W7BR>]@2_CNFM_[0>$;5E?Y5VIA1Y3C*]&*X]#3
M?#?A7XDZ7#JN@KKAM[>RT"&UTJ9AF%;YX0KD<99(FB!7(X\YNN*]?\V/^_\
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MYM2_;X_^?>X_[]&C[?'_ ,^]Q_WZ-&H">7>_],?S:F/!>NNW]R/Q:I/M\?\
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MYV)'50A)QD9R=0^/VDOI$LVA:+=S7$UJ[6DEPT8B:?RT=490^_;B6'Y@,9D
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M-=6^X_O/_'3_ (4GVJW_ .>G_CI_PK=HJN8=S"^U6_\ ST_\=/\ A1]JM_\
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M+8Z#.10!@7/PI\!W=OM;4[Y-D+QK+'J(5DMV:;=&#_SS/GR+],#/%:.G^ /
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MAR%9B!@$Y"@=@.@Z\"M'^U=-_P"?Z'_OJF!<HJG_ &KIO_/]#_WU1_:NF_\
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M_P#G\B_[ZJM"B?RD_P!K_OMO\:/*3_:_[[;_ !J#^TM/_P"?R+_OJC^TM/\
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MH\Z'_GM'_P!]"K'V>W_Y]X_^^!1]GM_^?>/_ +X%%P*_G0_\]H_^^A1YT/\
MSVC_ .^A5C[/;_\ /O'_ -\"C[/;_P#/O'_WP*+@5_.A_P">T?\ WT*/.A_Y
M[1_]]"K'V>W_ .?>/_O@4?9[?_GWC_[X%%P,MI8=Q_>Q]?[PI/-A_P">L?\
MWT*U?L]O_P ^\?\ WP*/L]O_ ,^\?_? I\P[F5YL/_/6/_OH4>;#_P ]8_\
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MS1,%O.FQU_X]I,E,$^:./]7@'Y^G%)#XIL9-*%[<)) SS21QVZH9)G"LPW;
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MZ+^='G1_\]%_.@!]%,\Z/_GHOYT>='_ST7\Z 'T4SSH_^>B_G1YT?_/1?SH
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MOK<7%G<1W$+='C8,#QGJ/K5ZO*IOA;)!HTT.GZU*;]+406TD@VK'B%HB!@G
M.X$\?PBNQ\(Z3=:'X3T_2;KRO.MD*MY+,RGYB>IYSSSVSG  P* .DHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#Q[XI7":A<:5H=OXB;1,W2227&S>A'3#CCUR#GKC/%;VI^#]&CT":^9&N=4M
M[*5!>MCS91Y9X8CJ/3T[5H>+O >A^,+%X+Z%H9RI"7,)VNG]"/8UPK>$_B):
M^%F\+-KTEU]D^6SOX7\MKF$G CE[JZ^H.&'N*ZX2C*,8QE:VYUQ:<4D[6.D\
M!^)I(?!6AZ?XKNTM];\M;;RG/[RY*C 95ZG(QGCKFLUVAG.N-&NI/K O)1:F
M#S3M.1M&1\@&>N>U7OAY\+]+\%I+J5Q(VI:_=#]_?SDNR@_P(3R%_4]ZZW0]
M,FTUM1\YD8W%Y)<)M[*V, ^]<]:,74]W8E2A&4G$Y77[S4O/BO//*G0TAFNH
MXSA97?\ UB^X"9/_  *MQKAI/B!8>7,6A?3G< -\I^=><4EOX5T^6UG;5[.W
MNK^Z=Y)9-N[&XG !(S@+@?A6?9Z#X@TV?3+J%K.ZFL[-[-O-E90PW@JV0I_A
M S[URVDG=CYZ<HV3U5U]Z_S-'Q9YMY:V^AVL[6\M\6+RHV"D:#).?<[5_P"!
M5D7C0ZQ\.Y=:N/,&H6]I(A9)679(F0W ./O"ME=!_M#4I=0UZUM9V\I(H8AF
M18\9+GD#J3Z= *K+X8N(-)\0:59M#':7H+6J9($;,F&!XX&0#QZFGRR;;[DP
ME&,5&^J:?^92U*QATS1M(DLC)$]S>VGF$S.V_GW)JKI^I7>C:[=7-Y,TFEWU
M[)"6<Y%M*#A?^ L./8XKH]4T2ZOK#2[>.2-7M)X)7+$X(3KCCK4D/A^.72]2
MT_4526&[N)9,+V5CD?0BAQ=]"U4C:TM;[DGA^1I)-79G9@+YPN3G VKP*WZY
FKPOH]]H]E/;ZA=+=3/.SB4=67 "Y]\#FNEK2-[:G/.W,^5W1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674279439696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PALATIN TECHNOLOGIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000911216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,548,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4078884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4B Cedar Brook Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">495&#8209;2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278160720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,384,214<span></span>
</td>
<td class="nump">$ 9,527,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">228,435<span></span>
</td>
<td class="nump">242,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,612,649<span></span>
</td>
<td class="nump">9,769,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">307,571<span></span>
</td>
<td class="nump">388,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">438,123<span></span>
</td>
<td class="nump">527,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">56,916<span></span>
</td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,415,259<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,949,028<span></span>
</td>
<td class="nump">4,101,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,573,292<span></span>
</td>
<td class="nump">4,185,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liabilities</a></td>
<td class="nump">319,520<span></span>
</td>
<td class="nump">380,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term finance lease liabilities</a></td>
<td class="nump">18,527<span></span>
</td>
<td class="nump">46,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,001,350<span></span>
</td>
<td class="nump">944,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,861,717<span></span>
</td>
<td class="nump">9,657,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">132,447<span></span>
</td>
<td class="nump">163,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">1,106,700<span></span>
</td>
<td class="nump">1,032,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,100,864<span></span>
</td>
<td class="nump">10,853,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 19,548,167 shares as of September 30, 2024 and 17,926,640 shares as of June 30, 2024</a></td>
<td class="nump">195,481<span></span>
</td>
<td class="nump">179,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">441,709,073<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(449,590,199)<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficiency</a></td>
<td class="num">(7,685,605)<span></span>
</td>
<td class="num">(111,497)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficiency</a></td>
<td class="nump">3,415,259<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of September 30, 2024: issued and outstanding 4,030 shares as of September 30, 2024 and June 30, 2024</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674275942576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">19,548,167<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">19,548,167<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674279359408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProductRevenueNet', window );">Product revenue, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,105,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,743,754<span></span>
</td>
<td class="nump">5,014,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,020,931<span></span>
</td>
<td class="nump">3,200,244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,764,685<span></span>
</td>
<td class="nump">8,214,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,764,685)<span></span>
</td>
<td class="num">(6,108,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER (EXPENSE) INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">78,576<span></span>
</td>
<td class="nump">71,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ForeignCurrencyTransactionLossGain', window );">Foreign currency transaction (loss) gain</a></td>
<td class="num">(131,600)<span></span>
</td>
<td class="nump">159,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,940)<span></span>
</td>
<td class="num">(10,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">682,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(58,964)<span></span>
</td>
<td class="nump">902,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (7,823,649)<span></span>
</td>
<td class="num">$ (5,205,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</a></td>
<td class="nump">19,845,106<span></span>
</td>
<td class="nump">12,170,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ForeignCurrencyTransactionLossGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ForeignCurrencyTransactionLossGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProductRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProductRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278619072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Contigently Redeemable Warrants</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">11,656,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2023</a></td>
<td class="num">$ (1,979,871)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 116,567<span></span>
</td>
<td class="nump">$ 263,400<span></span>
</td>
<td class="nump">$ 409,933,959<span></span>
</td>
<td class="num">$ (412,030,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation, amount</a></td>
<td class="nump">390,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">389,352<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, amount</a></td>
<td class="num">(56,401)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (255)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, amount</a></td>
<td class="nump">531,369<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">529,199<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,205,999)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,205,999)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">11,946,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="num">(6,320,566)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 119,466<span></span>
</td>
<td class="nump">263,400<span></span>
</td>
<td class="nump">410,796,364<span></span>
</td>
<td class="num">(417,236,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="num">(111,497)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 179,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation, amount</a></td>
<td class="nump">349,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">346,694<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, amount</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (547)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,935)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,823,649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,823,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceShares', window );">Shares released from abeyance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceAmount', window );">Shares released from abeyance, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,433<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,433)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">19,548,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="num">$ (7,685,605)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 195,481<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 441,709,073<span></span>
</td>
<td class="num">$ (449,590,199)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674279347056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (7,823,649)<span></span>
</td>
<td class="num">$ (5,205,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">80,790<span></span>
</td>
<td class="nump">87,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Decrease in right-of-use asset</a></td>
<td class="nump">89,198<span></span>
</td>
<td class="nump">88,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnrealizedForeignCurrencyTransactionLossGain', window );">Unrealized foreign currency transaction loss (gain)</a></td>
<td class="nump">131,600<span></span>
</td>
<td class="num">(159,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">349,023<span></span>
</td>
<td class="nump">390,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(682,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,567,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">13,837<span></span>
</td>
<td class="nump">563,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,072,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(152,901)<span></span>
</td>
<td class="num">(2,033,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">388,246<span></span>
</td>
<td class="nump">641,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(92,357)<span></span>
</td>
<td class="num">(90,382)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,016,213)<span></span>
</td>
<td class="num">(5,906,393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,992,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,992,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes related to restricted stock units</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="num">(56,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock and warrants, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">531,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(27,487)<span></span>
</td>
<td class="num">(26,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(126,969)<span></span>
</td>
<td class="nump">448,894<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,143,182)<span></span>
</td>
<td class="num">(2,464,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">9,527,396<span></span>
</td>
<td class="nump">7,989,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
<td class="nump">2,384,214<span></span>
</td>
<td class="nump">5,524,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 5,940<span></span>
</td>
<td class="nump">$ 10,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ChangeInFairValueOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnrealizedForeignCurrencyTransactionLossGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnrealizedForeignCurrencyTransactionLossGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674281669856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women.&#160;As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, and a co-formulation of bremelanotide with a phosphodiesterase type 5 inhibitor (&#8220;PDE5i&#8221;) for treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of September 30, 2024 of $449,590,199 and a net loss for the three months ended September 30, 2024, of $7,823,649. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of September 30, 2024, the Company&#8217;s cash and cash equivalents were $2,384,214 and current liabilities were $9,861,717. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40,&#160;<em>Presentation of Financial Statements&#160;&#8212;&#160;Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on our available cash and cash equivalents as of September 30, 2024, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company may be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the first half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and accounts receivable. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277750976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three months ended September 30, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276744928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revision of Previously Issued Financial Statements</em> - The Company has revised certain prior period amounts on the consolidated financial statements to correct a misstatement with respect to improperly classifying warrants as equity instead of as a warrant liability that is adjusted to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of ASC 815-40, <em>Contracts in Entity&#8217;s Own Equity</em>. As of September 30, 2023, The Company recorded an adjustment to record a liability for the warrants of $1,168,144 million , adjusted contingently redeemable warrants for $263,400, decreased additional paid-in capital for $5,619,090 and increased accumulated deficit for $4,187,546.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also recorded a gain of $682,400 as a result in the change in fair value of the warrant liabilities for the three months ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has assessed the impact of improperly classifying the warrants within equity rather than as a warranty liability that is adjusted through charges or credits to the income statement to reflect changes in the fair value of the warrants, and determined the impact is not material, quantitatively or qualitatively, to any prior period impacted. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em>&#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $1,974,575 and $9,089,113 in a money market account at September 30, 2024 and June 30, 2024, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligation were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three months ended September 30, 2023 were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">4,587,150</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Product sales allowances and accruals</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(2,481,173</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Net sales</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">2,105,977</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended September 30, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three ended September 30, 2024 and 2023 were 11,105,938 and 4,519,682, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of September 30, 2024, and 2023, respectively, due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278159056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(4) NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update&#160;(&#8220;ASU&#8221;) 2023-07,&#160;Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276849520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementTextBlock', window );">ASSET PURCHASE AGREEMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of September 30, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract', window );"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsTextBlock', window );">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsForVyleesiabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277315696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunTextBlock', window );">AGREEMENT WITH FOSUN</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278261312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongTextBlock', window );">AGREEMENT WITH KWANGDONG</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276848528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,823</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,656</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">228,435</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">242,271</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277746192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Carrying Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted&#160;prices&#160;in <br/>active markets<br/>(Level 1)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant unobservable&#160;inputs<br/>(Level 3)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">September 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,974,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,974,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">June 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276428832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(11) ACCRUED EXPENSES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September&#160;30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,761,718</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,238</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">324,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">139,731</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,573,292</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277707872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 14)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of September 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,661,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,554,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,106,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2024, the Company has $1,001,350 and $1,106,700 accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277339280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS DEFICIENCY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211;&#160;As of September 30, 2024, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of September 30, 2024, the Series A Conversion Price was $75.45, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.33 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of September 30, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Financing Transactions &#8211; </em>On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to 91,575 shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounting for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 12, 2023, the Company entered into a new equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Gross proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Fees</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Expenses</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Net proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three months ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Warrants</em> - On June 20, 2024, the Company entered into a letter agreement (the &#8220;Inducement Letter&#8221;) with a holder (the &#8220;Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, the Exercising Holder agreed to exercise, for cash, Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#8217;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the Existing Warrants by the Exercising Holder (the &#8220;Warrant Inducement&#8221;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the Exercising Holder.&#160;During the three months ended September 30, 2024, at the request of the Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of September 30, 2024, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:39%;"></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares of Common</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;"></td></tr><tr style="height:15px"><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Share</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>May 2022 Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">66,666 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 12.50 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">May 11, 2026</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>October 2022 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">90,909 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 6.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">October 31, 2027</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>October 2023 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">943,396 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 2.12 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">April 24, 2029</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>October 2023 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">117,925 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 2.65 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">October 20, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>January 2024 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,831,503 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 5.46 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">February 1, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>January 2024 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91,575 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 6.83 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">February 1, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>June 2024 Series A Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,727,273 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 1.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>June 2024 Series B Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,122,642 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 1.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td>*</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="3" style="mso-ignore: colspan;">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Options &#8211;</em> For the three months ended September 30, 2024, and 2023, the Company recorded stock-based compensation related to stock options of $177,734 and $205,317. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of stock option activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Term in Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.92</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Exercisable at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">927,524</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">10.81</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6.4</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected to vest at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,321,578</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2.83</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation related to restricted stock units of $171,289 and $185,019, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of restricted stock unit activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of September 30, 2024, due to a provision in the restricted stock unit agreements to delay delivery. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the vesting of restricted share units during the three months ended September 30, 2024, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278386880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock', window );">Revision of Previously Issued Financial Statements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revision of Previously Issued Financial Statements</em> - The Company has revised certain prior period amounts on the consolidated financial statements to correct a misstatement with respect to improperly classifying warrants as equity instead of as a warrant liability that is adjusted to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of ASC 815-40, <em>Contracts in Entity&#8217;s Own Equity</em>. As of September 30, 2023, The Company recorded an adjustment to record a liability for the warrants of $1,168,144 million , adjusted contingently redeemable warrants for $263,400, decreased additional paid-in capital for $5,619,090 and increased accumulated deficit for $4,187,546.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also recorded a gain of $682,400 as a result in the change in fair value of the warrant liabilities for the three months ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has assessed the impact of improperly classifying the warrants within equity rather than as a warranty liability that is adjusted through charges or credits to the income statement to reflect changes in the fair value of the warrants, and determined the impact is not material, quantitatively or qualitatively, to any prior period impacted. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em>&#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $1,974,575 and $9,089,113 in a money market account at September 30, 2024 and June 30, 2024, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligation were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three months ended September 30, 2023 were as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">4,587,150</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Product sales allowances and accruals</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(2,481,173</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Net sales</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">2,105,977</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended September 30, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three ended September 30, 2024 and 2023 were 11,105,938 and 4,519,682, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of September 30, 2024, and 2023, respectively, due to a provision in the restricted stock unit agreements to delay delivery.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of foreign currencies</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674281833264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfSalesTableTextBlock', window );">Schedule of sales</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">4,587,150</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Product sales allowances and accruals</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(2,481,173</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Net sales</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">2,105,977</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278473696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,823</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,956</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">144,656</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,248</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">228,435</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">242,271</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value asset measurement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Carrying Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Quoted&#160;prices&#160;in <br/>active markets<br/>(Level 1)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Significant unobservable&#160;inputs<br/>(Level 3)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;">September 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,974,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,974,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">June 30, 2024:</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277710256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schdule of Accrued Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September&#160;30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,761,718</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,238</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">324,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">139,731</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,573,292</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674281684160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 14)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock', window );">Schedule of inventory purchase commitments</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,661,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,554,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,106,700</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277372864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock', window );">Equity Distribution Agreement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Proceeds</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Gross proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Fees</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Expenses</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Net proceeds</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock', window );">Outstanding Stock Purchase Warrants</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:39%;"></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares of Common</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;"></td></tr><tr style="height:15px"><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Share</strong></p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>May 2022 Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">66,666 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 12.50 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">May 11, 2026</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>October 2022 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">90,909 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 6.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">October 31, 2027</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>October 2023 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">943,396 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 2.12 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">April 24, 2029</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>October 2023 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">117,925 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 2.65 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">October 20, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>January 2024 Private Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,831,503 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 5.46 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">February 1, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>January 2024 Placement Agent Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">91,575 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 6.83 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">February 1, 2028</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td>June 2024 Series A Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,727,273 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 1.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td>June 2024 Series B Warrants</td><td style="PADDING-RIGHT: 15px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,122,642 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">$ 1.88 </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td>*</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Term in Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.92</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding - September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">8.0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Exercisable at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">927,524</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">10.81</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">6.4</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Expected to vest at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,321,578</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">2.83</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Units</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfEquityDistributionAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674446880128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RetainedEarningAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 449,590,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,823,649)<span></span>
</td>
<td class="num">$ (5,205,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="nump">159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,384,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 9,861,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,657,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RetainedEarningAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RetainedEarningAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276816896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Product Revenue [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevenuesGross', window );">Gross product sales</a></td>
<td class="nump">$ 4,587,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProductSalesAllowancesAndAccruals', window );">Product sales allowances and accruals</a></td>
<td class="num">(2,481,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 2,105,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProductSalesAllowancesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProductSalesAllowancesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevenuesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevenuesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674274540160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential number of common shares excluded from diluted EPS</a></td>
<td class="nump">11,105,938<span></span>
</td>
<td class="nump">4,519,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitLiabilityAmount', window );">Liability for the warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Contingently redeemable warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,619,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Increased accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,187,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Weighted average vested restricted stock units</a></td>
<td class="nump">279,700<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_MoneyMarketAccountsAndTreasuryBills', window );">Money market account and treasury bills</a></td>
<td class="nump">$ 1,974,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_MoneyMarketAccountsAndTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_MoneyMarketAccountsAndTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480081/944-40-50-7B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480046/944-40-55-29G<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674281808384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Payable the settlement of certain purchase commitments</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivablePurchase', window );">Acounts receiveble</a></td>
<td class="nump">171,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PaymentsToSalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="nump">159,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Upfront purchase price amount</a></td>
<td class="nump">9,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain of the sale</a></td>
<td class="nump">$ 7,781,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PaymentsToSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PaymentsToSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivablePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivablePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276374672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits', window );">Company License Agreement Recievables</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront Payments</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UpfrontPaymentOfLess', window );">Upfront payment of less</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UpfrontPaymentOfLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UpfrontPaymentOfLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278511200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Recievable under company agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront payments</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_taxexpenses', window );">Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_taxexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_taxexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of all receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674276379344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidClinicalStudyCosts', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 39,823<span></span>
</td>
<td class="nump">$ 23,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidInsurancePremiums', window );">Insurance premiums</a></td>
<td class="nump">43,956<span></span>
</td>
<td class="nump">71,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">144,656<span></span>
</td>
<td class="nump">147,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 228,435<span></span>
</td>
<td class="nump">$ 242,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidClinicalStudyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidClinicalStudyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277241536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">$ 1,974,575<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">1,974,575<span></span>
</td>
<td class="nump">9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CarryingValueDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CarryingValueDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674281866400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CostClinicalStudy', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 3,761,718<span></span>
</td>
<td class="nump">$ 1,509,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OtherResearchRelatedExpenses', window );">Other research related expenses</a></td>
<td class="nump">159,965<span></span>
</td>
<td class="nump">65,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">187,238<span></span>
</td>
<td class="nump">284,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PersonalCost', window );">Personal cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,771,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedSellingExpenses', window );">Selling expenses</a></td>
<td class="nump">324,640<span></span>
</td>
<td class="nump">351,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">139,731<span></span>
</td>
<td class="nump">201,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_TotaAcrruedLiabilities', window );">Total</a></td>
<td class="nump">$ 4,573,292<span></span>
</td>
<td class="nump">$ 4,185,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedSellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedSellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CostClinicalStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CostClinicalStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OtherResearchRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OtherResearchRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PersonalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PersonalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_TotaAcrruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_TotaAcrruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277368320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 2,661,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CurrentMember', window );">Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">1,554,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember', window );">1 - 3 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 1,106,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674278699232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies (Note 14)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OtherLiabilitiesCurrents', window );">Other Liabilities Current</a></td>
<td class="nump">$ 1,001,350<span></span>
</td>
<td class="nump">$ 944,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedOtherLongTermLiabilities', window );">Accrued Other long-term Liabilities</a></td>
<td class="nump">$ 1,106,700<span></span>
</td>
<td class="nump">$ 1,032,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OtherLiabilitiesCurrents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OtherLiabilitiesCurrents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674275939920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 547,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(16,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 531,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember', window );">Cumulative From Inception</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 1,744,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(52,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="nump">$ 126,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 1,565,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityExpensesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityExpensesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityGrossProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityGrossProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674279501696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember', window );">May 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">66,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">May 11, 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember', window );">June 2024 Seris A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">2,727,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">June 24, 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember', window );">October 2022 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">90,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 31, 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember', window );">October 2023 Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">943,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">April 24, 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember', window );">October 2023 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">117,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 20, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember', window );">January 2024 Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,831,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember', window );">January 2024 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">91,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember', window );">June 2024 Seris B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">2,122,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">June 24, 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisePricePerShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisePricePerShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_LatestTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_LatestTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674277350240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 2)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance', window );">Number of Options Outstanding, Beginning | shares</a></td>
<td class="nump">2,263,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01', window );">Number of Options Expired | shares</a></td>
<td class="num">(14,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance', window );">Number of Options Outstanding, Ending | shares</a></td>
<td class="nump">2,249,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">927,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance', window );">Number of Options Expected to vest | shares</a></td>
<td class="nump">1,321,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">7.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">6.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="nump">10.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice', window );">Weighted Average Exercise Price Options Expected to vest</a></td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Term in Years Options outstanding at beginning of year</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term in Years Options outstanding at end of year</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options exercisable at end of year</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options Expected to vest</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to vest | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to outstanding | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value Options Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674279338848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RestrictedStockVestedInPeriod', window );">Vested</a></td>
<td class="num">(232,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expirations</a></td>
<td class="num">(2,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at ending of year</a></td>
<td class="nump">1,139,313<span></span>
</td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RestrictedStockVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RestrictedStockVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45674273237760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 12, 2023</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockBasedCompensationToStockOptions', window );">Stock-based compensation to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,734<span></span>
</td>
<td class="nump">$ 205,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGranted', window );">Unvested performance-based stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,945<span></span>
</td>
<td class="nump">88,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits', window );">Stock-based compensation related to restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,289<span></span>
</td>
<td class="nump">$ 185,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits', window );">Number of outstanding shares of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits', window );">Unvested performance-based stock options granted estricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,549<span></span>
</td>
<td class="nump">59,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU', window );">Restricted stock units number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,443<span></span>
</td>
<td class="nump">152,432<span></span>
</td>
<td class="nump">40,707<span></span>
</td>
<td class="nump">22,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,109,117<span></span>
</td>
<td class="nump">$ 4,573,948<span></span>
</td>
<td class="nump">$ 9,224,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfSecuritiesPurchaseAgreement', window );">Description of securities purchase agreement</a></td>
<td class="text">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA', window );">Purchase of warrant of common stock series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,849,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants', window );">Description of existing holder purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the Existing Warrants by the Exercising Holder (the &#8220;Warrant Inducement&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisingHolderReleasedShares', window );">Exercising holder released shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantsToPurchaseShares', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,078,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember', window );">2024 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember', window );">Convertible Series A Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock were outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CashAvailableForDistributionsAdditional', window );">Distributable value of dividend additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember', window );">2023 Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantShares', window );">Purchase of warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,033,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CashAvailableForDistributionsAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CashAvailableForDistributionsAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfExistingHolderPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisingHolderReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisingHolderReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_NumberOfOutstandingSharesOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantOfCommonStockSeriesA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockBasedCompensationToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockBasedCompensationToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&\$B+U&L<[@!/4HY28BWN %#'B<\[>BJI%$NTB]=O^MR]?_JV9<G$E'&//2
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MZ?ZD'*:ZA01A O3]->?J?F*:E*8IC?X"4$L#!!0    ( ,E(;EFG94@#MP0
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M8F4M(/]?<RY>;NI39_N3DK-_ 5!+ P04    " #)2&Y9:_-M+<8&  "F&@
M&    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*U9;5/J.!3^*QEV9\<[<[DT
MZ;NKS"#B7F8475'W<VP#9&T;-@FH]]=OTB(%FD:=\8NT\>3T.2\YSTER\LSX
MDU@0(L%+GA7BM+.0<GG<ZXED07(L?K E*=1_9HSG6*I7/N^))2<X+2?E60\Y
M3M#+,2TZ_9-R[(;W3]A*9K0@-QR(59YC_GI&,O9\VH&=MX%;.E](/=#KGRSQ
MG$R)O%_></76VVI):4X*05D!.)F==@;P>.B6$TJ)!TJ>Q<XST*8\,O:D7\;I
M:<?1B$A&$JE58/6S)D.295J3PO'?1FEG^TT]<??Y3?M%:;PRYA$+,F39/S25
MB]-.U $IF>%5)F_9\T^R,<C7^A*6B?(O>*YDPZ #DI60+-],5@AR6E2_^&7C
MB)T)2H]Y MI,0(<3O)8)[F:"6QI:(2O-.L<2]T\X>P9<2RMM^J'T33E;64,+
M'<:IY.J_5,V3_2$K!,MHBB5)P52J'Q4C*0";@2$6"W"AXBS T:K JY0JF6^@
M"^ZGY^#H]V\G/:D :#6]9/.QL^ICJ.5C+KABA5P(,"I2DN[/[RG@6_3H#?T9
MLBJ<DN4/X#K? 7*09\ S_/ATUP+'W3K3+?6Y;<X<3'^"B\OK?Z;@XO;Z"ES?
MC&X'=^/)7V PO!L_C._&H^FQR6V56L^L5J_D8['$"3GMJ*4J"%^33O^/WV#@
M_&FR^8N4[7G VWK LVGO3U3AR9@0)B.KF4$Y4U>7=;\;1L@-O/BDM]XUP"#H
M(\>/XUIP#YR_!>=;PS-(_U4+JLIOR5012EB1T(R 8H-:C^KG1&?^2J@500N@
M*B;'DA;SJN1028DP!M'_RB!^D;(]/P5;/P76()X3I32AN*JS10IPSKBDO\H!
MD^65.G\G8)$3QLY!6 U2H>N'YIB&6ZSA.U@3Q5Z"Z$AQ7;*[;-95H0-8"")-
M8,,FC!C&T0%8@U3D!ZX9;+0%&UG!WA<*:T9_J<12!*P8IE EGG-2)*] <EP(
M7'%;F8M'<T7"QB(;-;!!5X7^T-]-L2[TX]!WS$;$6R-BJQ%3R9*GKJ;.%"0L
M5_V$:$V,N '!]>*RUNXA-8C%CNL&9J#0J;G-L4(=+G Q+U-CABD':YRMB&:V
MC.)'FE'Y"I),Y0F=467+,^8J!-)8NC;?V45XZ&V#2#>(D.>TN!ON,#2TLTII
MA3BH13J]1;DZWZQIJTL;]5]4F+Y*V[XS4.T,9 WI($G82A=P5:$(7>/'C!AM
M1N\'K"D"_2!$05O ZBX 6BFV?\/)$M,4D!>].$@5)287A&_"9D3L&E9UY(:'
MJ)MBJBSY7M0"NB9N:&?N<;%6Q,BXRB(C/.]]AS9%NM )$?)A"[B:N*&5[^JH
M+_%K:\A]4[U#L0,/<1H$D2HW4=3"1; F3FAG3H63KT@=>2/.)@^J3R,O.(39
ME L\B"!J 5DS)K13YO6VB&0E<^[4#R/>)A5V8[1+W!N\)CG'C=KPUJ0)[:PY
M^4A'9D1N8,#0@0&"AP1DDO1C)W#C%L:'-5O"^%-[@O'D833]R)X 6FGXTV7[
MB[3M;]-J)D9V)K["<L4UX2KVS3%_(E(O8R!(HH=;XH?>9UV#"(IC%,4M11S5
MK(NL1%9GW9*S-57;5?#XJI)O3<0',F^CVXJ\*6)'7E,D0I_*N(OQ9# 9?B#C
MD)5Z/YMQ7Z5MWPLU":-W2!B_ZIV>3KAG*A<+EJ4Z;A*_$-T\9.6!1[D+%)+3
M1+\)W=F"54'-#(V:U-N-8V^GP&T,-\CY@>>TL""J*1K9*?J&LX205( 99SE0
M_000."L;6M6'YVK?4!F@NXVW9O:[WL\:C7F?SPTBO@O=H&47CFHV1W8VWPG-
MC!:X2,B&B=AC1N?E9L(< !-QAUYTR$1&N< )O1;@-;TC.[UO:\+1AHJ^[56'
MRI@/5(<FLW<A"N+@\"#$(.AY412W&5*W ,C> DQ&=^!\-+P=#:8CQ4B@+!F#
MR7GU,/K[?OPPN!Q-[J9&^ :B#Z'GPN9*,$BJ1L<+G+8<JIL"9&\*6A%_!X]D
M3HM"AT$EF&H5*$N-9C0Y/_91Z,:'C9A!,(RCV&_K;%#=&R#[5MIB!-%;!BO\
MYJ89N9&'H'<(ORGH^\B+PY;6QJU)W76L1#.]O[FY'%TIP(-+L&4=E4\7U[=7
M@[OQ]<1\V&EM%3Y]VOE%VO9]4+<)KKU-* _)R]W>C'%5$231A&(T&S:.-?W8
M.RRZ!BGH1(U4Z^V<^.>$S\N+$ '*75)U?+X=W5ZV#,HKAH/Q,W@\K*Y,:C75
M#<X5YFH="56:9TJE\R-4&<2K2Y'J1;)E>:_PR*1D>?FX(#@E7 NH_\\8DV\O
M^@/;JZG^_U!+ P04    " #)2&Y9Y':QD2P)  !F%0  &    'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;)U8:V_<MA+]*\2V*%I@[7W8SLL/8&TWJ2^:Q(C3
M%KC?*(F[XC5%*B3EC?+K[YFA)&L=VP'ZP5X].,-YG#DSU,G6^=M0*A7%U\K8
M<#HI8ZS?S&8A+U4EP[ZKE<6;M?.5C+CUFUFHO9(%"U5FMIS/7\PJJ>WD[(2?
M7?NS$]=$HZVZ]B(T525]>ZZ,VYY.%I/^P2>]*2,]F)V=U'*C;E3\J[[VN)L-
M6@I=*1NTL\*K]>EDM7AS?DCK><'?6FW#Z%J0)YESMW1S59Q.YF20,BJ/I$'B
MYTY=*&-($<SXTNF<#%N2X/BZU_Z6?8<OF0SJPIE_=!'+T\FKB2C46C8F?G+;
M/U3GSQ'IRYT)_%]LT]K%P43D38BNZH1A0:5M^I5?NSB,!%[-GQ!8=@)+MCMM
MQ%9>RBC/3KS;"D^KH8TNV%66AG':4E)NHL=;#;EX]O'3N]6'J_^N/E]]_' R
MB]!(SV=Y)WV>I)=/2!^(]\[&,HC?;:&*7?D9+!G,6?;FG"^?57BCZGUQ,)^*
MY7QY^(R^@\&] ]9W\"_=2]*'CTM30;P)M<S5Z02(#\K?J<G9+S\M7LR/G['M
M<+#M\#GM/[3M>>E?%[^)L0;Q0<;&*^'6XKP)6!R">*^,M"YW/FHK/JE<U=%Y
M<=.&J*I]\;E4XL)5M;3M+S^]6BY>'@=1>XT5N:LJY7,M#1ZXHLGC5/S=&J6"
MAO<O#X^G8BN#D#7>WJE"9*V(4/;7_LV^>.M<(:0MQ*5O-F)5 +,Z1"^Y!G^E
MC9;SX[>7*[Y:'/\F8-I_&JN0\<5K 99A51$$$U'[D?PIV]JEZA5!?6U@50%+
MX&NA@_.%\H/>/VXN+\>*D34H<;5L J2V#C?[8A5(,#<NP'0L^N"B$D=3[*M#
M[V_R+__28!OV[P*K(]9=EQ)<D*LFZER:,!57-M\?]N]6#2; Y4N$O<I@X^(U
MH_I@7WQLO+#@JWZO0MV!'&MVE_W44:N 6*#^*2-@2VU:4M8$3G!&;E%JHR[4
M5"!F#D'SXOW%H1=RXRCB,&VK8RFB]M]4+=-**=[]>;VWZ->D<(]#[3)$-K:0
M+75>"CQ5% !XC9V7%"W*3E"Y0X:_--+C/<DA%LH6THM6X1\5[Y1!((&E/6H=
MC4D(>&A],E**NG0!?P4<ATK:+;8UTH(M2YUIPFT?Y.O+WX_T$.+O7(#!B*$!
M.MJP;FPB?\("#,"2  \D8NX$#$!;"36Y$IU@M:)REF,IZW:G0@2P@7R[/EG:
M;J:X1F\L>%_J4,$U/N?$^2=R.D6*%D.*>@#TJ:H!1!NIZF .^P2[UT:B7<+_
M-@6TB4Y7%14,0*P0*$B'!KD"8 LL4NWPIL]B;_JM=5M+ZV[A7P0OV/]Q?,BV
M((+.<SD5S9VB6SBG9:: <C@&^D -Q;)-2=TQ*G-;9?H==T.6*:,1AB[B!)Q=
M[T%'0$"@Y(S#54H4>N:=)!Z)>F]G.[5>([TAQ:*N"6T(%JK1Z&]*5"HO)917
M =#=8*@8N EY<AM0 2JJ&K-B8#(D$[S:C$!*,EV<NR6T(^78-/V:'<,2DI".
M'\'FWF\.BP2/=>2&N\KA%L^AWZI=2WW'WRD'7.J=)GX0*FD,Y#'N- !_SP(/
MD<61BBTYW-4Z2U<JRLP9G>]Y[!D1MYY;@01M<],49+J7?D 7RSE?D[':%J!#
MB@O<']K/)QUN4Z;^U&#2@C;C3K,X)A)&!-'N8V+'ON=/.?(/VU(N0\F*^$)!
MV1T1#KF'<A<_+Z<'KPZGR\5A6M1X3T R0#!Y2V2:UKV>OGJQF+Y<O-P7[Z4%
M/AAP&BQGBS &DOJ*X)''N:QU1-QVJQM(0@D9D)NO'6I)B;K!%;+/!M @.A(>
M1S!''Z?.L8/X#F\/O4[5,B3;NXV754CY?R">^!^VQ#6RZ 9FV04CWF$(#[P9
MM6Y-HS4GXJVVTG+#7^6Y:RS[?A,E<3HB<^[P<]^]5S?G _\^NOX"1+[N$#&(
MK6XN!JG/*(4<"3_:.T3BKVFXLG$HOGMKH#)RDD)"SO)8O'.TUX6SN?)6G$OJ
MXB2&IBKOI#8R _R?!HQ\$GC5/2+0[I!;3AJT<YV&)@M1IB(J7)/%A!$HS'#6
M>31_"7TMX0K*$*)&T?92;-B%O'.! $75SJUS[5W%R@I"%2Y0:%@(VM$%U^5Z
MB$VXCPV5I0ZA4<5W[*/@>",Y/SR&J0V5 TQR6<293<@"=8FX0R&Z)6.4#%HW
M:9JL51K=0M]+4E!$UB3JHB9J=*7)M$$I*:&8P_?.7.J69""]*506>6C!9-'D
MS(B@.0L%ZBOZ*5/H2JR12K( 2KW41#??&^J8_%-+ (%B1M)5;5(*<Q=BVB&9
M#Y2:0M#T]FBNLHZTIE3I.-$Q2NZ]3T77!06E$VK%U76U4[D4;PH(0Q"684ZB
M];) ,"B=C[B #/1:%6;O(NP0()B$K,X4Y21/(:[D[8ZFD8]0!D1Q6CF46 /-
M3 *PK)+MD#[#A)Q@(0.&UD1<H0DLEF(+XZ'+C#/4D] NS$@S=SENW9&ZG9'M
M-)FFTLB8(YB(Z;3?@Q&@"#J60D,%@ ?<_X@-I,_+[XBNWYU6ZAA&YQ3]+9$'
ML  .Y 5@Y$ %-\ ^QTPE;9 <K,=2U]@^<0EQ/?=O2V4QL"OB C*:AF)J&NXI
MY9Q#NZ.>0I21:]V1@CB!N^@88ZG$$E)S2<,^>1DPJMV6SE S)CDZN AJ]N0D
M)O"N?6BR"=,6#\(I/S\FCC1K*<5')2C#.L"AJ2CG.SC4QCQ'8O>V(SBH06R0
MVDPG0U3PH*#H+6;<(75X/4(B8P8OPCJ%E%Z/^SES.]*O8W*D.YE8^E)#EB+Y
MZ:C4U34=^SJ_K'NL$$EAUC<3!E<W170V=TMVX(BB>%"O5'9Y?\88#1'/=Z.!
M[_D:2%RGJN.H S6A6:.;TNF%\D\6]]:9EF?D7-><XWM;>RI-.*4-UMH'ZFQF
M_>B![>C[DJ:)D^;2E$/,/*!MG*-5V$N!JG#* CA1N;5L4QJ@N:G)R)\71Z^G
M\_F<_BBB+$>ON^\(XS,UGRD@C/&3;";"XO9N8]][NJGQL8\NL]&W+Y#!AK_P
M,=W;F#Z##4^'CXBK].WL?GGZ OE>^HW&;D:M(3K??WDT$3Y]U4LWT=7\)2US
M,;J*+TL%=O>T ._7#G-V=T,;#)]6S_X/4$L#!!0    ( ,E(;ED(9$KO^@,
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M&:!E 7K/TZ _L('AJVKQ/U!+ P04    " #)2&Y9-=BMGBL+  "J'   &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+59;4\;.Q;^*U;NU54K!4@"%-H"
M$N5"+U)?$)2N]J,SXR2^G=A3VT/(_OI]SK$]F83 =K5:J:+)V#X^+\]YSCF3
MDX5U/_Q,J2 >YY7QI[U9"/6[O3U?S-1<^EU;*X.5B75S&?#53?=\[90L^="\
MVAL-!F_VYE*;WMD)/[MQ9R>V"94VZL8)W\SGTBT_J,HN3GO#7GYPJZ>S0 _V
MSDYJ.55W*MS7-P[?]EHII9XKX[4UPJG):>]\^.[# >WG#=^U6OC.9T&6C*W]
M05^NR]/>@!12E2H"29#X[T%=J*HB05#C9Y+9:Z^D@]W/6?H5VPY;QM*K"UO]
M0Y=A=MH[[HE23613A5N[^$LE>PY)7F$KSW_%(NX]V.^)HO'!SM-A:##7)OXO
M'Y,?.@>.!\\<&*4#(]8[7L1:_BF#/#MQ=B$<[88T^L"F\FDHIPT%Y2XXK&J<
M"V=W]Y\_G]_^4WR]$G?7'[]<7UU?G'_Y)LXO+K[>?_EV_>6CN/GZZ?KB^O+N
M9"_@/CJU5R39'Z+LT3.R]\5G:\+,BTM3JG+]_![T;)4=964_C%X4>*?J7;$_
MZ(O18'3P@KS]UOA]EK?_?S$^RC[8+IN2Z9VO9:%.>\@6K]R#ZIW]\=OPS>#]
M"YH?M)H?O"3]?]3\1=G;-7^U_UK\^J7BQFE3Z+I27MB)N+#&VTJ7DA/Q5CUH
MSFFLW#A\L8VOEN+:^T:5XDH;B:.R$G=!!H7\#YX$!(<$]D(;H"GHL/SCM^/1
M\.B]%U\7>/2SP2/Q;::P=5Y+LQ2R\A:L45@'[ DIIB HNO'W-\>C_L%@(*3'
M4]B']"6I 6>+F3131=\F4COQ(*M&T1E:6TCGI FBTG*L*QTT3 ,G\EJ8.:7$
M/()=$=@%H KEQ\IEO.[OKJDWH^N]5_A7L@R-YT6@V_#)@70=?%)4V*,G2VVF
M724\2"+,H*:*=CN)15)%FFA6VK=LM5W2(NS$8ODW6(4O=;:9SLAH-Z4X.5$X
M56I(#S:J9 H[5\+G.-!S<"81:G*5SYY[UE^^+Z0IP9-!.=#7NK%0Q]@ .L,B
M(MX7/QM)P97$U# ?*N%)U3[HDP;DO=IIK,%'VI9)F"IWQ7E!X8:S>&O'VPM=
M5<GRM;,4 VRT'A:TN/,KW$FG!.> (8]1N N2Z%@?43>NQE%VPJ0)C2,IR*:I
MWQ7WGCUQZ8,F\P!AZ6=]_LMHA:_XABMRW/?LN!7XKXT/KDGHY["(6^U_(&$(
M&H@G>94$U1R9:VBE'7^$F$_63'<^0<52G -@$/%)25*4$'C[]9Z1Q^[7!DB6
M%7P]QPY8@%1!<*T/?;&8Z6+&!CM-AR,D>+^0<]O$N^AI1=([6&LQ1AZ+B[5<
M1F/FLE1T!U;&"NNJ(P%W85,1P0:V4'U15XWGD.>;2^T8?U"1U"\:1TJ#:.*V
M* C/(0(.\$0!BCRQ*U#%!3D/P4,Z\48?8;+F$M^,/?(*Y[M>2=F"MJ:C+V&:
M;&'N -XY3U]T33)HFS%IZ16RI/&O$\P5PEJ*5[(H',CQ]88S^]%NNJ<QN-<%
M_2_H.I854,2 >L$=# FA'M'>$?R?1DKS;CLU+)0Z**2&D]3F[%#-H&X(>^R#
M<AL^B;Z.&:5^T=,K]1N?Z6[]NKE"I@)3SLY?PDQF+R5=I:%:"@1HF<D5AC5>
M39H*09DHD1@\K6Z$MC&M?]-34)J?* >K%P;_S72=CS6@?5 V(X -3&ID"DH7
MY:_L7.FMD6/B>:0TU2><48_*%<@W  !HY8*)IZ :,*Y76Z_:!5LD%BN><?7*
MNVVXUKRPW08P:CP7"W?:M2:X@Q!BI!594ATRG7S+0/.*^9/HG2.IL1N'0KO!
MFFV)\[1Z<F./BZB"!+M2A*Y=J4A*V7&EI]&$%N:QA-+>G(L<<9@X'.5*SGN]
MCU=G]2#6@J'I9I;@9_#0#A].@IE6BZJA-@ QQ01"-:$OI@J0(>Z$2K)$FFO"
M-U>2)+PMIYT2!(V2$]%$094$[L= >)?)35QKIS$'TMU>C"W42^N&_&1VVI2I
MK8D$$I[Q*A5:5%-BLMSEK([%)H/2M.JD85S<I?Y.&=2SVQ@1]ONK&ZZZ*2<\
MBA\9]GU9*>7UZ_8((V+5[+&#+W@(HIR[-JR3*YE6>/'\[@(NJ74AW@S>K%O3
M02;ZJ;(!S[ITS6*F##,!',MS+;/E"B4+(!)*!NTGFOATV2:^(R@7I" FM90/
M63JY+(ULRNV*&[66\6V_6JR;EP\@%L_(75"/DN\G?JQ3BF#_@UIFJD??5*E<
MM6V1"B.;NBD-S7B,,&"1"P)9V57_F^-"'3&0ZP;(2HFR49ODQG';,(S\VQJ7
M7!HX;SH4H%M+TH#0*5\\U/:%45Q,'Z2C00%]?647M(YDN%F/*_L6)8F$X 2A
MS'=@EB^[!R:I0R=E_#JOL&/R=MCH:T7=&%J:&EWR7!;4]:>"OYA9R"<DRP)]
MF(] IU(>F3"64?8W]SRI99<U(O'(32'LWQ^@9BTWM&BGEGK3ON2+E0\X.5,7
M0;=JD[Y,%-6!4OL8/P+7#E0B^H*#V+^0/G5RCC65NM0R#0-C6?SP"1WCZ*7L
MZNA4CB9/6*CA?ZLB,3!:8",<56R?@<@[B:*]1C).="&)(CXZB[I:K\FTDPD1
M]GBY\7S#V%^>MY*2=(HD^'=;;_U='/0/CX_ZP\/!AHV=>YFQJ06#R>(5QL?C
M87]XM"]>BR]J)6C4'PX.^V^/CK8R(.?_Z#V>39M*!NO07&H<#&#-5<]% X=Z
M3,6C[70X^V5\C85FO%C+0719><2S;21SRH_S&E!#*')0=L703E6Q.#/;SS0>
MYQ$"Y\'JK8:;W6!*I3R!F11M>K:RBOJ.*!7MYAUY:8=>H %5=LE)17[=XH0X
ME)->D5<2B70(!GF:YD,T'*5%+4T=10)(!1^9.(%1?U%144/P1)VG)QX(K<&1
ML>K:Q=R:R#/SZGIC%&N7V^*O!(2._6DVCJ,A&>L;.,D_\81.&-OB"U9T7<?<
M(\AY&P#TNH:<O,DB?,*W=8_<XY2>CQOG5^T%M6P2[64:U#%HVSA4QAF+;<?G
MJI)C&_L0(:=(P'EN!5@;Y1XTYXI3N:QNT\B5/F%K0Q&Y4C-V*R&_H:&<3.WG
MLZJV#512I]-FQTS@UU% 0'+>LX+X+7%\NQ,CQ(C@6K:JSAS&U<[,=3H5(/B+
MR%NZD"<.?BLAD?*K0[OBS\ZUSU!!:AD!4TIX%(LQ#4<TDU#5$'(24I/Q4M+]
MFO"#PV>%%_2NHI1.+.&S]61_ OGN[;<IS5^XE:?*GPU<Q>^[XD0YVF[G6%'^
M:?-@ 302WXUAUYD7C-OS.#.+RPP-9N#A>Q1^6_S8^<#1)9Q@5:XH&ANNXWNO
M;_(1IXCA/W'=@ K8CJHC[F9DR262CE[V\$I\=/5?%*@#UILJ%7H<\&]9<J$
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MJ6U-M79@4P@+Q$>-Z$<MZ(@$,P<,JGHK"9P2A'L&#RHX N-<^*[#)-@6CK_
M@6]'"H1R:$1)2TY_JJ9@:C BL!$$9?%&GU#$UO+;0M>2PY8"JDH*<LJ@,]I6
M&/J;?/;5,"E)BM &*F+0Y%RX,>+C#1A"+A13F? "'7D:B"Z@5A(M$9([OE]F
MWI .V4Z"G6'4BGU1S64=ZL(G&A 6(2.4G3:"R@L%E?[Z[*'L%^*?=;V4XWLK
M]\X$<+%3(B=^(CA!1%:3[[EWP7/^ERNP@,[I0G3EM3?>>B/)3\SSQC6@Z4:.
MV(SL>$9F+ G:":7\MX?E=$LPPZSYMG8O0]OI!<+##1ZJV0NZ)_5[2/T.O-4
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M<@$R)B3GZ9_,*D]%\%U.8-#P[HL,8$YY9581F^XS77MH3F++IM"]GRBA-+F
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M%OAS@1P;8'UI0;1YX0#='R"S?P%02P,$%     @ R4AN659H=-HJ P  :@<
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MHAKO8;E&) $@DT!*)NN,?+5&>'P1B(9W*"<1=<IEON=VU@YHS6T!4[H:@H"
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MO>M>-E3BDI??BTSE,VML089;VI1JS??7>.AG8/A27LKV"_LN-R 6I(U4O#J
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MJUR9M9SZ$*MLP]8!DP1>.!C_A2;IZIL:]AR>Z "0)3FINZJ6;V#B*.6=*'6
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M=UJ ^W-CBOJ"&#1OS+[Z'U!+ P04    " #)2&Y91)D&&2$,  #8)   &0
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MKR%Q"T:"HZ!$M&M@)3CW8TG^+H.:&"\O? R$NYV8&; 7UG/24[Y?ATQA<I]
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MUE50DOM*$SKX6(\NF-$NCQ&MR%5M *#NG)2\G47XA*OK'JG'*KV:5=8U0(?
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MQ<;Z\09Q7".&;R!V8"J%R31,1(+)G_D^L6LHAEN*X_ @X!S+4^@$+0B#L'L
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MO6&/K&#-JTS?B*>OL#M/8/@2D2G[2Y[JO5[8(TFEM,AW8%20IT7]SY]W?C@
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ML,GML#NWR]>7$VM16QYW$GQ2=*XJ6UXPNW=Y?F_?3JP]DT>0V J\3_</WV_
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MTG2 [PL!N<.^8AR4#[/^?U!+ P04    " #)2&Y9&DJ&4+0"  #3!@  &0
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M;"@S@]D$@E9ZMBVID)-2+S-YEP%3"?)]2JG8!:I <SM&/P%02P,$%     @
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M2=7TS3!3US)P':#>+QF3AXE.4%_T\1]02P,$%     @ R4AN6?B^1?ZG @
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M1ZH"O&W [42RJNEA]TRJCM@,,_5F =<!:G_#F'R>Z+;8OX+A'U!+ P04
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M#'N%N.@C&J"?@+GH+58ORW\6*^@T!J]<K.#%JW)=)WA9+/ND-_68FV.^(Z5
M!6P5TKF^46GS9G0TAF25:=<UDZKYS397TQ:X=E#W6\;DT= 3H)O?\5]02P,$
M%     @ R4AN64-;U3IJ @  S04  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&ULK51=3]LP%/TK5C9-( WB?% VED:"%+9.:T 4MF<WN6TL'#NSG9;]
M^]E)B *D: ][27SM>X[/N<F]T4[(!U4 :/18,JZF3J%U=>:Z*BN@).I85,#-
MR5K(DF@3RHVK*@DD;T E<WV,)VY)*'?BJ-F[D7$D:LTHAQN)5%V61/ZY "9V
M4\=SGC9NZ:;0=L.-HXIL8 GZOKJ1)G)[EIR6P!45'$E83YUS[RP);7Z3\)/"
M3@W6R#I9"?%@@WD^=; 5! PR;1F(>6TA <8LD9'QN^-T^BLM<+A^8K]JO!LO
M*Z(@$>P7S74Q=3XY*(<UJ9F^%;MOT/DYL7R98*IYHEV;.\$.RFJE1=F!C8*2
M\O9-'KLZ# !>N ?@=P#_7P%!!P@:HZVRQM:,:!)'4NR0M-F&S2Z:VC1HXX9R
M^Q676II3:G Z3JX7B_G=XC*]6Z+S=(:2Z_1NGGZ]3)/YY1(=S$ 3RA1*B93$
M%OP0':'[Y0P=O#^,7&T$6!HWZRZ[:"_S]URVA.H8!?@C\K$?CL"3M^'?:[X/
M[AK;O7>_]^XW?,$^[Z(LJ3:_I%:(\!QE@FO*-\ S"@H=I$(#\L)1GRUQ.$YL
M.^],522#J6-:2X'<@A-_>.=-\)<QU_^)[%D-@KX&P5OL\;4N0*(?E*PHH]KZ
M3FHI34G&7+=4DX;*CH=M[&'L!2<X<K=#0Z_S/H>A-TA[)C7LI89O2CW/,EE#
MCEK)3/#-D099#L6/B0Y?B_;PY!2_%#V2AP,_P"]5NX-FLX-N0>2&<H48K T2
M'Y^>.$BVPZ,-M*B:_EL);;JY619FWH*T">9\+<R/U@6VI?L)'O\%4$L#!!0
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M D6P4D.=3D\EA.>G[;PA69J=<!=,JO-R=KL!&@#7'=3[%6/RT- .RO\\QK\
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M^:PHUHJ.H%E>7(RID*5*WES(^A:8"I#/9Y2*34=-4%7,P3]02P,$%     @
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M5N5!VO7&!YVN5YL9G6TDZI5MH7\0"AX:EJT*8F_'QF2B#MJ:A\9<0VDVE.9
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MET11DO@1P/P*H@A#8#?B"*8 -&!(%#7GX,YY%*[/J7#S.]'D%U!+ P04
M" #)2&Y9EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M2P$"% ,4    " #)2&Y9!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,E(;EF(!MSQ[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ,E(;EF97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ R4AN6=,D[,7/!0  OAX  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ,E(;ED0N:.[LP4  .P6   8              " @1(.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #)2&Y9O9&1$^X"  "@"@  &
M            @('[$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ R4AN6:=E2 .W!   #Q   !@              ("!'Q<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,E(;EF^O>-FS 8  #4I
M   8              " @0P<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #)2&Y9:_-M+<8&  "F&@  &               @($.(P
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ R4AN6>1VL9$L
M"0  9A4  !@              ("!"BH  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( ,E(;ED(9$KO^@,  &$)   8              "
M@6PS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #)2&Y9
M-=BMGBL+  "J'   &               @(&<-P  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ R4AN62G[(A>2 P  /@@  !D
M     ("!_4(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M" #)2&Y9-H10FV$%  ",#   &0              @('&1@  >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,E(;EE6:'3:*@,  &H'   9
M              " @5Y,  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ R4AN6<0'NB9J P  ?P<  !D              ("!OT\  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #)2&Y9;'*]66H#
M  "3!P  &0              @(%@4P  >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( ,E(;EEP)M5^>P(  +<%   9              "
M@0%7  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ R4AN
M629.Q^72 P  )PD  !D              ("!LUD  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #)2&Y9+Y]'8:@"  #/!0  &0
M        @(&\70  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( ,E(;ED5ND5!] 0  !X+   9              " @9M@  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ R4AN624/<=^0#0  /2L
M !D              ("!QF4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #)2&Y91)D&&2$,  #8)   &0              @(&-<P
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,E(;EEFEA"R
M70(  #L%   9              " @>5_  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ R4AN61HF5_^5 @  C@4  !D
M ("!>8(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #)
M2&Y9U%'TP)D"  #;!0  &0              @(%%A0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,E(;ED/%PT4LP(  +T%   9
M          " @16(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ R4AN69L4U'MA @  . 4  !D              ("!_XH  'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #)2&Y9&[_QJL $  #U
M"P  &0              @(&7C0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( ,E(;EE=:$/ &P,  .$*   9              " @8Z2
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ R4AN65@:
M1EY: @  (P4  !D              ("!X)4  'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    " #)2&Y9:_]%&=H#  "D#0  &0
M    @(%QF   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M ,E(;ED:2H90M (  -,&   9              " @8*<  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ R4AN62\J';N1 @  *0<  !D
M             ("!;9\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #)2&Y9=#V%9[H"  #T!P  &0              @($UH@  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,E(;EGXOD7^IP(
M !$'   9              " @2:E  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ R4AN64AER#5Z @  BP@  !D              ("!
M!*@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #)2&Y9
M/4Z]#>$"  "J"   &0              @(&UJ@  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,E(;EFM*@3.1P(  ,L%   9
M      " @<VM  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ R4AN64-;U3IJ @  S04  !D              ("!2[   'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #)2&Y9E<C)J!0#  "2"@
M&0              @('LL@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( ,E(;EECTL,3=P0   07   9              " @3>V  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ R4AN65!]F'0D
M!   _Q   !D              ("!Y;H  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #)2&Y9DO54[$,#   ]#P  &0
M@(% OP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,E(
M;EE1T$%O10X  '23   9              " @;K"  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ R4AN64F4&-,< P  -!(   T
M         ( !-M$  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #)2&Y9EXJ[
M',     3 @  "P              @ %]U   7W)E;',O+G)E;'-02P$"% ,4
M    " #)2&Y9L%W83>0#  !K'   #P              @ %FU0  >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ R4AN6;[+,T&9 0  =1D  !H
M     ( !=]D  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ R4AN62/5;@VH 0  N!D  !,              ( !2-L  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #( ,@"5#0  (=T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>77</ContextCount>
  <ElementCount>235</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements</Role>
      <ShortName>NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - ASSET PURCHASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreement</Role>
      <ShortName>ASSET PURCHASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi</Role>
      <ShortName>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - AGREEMENT WITH FOSUN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosun</Role>
      <ShortName>AGREEMENT WITH FOSUN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - AGREEMENT WITH KWANGDONG</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdong</Role>
      <ShortName>AGREEMENT WITH KWANGDONG</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - STOCKHOLDERS DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiency</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyTables</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiency</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>ORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/ORGANIZATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AssetPurchaseAgreement</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosunDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH FOSUN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithFosun</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdongDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH KWANGDONG (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithKwangdong</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails1</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails2</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails3</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptn-20240930.xsd</File>
    <File>ptn-20240930_cal.xml</File>
    <File>ptn-20240930_def.xml</File>
    <File>ptn-20240930_lab.xml</File>
    <File>ptn-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ptn_10q.htm">ptn_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ptn_10qimg15.jpg</File>
    <File>ptn_10qimg17.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="275">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ptn_10q.htm": {
   "nsprefix": "ptn",
   "nsuri": "http://ptn.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "ptn-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptn-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptn-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptn-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptn-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ptn_10q.htm"
     ]
    }
   },
   "keyStandard": 160,
   "keyCustom": 75,
   "axisStandard": 7,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 18,
   "hidden": {
    "total": 19,
    "http://fasb.org/us-gaap/2024": 14,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 77,
   "entityCount": 1,
   "segmentCount": 25,
   "elementCount": 313,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 275,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://ptn.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheets",
     "longName": "000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - Consolidated Statements of Operations (unaudited)",
     "shortName": "Consolidated Statements of Operations (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ProductRevenueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ProductRevenueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
     "longName": "000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "shortName": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://ptn.com/role/ORGANIZATION",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ptn.com/role/BasisOfPresentation",
     "longName": "000008 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements",
     "longName": "000010 - Disclosure - NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS",
     "shortName": "NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ptn.com/role/AssetPurchaseAgreement",
     "longName": "000011 - Disclosure - ASSET PURCHASE AGREEMENT",
     "shortName": "ASSET PURCHASE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi",
     "longName": "000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "shortName": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ptn.com/role/AgreementWithFosun",
     "longName": "000013 - Disclosure - AGREEMENT WITH FOSUN",
     "shortName": "AGREEMENT WITH FOSUN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ptn.com/role/AgreementWithKwangdong",
     "longName": "000014 - Disclosure - AGREEMENT WITH KWANGDONG",
     "shortName": "AGREEMENT WITH KWANGDONG",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ptn.com/role/FairValueMeasurements",
     "longName": "000016 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ptn.com/role/AccruedExpenses",
     "longName": "000017 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ptn.com/role/CommitmentsAndContingencies",
     "longName": "000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ptn.com/role/StockholdersDeficiency",
     "longName": "000019 - Disclosure - STOCKHOLDERS DEFICIENCY",
     "shortName": "STOCKHOLDERS DEFICIENCY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ptn.com/role/FairValueMeasurementsTables",
     "longName": "000023 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ptn.com/role/AccruedExpensesTables",
     "longName": "000024 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesTables",
     "longName": "000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ptn.com/role/StockholdersDeficiencyTables",
     "longName": "000026 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ptn.com/role/OrganizationDetailsNarrative",
     "longName": "000027 - Disclosure - ORGANIZATION (Details Narrative)",
     "shortName": "ORGANIZATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:RetainedEarningAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:RetainedEarningAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30_us-gaap_ProductMember",
      "name": "ptn:RevenuesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfSalesTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30_us-gaap_ProductMember",
      "name": "ptn:RevenuesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfSalesTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative",
     "longName": "000030 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)",
     "shortName": "ASSET PURCHASE AGREEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
     "longName": "000031 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)",
     "shortName": "AGREEMENT WITH FOSUN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative",
     "longName": "000032 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)",
     "shortName": "AGREEMENT WITH KWANGDONG (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "000033 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ptn.com/role/FairValueMeasurementsDetails",
     "longName": "000034 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:CarryingValueDuringTheYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:CarryingValueDuringTheYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ptn.com/role/AccruedExpensesDetails",
     "longName": "000035 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:CostClinicalStudy",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:CostClinicalStudy",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:OtherLiabilitiesCurrents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptn:OtherLiabilitiesCurrents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails",
     "longName": "000038 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails1",
     "longName": "000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails2",
     "longName": "000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails3",
     "longName": "000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:RestrictedStockVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
     "longName": "000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:StockBasedCompensationToStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-09-30",
      "name": "ptn:StockBasedCompensationToStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r463"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_AccountsReceivablePurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivablePurchase",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acounts receiveble",
        "documentation": "Amount of increase from purchase of accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptn_AccruedLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AccruedOtherLongTermLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AccruedOtherLongTermLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Other long-term Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptn_AccruedSellingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AccruedSellingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r463",
      "r590"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "[Additional Paid in Capital, Common Stock]",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r501",
      "r502",
      "r503",
      "r504",
      "r548",
      "r591"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory purchase commitments",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ptn_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AggregateValue",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate value"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AgreementWithFosunAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH FOSUN"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AgreementWithFosunTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosun"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH FOSUN",
        "label": "[AGREEMENT WITH FOSUN]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AgreementWithKwangdongAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH KWANGDONG"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AgreementWithKwangdongTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdong"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH KWANGDONG",
        "label": "[AGREEMENT WITH KWANGDONG]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential number of common shares excluded from diluted EPS",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ptn_AssetPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AssetPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSET PURCHASE AGREEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AssetPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "AssetPurchaseAgreementTextBlock",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSET PURCHASE AGREEMENT",
        "label": "[ASSET PURCHASE AGREEMENT]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r99",
      "r122",
      "r153",
      "r157",
      "r163",
      "r164",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r269",
      "r273",
      "r302",
      "r334",
      "r402",
      "r450",
      "r451",
      "r463",
      "r480",
      "r518",
      "r519",
      "r556"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r104",
      "r122",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r269",
      "r273",
      "r302",
      "r463",
      "r518",
      "r519",
      "r556"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "ptn_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ptn_CarryingValueDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "CarryingValueDuringTheYear",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "[Cash and Cash Equivalents, at Carrying Value]",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r443"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashAvailableForDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAvailableForDistributions",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend",
        "documentation": "Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CashAvailableForDistributionsAdditional": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "CashAvailableForDistributionsAdditional",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend additional"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57",
      "r119"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r57"
     ]
    },
    "ptn_ChangeInFairValueOfLiabilityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ChangeInFairValueOfLiabilityClassifiedWarrants",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of liability classified warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r100",
      "r101",
      "r102",
      "r122",
      "r144",
      "r145",
      "r147",
      "r149",
      "r155",
      "r156",
      "r170",
      "r180",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r192",
      "r193",
      "r196",
      "r199",
      "r205",
      "r302",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r390",
      "r411",
      "r428",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r487",
      "r499",
      "r505"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r178",
      "r179",
      "r439",
      "r514",
      "r515"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r501",
      "r502",
      "r504",
      "r548",
      "r589",
      "r591"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r390"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r390",
      "r408",
      "r591",
      "r592"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 19,548,167 shares as of September 30, 2024 and 17,926,640 shares as of June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r336",
      "r463"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r85"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r445"
     ]
    },
    "ptn_ContigentlyRedeemableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ContigentlyRedeemableWarrantsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contigently Redeemable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConvertibleSeriesAPreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ConvertibleSeriesAPreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series A Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CostClinicalStudy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "CostClinicalStudy",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Clinical / regulatory costs",
        "label": "[Clinical / regulatory costs]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CumulativeEarningsDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CumulativeEarningsDeficit",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increased accumulated deficit",
        "documentation": "Amount of cumulative earnings (deficits) for relevant time periods."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CumulativeFromInceptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "CumulativeFromInceptionMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative From Inception"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "CurrentMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleLiquidationPreferencePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible shares",
        "documentation": "Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "ptn_DescriptionOfExistingHolderPurchaseOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "DescriptionOfExistingHolderPurchaseOfWarrants",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of existing holder purchase of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DescriptionOfSecuritiesPurchaseAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "DescriptionOfSecuritiesPurchaseAgreement",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r143",
      "r144",
      "r147",
      "r148",
      "r149",
      "r152",
      "r264",
      "r267",
      "r285",
      "r286",
      "r331",
      "r344",
      "r447"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r151"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r92",
      "r108",
      "r109",
      "r110",
      "r123",
      "r124",
      "r125",
      "r129",
      "r136",
      "r138",
      "r140",
      "r154",
      "r171",
      "r174",
      "r176",
      "r207",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r320",
      "r343",
      "r353",
      "r354",
      "r355",
      "r371",
      "r428"
     ]
    },
    "ptn_EquityExpensesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityExpensesProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Expenses, Proceeds",
        "label": "[Equity Expenses, Proceeds]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityExpensesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityExpensesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Expenses, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityFeesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityFeesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Fees, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityGrossProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityGrossProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityNetProceedsProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "EquityNetProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisePricePerShareWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ExercisePricePerShareWarrantsOutstanding",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisingHolderReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ExercisingHolderReleasedShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercising holder released shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value asset measurement",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r549",
      "r550",
      "r554"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level Axis",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r323",
      "r324",
      "r325",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r330",
      "r460",
      "r462"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r213",
      "r288",
      "r296",
      "r323",
      "r455",
      "r456",
      "r457",
      "r460"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r213",
      "r288",
      "r289",
      "r296",
      "r324",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r460"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r325",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r323",
      "r324",
      "r325",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r460",
      "r461"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligations",
        "label": "[Finance Lease, Principal Payments]",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317"
     ]
    },
    "ptn_ForeignCurrencyTransactionLossGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ForeignCurrencyTransactionLossGain",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction (loss) gain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation of foreign currencies",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain of the sale",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ptn_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r63"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r364"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company License Agreement Recievables",
        "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r497"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "[Interest Expense, Operating and Nonoperating]",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r157",
      "r160",
      "r161",
      "r164",
      "r310",
      "r450",
      "r451"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r117",
      "r118"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r444",
      "r463"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "JanuaryTwoZeroTwoFourPrivateWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "JuneTwoThousandTwentyFourSerisAWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2024 Seris A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "JuneTwoThousandTwentyFourSerisBWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2024 Seris B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_LatestTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "LatestTerminationDate",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Termination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r122",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r270",
      "r273",
      "r274",
      "r302",
      "r389",
      "r448",
      "r480",
      "r518",
      "r556",
      "r557"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' deficiency",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r76",
      "r338",
      "r463",
      "r500",
      "r512",
      "r555"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' deficiency:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "verboseLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r96",
      "r122",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r270",
      "r273",
      "r274",
      "r302",
      "r463",
      "r518",
      "r556",
      "r557"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsForVyleesiabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ManufacturingSupplyAgreementsForVyleesiabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ManufacturingSupplyAgreementsTextBlock",
     "presentation": [
      "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
        "label": "[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketRiskBenefitLiabilityAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for the warrants amount",
        "documentation": "Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r466",
      "r551",
      "r552",
      "r553"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ptn_MayTwoThousandTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "MayTwoThousandTwentyTwoWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_MoneyMarketAccountsAndTreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "MoneyMarketAccountsAndTreasuryBills",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market account and treasury bills"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r60",
      "r77",
      "r94",
      "r105",
      "r106",
      "r110",
      "r122",
      "r128",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r146",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r264",
      "r267",
      "r286",
      "r302",
      "r342",
      "r410",
      "r426",
      "r427",
      "r478",
      "r518"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://ptn.com/role/NewAndRecentlyAdoptedAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r93",
      "r126",
      "r127",
      "r130",
      "r131",
      "r141",
      "r142",
      "r168",
      "r172",
      "r173",
      "r262",
      "r263",
      "r265",
      "r267",
      "r280",
      "r283",
      "r319",
      "r321",
      "r322",
      "r327",
      "r328",
      "r329",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "ptn_NumberOfOutstandingSharesOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "NumberOfOutstandingSharesOfRestrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of outstanding shares of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2022 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OctoberTwoZeroTwoThreePlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2023 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OctoberTwoZeroTwoThreePrivateWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2023 Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recievable under company agreement",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ptn_OneToThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OneToThreeYearsMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 - 3 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r449",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in right-of-use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ptn_OrganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OrganizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r73",
      "r361",
      "r362"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "[Other Accrued Liabilities, Current]",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r463"
     ]
    },
    "ptn_OtherLiabilitiesCurrents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OtherLiabilitiesCurrents",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "documentation": "Amount of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r75",
      "r559"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "[Other Nonoperating Income (Expense)]",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER (EXPENSE) INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r513"
     ]
    },
    "ptn_OtherResearchRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "OtherResearchRelatedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other research related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForPurchaseOfOtherAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForPurchaseOfOtherAssets1",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable the settlement of certain purchase commitments",
        "documentation": "Amount of cash paid to purchase other assets as part of operating activities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payments",
        "verboseLabel": "Upfront payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r496"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of withholding taxes related to restricted stock units",
        "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_PaymentsToAcquireReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireReceivables",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment receivable",
        "documentation": "The cash outflow for the purchase of all receivables."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ptn_PaymentsToSalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PaymentsToSalesBasedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales-based milestone payments",
        "label": "[Sales-based milestone payments]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PersonalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PersonalCost",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personal cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r192"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r390"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r192"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Convertible preferred stock were outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r390",
      "r408",
      "r591",
      "r592"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of September 30, 2024: issued and outstanding 4,030 shares as of September 30, 2024 and June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r335",
      "r463"
     ]
    },
    "ptn_PrepaidClinicalStudyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PrepaidClinicalStudyCosts",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical / regulatory costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PrepaidInsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PrepaidInsurancePremiums",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Fees, Proceeds",
        "label": "[Proceeds from Fees Received]",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock and warrants, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Proceeds",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from exercise of Existing Warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenue [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service Axis"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r326",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r442",
      "r454",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r516",
      "r517",
      "r520",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "ptn_ProductRevenueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ProductRevenueNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product revenue, net"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ProductSalesAllowancesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ProductSalesAllowancesAndAccruals",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product sales allowances and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "auth_ref": [
      "r165",
      "r326",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r442",
      "r454",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r516",
      "r517",
      "r520",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r105",
      "r106",
      "r115",
      "r122",
      "r128",
      "r136",
      "r139",
      "r140",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r264",
      "r267",
      "r268",
      "r271",
      "r272",
      "r286",
      "r302",
      "r332",
      "r341",
      "r370",
      "r410",
      "r426",
      "r427",
      "r458",
      "r459",
      "r479",
      "r493",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r318",
      "r333",
      "r340",
      "r463"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r86",
      "r89",
      "r339"
     ]
    },
    "ptn_PurchaseOfWarrantOfCommonStockSeriesA": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PurchaseOfWarrantOfCommonStockSeriesA",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant of common stock series A"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PurchaseOfWarrantShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "PurchaseOfWarrantShares",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently redeemable warrants amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r65",
      "r66"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r440",
      "r450",
      "r558"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ptn_RestrictedStockVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "RestrictedStockVestedInPeriod",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_RetainedEarningAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "RetainedEarningAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "[Accumulated deficit]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r337",
      "r356",
      "r360",
      "r369",
      "r391",
      "r463"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r123",
      "r124",
      "r125",
      "r129",
      "r136",
      "r138",
      "r140",
      "r171",
      "r174",
      "r176",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r277",
      "r278",
      "r281",
      "r284",
      "r311",
      "r312",
      "r353",
      "r355",
      "r371",
      "r591"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r441",
      "r446"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r111",
      "r122",
      "r153",
      "r158",
      "r159",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r170",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r302",
      "r332",
      "r450",
      "r518"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_RevenuesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "RevenuesGross",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross product sales"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Previously Issued Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SaleOfCommonStockNetOfCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SaleOfCommonStockNetOfCostsAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SaleOfCommonStockNetOfCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SaleOfCommonStockNetOfCostsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SalesBasedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales-based milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schdule of Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfEquityDistributionAgreementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ScheduleOfEquityDistributionAgreementTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory purchase commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfSalesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ScheduleOfSalesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ScheduleOfStockPurchaseWarrantsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ptn_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SeriesAConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SeriesAConvertiblePreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at beginning of year",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "[Outstanding at beginning of year]",
        "periodEndLabel": "Outstanding at ending of year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expirations",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Number of shares outstanding granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units number of shares outstanding granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Exercied",
        "label": "[Number of Options Exercied]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Forfeited",
        "label": "[Number of Options Forfeited]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r218",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options exercisable at end of year",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at end of year",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options Expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SharesOfCommonStock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of Common Stock",
        "verboseLabel": "Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SharesReleasedFromAbeyanceAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "SharesReleasedFromAbeyanceShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r120"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Class Of Stock Axis",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r100",
      "r101",
      "r102",
      "r122",
      "r144",
      "r145",
      "r147",
      "r149",
      "r155",
      "r156",
      "r170",
      "r180",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r192",
      "r193",
      "r196",
      "r199",
      "r205",
      "r302",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r390",
      "r411",
      "r428",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r487",
      "r499",
      "r505"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r46",
      "r47",
      "r92",
      "r108",
      "r109",
      "r110",
      "r123",
      "r124",
      "r125",
      "r129",
      "r136",
      "r138",
      "r140",
      "r154",
      "r171",
      "r174",
      "r176",
      "r207",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r320",
      "r343",
      "r353",
      "r354",
      "r355",
      "r371",
      "r428"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r154",
      "r312",
      "r326",
      "r363",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r473"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r154",
      "r169",
      "r312",
      "r326",
      "r363",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r428",
      "r473"
     ]
    },
    "ptn_StockBasedCompensationToStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "StockBasedCompensationToStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation to stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r68"
     ]
    },
    "ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitshares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Withholding taxes related to restricted stock units, shares",
        "label": "[Withholding taxes related to restricted stock units, shares]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, amount",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r42",
      "r43",
      "r68"
     ]
    },
    "ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation related to restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_StockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "StockWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficiency",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r62",
      "r392",
      "r408",
      "r429",
      "r430",
      "r463",
      "r480",
      "r500",
      "r512",
      "r555",
      "r591"
     ]
    },
    "ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS DEFICIENCY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS DEFICIENCY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r121",
      "r191",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r282",
      "r431",
      "r432",
      "r438"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalDeferredPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront purchase price amount",
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "ptn_TotaAcrruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "TotaAcrruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Total]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwentyTwentyThreeEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "TwentyTwentyThreeEquityDistributionAgreementMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "TwoThousandTwentyFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnrealizedForeignCurrencyTransactionLossGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "UnrealizedForeignCurrencyTransactionLossGain",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized foreign currency transaction loss (gain)"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "UnvestedPerformanceBasedStockOptionsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted estricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UpfrontPaymentOfLess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "UpfrontPaymentOfLess",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment of less"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r83",
      "r84",
      "r87",
      "r88"
     ]
    },
    "ptn_WarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "WarrantsToPurchaseShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r149"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average vested restricted stock units",
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_taxexpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20240930",
     "localname": "taxexpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29G"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001654954-24-014335-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-24-014335-xbrl.zip
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M.5 'STV<E@<1HVY: DQ,MKVUXD4NB!9I-!DB(';435@482?;ZOH0%,$(ZMH
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M?',M.&VNVW4J^>-1=,1^^1]02P,$%     @ R4AN61^VDC0C%@  83\! !0
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M(I2;]:Z=EZ,I_1S_>$3<_NO_ 5!+ P04    " #)2&Y95#1T07I$  #G?@,
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M <_15^B[E]]>41 CW+Y-\HRB=1SC30P_(-**4Y]>MVA(47L5V-C 3L<SM+!
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MT1F[B%ICZH(<<"EQ@4]*5<>90/P?"Q1;"60M:2%G N3*S*D? (?Q&5:G>Y1
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MFW'S> FCP ^>XCL4T8FCIDR-7/IT2K$!1=5J8&'!M:TW&]D0$FP%MO90!DK
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M*.Q?60.TS<!N@V^Z'+P85;U K'BPA[# =)-_CV)$-C[WB%Z8O10?.,K)]>B
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M!4V^7&!-!U2G?B8)I*) )<ENB,2.H^N/-?9DK'( 'U\'=RCR0U?6FY5Q-()
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M^8O>DH^W(BZ!+&1";N$I(I0&K^@2IG#[#L>^?M-[\+%<W)V/C;3"^K]\K.#
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MA]:JW?6FT]W@< A@.[YN2N+7>;J)TH1><"(E_B>2(=Z/@69JGBF)R]M0,N\
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MZ*:G3%U)D@34<)@MC2J4TX2B=]'Z3V^['W\)4(R9\?3VA503K0E4/YZCS/Y
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MVQ ## W92+2'KLPSM#=GMQ.W$L-\)C_Z)O0)CPDL69#4_T'DL3C <- _'Q'
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M[B^3[=\FC/18G88#KN+:PHOI=5657HC[I98?QM22Y M[1BM>U[/?-5A*:%V
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M K/8UZG\"G",XFLX/Z7YT87G3#;&)8L(MRP!GYL^ADXD<.)5V(( O@</TFC
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M(6LNX/,-P<W<]TNA&]L'W :!Y(V@V]@*NK'G3AV_@!A5,L$&8)*J@3.,15E
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MFJ&:J%0QLQ4?QM8%NNKHKH3Y%X8^[URG^DY]GV;@G!<^8&A#NT.PA0*B2^^
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MWG)&6]T.WMCL=O!&!H=B"7T3E\E_E]Y%4OF]=/.7;WB3 [@[_.0X>F4T[0%
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M.5LJ?J(0]G1F/>;:I^U#<Z4A8T09J\^LU'>8^J.D#N =%Y)JOJH3%YY;H=Q
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MHMDLHNAP2JQ N'QSO^/-Y.NLE* I4IK2YA96>>)#8=Z.[CN!6<6_Q"ORT2Q
M2\+S>5T4'?/PC#'=@#T(,TC1: CW+(?1]'KB/#V]Z.[PPF97E'E!C:-CZYB.
MSU[-3:P(8K+T@8V=F3!7DGX#WNFKUH\@B0-L1E%>RK,Y8UD7;MA\Q7>T(<]N
MPL9O(@W/Y/5*JC7EZ9SS6<4G(TY$F;XXM-.:2H'Z9EMLPH,[XE3$!;(^H;OM
M.Y//8.MF<@&/(K>;-;G>K*<[_/-G7ZZ5=S3][:Z#++?:LJ(D;VNA' *D$9L$
M5<M!4@W(HI06!;C<F;- $1,E-R6/<?5ZH@3W"[AL5&8;ZSW9C=*EN%@X &F
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MYOB:^G>3T)U!K;<2$_!-I6MI4G>.1XN"'>;Y-<(Y=$0K22R(#7RFX.W49C-
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M?TU<9Q7<7A>KY5Z)GN+&H7@66S!R2L\R7-O,%;@4N!P[>"X<5A\.1%(@O_+
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M[,L?5O_X_.+ZY-CJ'QV=?SL#TOG5NK@\/X._CTZ^PB-7+W!ZSU8=ZPPKL*-
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M8<V8-=B[OTEUJ5GS2PNV9$(L":INYI4K#0UMM,ZM\/)F+E>7CDW2FNR?(^W
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M._<K0] T96[%"?#T3<IOE (#-DQS*W0HYNM&_E@"$]N2\6M=P/6>6A<KH%=
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MJI6W5)(:N-4!5J6+7PF>%(N[KS"BORQE;JLSW;\S+;%QORI=O+.*FDOA6@#
M3 7:G90LMCMMQ^XX]Q>N*L&Q50BSC#"U1R',D^J<V:U:S^Z\]JJ8+UVPF--
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M!K  ?@>N87IV9^Z"3B_T!+(M%W:+ZX)A/7A@&"-6CA-R/(),XL/(/#.><+Q
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MI>>/O%MO!/<%QGJ$:K7N#=S@-XB9Q/Y="[$T1,>L',X2X[%@UFUN R"F7;B
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M/.KZ>*H.B<11K$+>SX0*B6J91# V;/ BCIX-N.@]CI[U6UOGZ%G_YF:.GC=
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M C8C2O5PG)\X1?:S3%W;-.O 'Q4T0]<)  3^@P$E%F#:E? C[HEJ=*;G8/5
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M4FN;6VH86VH\>4M=V%%!6S!XBU>)R*N6>4!"RVJZ6$%^ ;:+2HG0MF 5*-O
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M('V"\ S"J8>H$%@7B)2G-D@3L'C:Q@0H!.= ?E2O_70%$C>BX!G@'(QT \O
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MNUF0:/%E=9E+08-.4\H**!Z/0>VDZR$8 !3BA6EK& 8';I9,@2@&B-K(Y4F
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M4$NB\S'\*L)GD:U*<(W]7R4_5LO?PO(KV:<:LQISG\;<']FGKF6?-Q:\MP2
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M*@.*\>=A;@VV);X/Q5P7S1<HFL&GB1O3YU#<>%$<8IA[-!=#6N<4 &6L)K*
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M;4Y0"]296RX+HMV3PQJV!J)U%2_#%$^B0@0)[B];3NO%-_O/A35G;.ET?DL
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MN.+#YVZ]68VOU"/6TPDBMTKB">,2T.?"Q5-DC/21-%>D4IA;\$I OU=JW]U
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M\Y 7/.("V]\&B8&OCWGN+BW/<I$QGR( *^9E\''C 6@J</8]W.''S<?#!PC
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M:H( =FD\'%75\4>>$O]#6.!YCFLP(0)0./$'LX^1 )[!=EN1@+Q8_R/PUE]
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ME0IZZJ)I'$H*FD)RPVNZENH]*8L@!."_D'BD 9$J[ 1"D1J=>]6LTK%C.$P
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MS2):$MTWY$[.A1F,,]5&]G2(?<]NP!Z52F_<(A*H$Z6!'?2<%/8)=P=O)VA
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MX*.\9.UG>:>H6@A+D6 R+4BC6IF7.^GM^$!UN&-7XU!TGFC[@<-;>;UZ-\B
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MK!/69&<]=,L$%KO>%K-^-O/50Z=1)T^'$!!!$8P?LYG\HRY79IT-J7RY/V:
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M=]2?US _S9:3FW&-[G%(K'<O^-<DJN5+R!:H #Z.@PL:=!&JJ=]%'L,]91
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MG)4P5AA+*B*AL)[;< <<(K"IJ&*$W]1C94>:!JG0U7GWK%>0NYM"Z//""93
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ML")'&[USH-[#K6J7I<ER]S,EMSPWYONF508G$JH=TJ=-<ZFUL_Q^F\X^5D)
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MX-B%BJLG22;IO4]C$W8+\NA#\>9N42F/WBE<=)(\A5>)+9!,_E5S=KU;#WS
MW^1#W'>CEK^4 Y1^\-<B^-7=E!K\XX6\+C;X@31AOW:U(CM Q<VO/>E0,U/&
MIYYY^3?;Q#_T6NT=&F4Y@>YZ<WHNX#+-RI8UV!!R;Q:9?F)@68UJ@*M#X.3H
M>,%4_1@6/?>-,SB:9?.$BW$'+[!W_6'*%17(F#Y_!CO!V)U/\A5"\L-ID0DO
M\:)8(27%@]A'G1A?]CS(X'%9'N!*;QWJS>0V*_K)TX0 I1AI_@S[J9W.<W(3
M-O5[:>)ERQDI/C7G6N\\8N9!80(.Q.O'HP\W[EIYM6VX[TWR[]WF>T1/>M+T
M+>PTL&F]5*)N#AS8P!.O6%H>M*)06E,ZDC',Y2 V;NIC%K?0K9/5/AB6J[?$
MV,P9@9J7B0'=EQ58>$C6 B2S]"7?-8]W*-"Y+#,(85FHYIJT*]W#;'AV&T[O
M'7S>_73PT3.;3Q4[L^VXW 9E.UD1&6XU!A&)C(5QZ78BBL_W%4SXMJ:DT'ES
M=GF,,TUOI^&G=QF;5F+D98B1,@-<F=.**:IWF-O8)T7?K>R^K%-KYB 8GS)(
MS)";MN<I)0)N&RCJX:X4M5_83GB#=H/2"V_M:I:((R!L/P5C9)(R0Y9GG"C"
M2@.QVA1J_ 0W;ZGH]V,4K434J<:HE_MP]4GU;Y3;B1O8<:1KWR<4<</*0./P
M9)XI&OKGAI1BLMUC&"[HFR]#LN30J[@1KLUW>O%6=;GPEP^^WL4T!X0=4;-/
ML"\9A0 QO=4;1(<KPC&4X[6_#F<+ 5>7E")KG3L[Y19$:"-@$S6.7W,>QN4?
M\&?'>"7-[@QJ&1TP71_:WW/]<>4*@,OH>@5X; L\H9J]D/:$7+"#WC4>,/Y,
M/=X$7V_JU;F01JY(;G7DJK.YWM5;L.%8/S;CT(4V78>_6]/7-D,?_*AA4$N^
MMH;1+G._NZ3S1^\W1ZQH%-@S+ZV2RXC]\P'?BKV^%E"@+X<1I55-WSO^Y'!F
ME2$FO8QE/]/$L5B-9RH4S0P+;[:--*X 5E)(+V@/VA[2B@T)%U:O8$X/&%29
MICNG7CG^?&GYJ[-6V;P#7HF%79Y9@\JO?X?7 AZO%<1M^$7,[&**!*Q,YZMP
M'2,2$';*!H^9UG"1G%8JJYQ[@_>WK[?6AG,^88Y_?050 @MF=-5? ;)!R6J7
M#:#3XRHD@S(0*.S7[MC5@5S,I9DKP!"P)W=O&[P&61YN=/BU"W<@8W/WUR[<
M,WYK5$_WQ@/8OK5)L]<Z])A^USKF]\/@9^$R2F0 \!B]3)K6?\]"WO0'V2/1
MOFWILX%?W7#JQ'7M!3OD_& 8;'DMF2*D9%3=T,$F=8@#HT+@KT[^,AW_8N^:
M?&79HP#0?N<"XE* S%AH YJX3K9L[7 M#*2[5U9"# 8C/*; L]DYE_6@FXV_
M]P08Q&IGSTQ.*V@,MB]Y+R;B?U/O\[=0XM+^7TKLEHN-A[Q(\#Y_ZK_(S_C/
MY(N6OD/ /"]7&W4E?G4QYX^!ITO7"DR"_"T[KB;(AGOJ3.AAQD9\Z@'L,.^W
M,',1 \$(3WTDLY\WL/)[2Q.6E*-1:M]&M@S?&ZS"Z8]]'F1&"Y0*Z;6Z!U]4
M,N']7#2".[RX&+/6KS%9;L5I&BYL(?/,RUGFEE"_[ =M#Q78/?MX"[R(N!KY
MGM(^8JWNG[J\[YGH4502^XOPI]'WGG*MW>-&9K9@I3?%J&MCA!2NI '^[^B"
M[E8)DW/-?X!LA84L'H #$6([L7'1*=2[K[)9/O/]C!O=8RLPX'!*NU/KV/F8
M1Z2%U X6$]DCU 0F=L6VP9ZVT3.O>JV!;^69Q]_^([XR,I&L"_L^)_$)^:D0
M"SH\,J)7G C.V#:RKESD$T4ZOP(-8J]OHA%D)\Q,Z,6<A!GZ)]JD>4S,P%J)
M!-->CG#C5G[7W9$SH'?C^W"JU:FI>5]VYRQDZ8L$T%NW8O0*4 X)0<=U\<&!
M]I&L12L&ACO5+H?=>NSNNQ*)YBI<E*&]4Y3!'"J _<-VP[RT)HGRO>W6EI8K
M8HJKR<V,J*&=(RO6*2P)X'Y!WTAP;P_37N [E]U<TH0<T>9CYEOJ7[*5"X)Q
MY.RJZ;%:3JKTJ#'@M!70UZF$"EQS*)5U^296V&G.3:@&@N_OH(>1HJ&A4<SP
MG#@4>Z0:#14=G*^6ZRF^5I3[)NEX7I@5I,-P"_",G-5R=^B^'/RK]X,=6-N9
M0^@KRAZ%?66] E"IBJN/@_O]9%NGCM*FJ%B*"!FG+BK 0PMBE.H<2T,): V?
M=#'E<X;N?8YX*^=UH5C"MZSWI5A_S+*@Y]+OQ#E@>TRHW)E9VYU2@KH?1\OS
M"6;B%%+JW1E[8+O*8-#VZ+R*9J1WQIMZ5S8U_WO.3](G,S-3,[>K/]22N=7^
MT/ZP@BU&CT'/-AOFRS8@P6UU5#)E>;:<4S!I39:5I<RW00:59%AZ8NI'X%V&
M>LA>_71+A);ZPT-@JYP%:)=O)L^)@. R]T[VH\W^6[CW[ASYIT7KN'3TNE0H
MD\$%X^='D[K4JU+<"";+2?=(M2,] 7QL7))P[]B59:"_1Q<RLGM7)[M@H*4Y
M%*\RE)ZL'-(Y<2;:KM/E.:"PR;=Q_RL=B@BM=^O;VI":L3>N:PW *X#)M+[5
M1'I,*Z&UVNS,C$_*$ZA5:%[X"%8F+&#NA1252PA@E;M.'*X8%*Q;DK)KGS7T
MI=#\_;8F]EMHMQ69[ZBZ3Q\1H<31*$TLZ\Y8A+G_ R=X;93+\H/NT6.4NQ?]
M@5B"CH*8)XA]M#4(R"C0ERUI;Z';@.:4:82V)DDUMZ.L*@)N%?Z-.MBTB"&$
M?NQ.,$841/8$//])KX6S.#N=^HN@>WR/BV5459PQY?4.=::-DE-)]-RYF$<4
M+I:@NYG5$2(5S'&C=](Z(DZCM@R8WE<+G\I+?R#RPY-Q27DXBS.QKNGET^VU
MN"DV:QV5'K4TLTD@8O!CCJ #X.0GC!YE #!CH]"1$_/'O^V_*F0N3>E[I.W=
M:*1@S*5,P3_$8$WYZEWM4TJ.V_CU#_UPDO@L/_^C90[> A;*J]YL'_[K%S3>
M!7;P7?U5 MA\<C"TD<RQZA5L2G.J<QQ!%)[S(VFMB%HCW@4%YA7<&XKPP@+L
M*XI+P04^3TT;6!X_E\@32L8M0_]@=1Y']43.&#7_=!(BXN@T;/X1B@ -?#%4
M?./#]XWV48\]XUX+S#[8$D=L91]G2NBQ.*Y7XR>RBP-B3V0FW">IA"]<4G\2
M79,5554V;N?ZD']/$=,NGY2QO8VYL_,TS+/)]T%$B8W6[-W,87O?+H?7N(45
M6W.CHXKWM9M=E?VJ]D<^% @ZE2\,D:REO#+:[U==07I]\5L SVXO6&O/D+QG
M9GL@<R 2T-X@$?.T4L[74)8AVE%&>%UUTKI!8FC+MM ^W5,7L34SHN:!HF=F
MX^H>*2SB6$@U_Y;0N:O'2^L/2A]146_VM2KZR""4^7J8*B.L<'@4WC3TDW<0
M;W/'8J%; %QJ*RRLW(WNIH,%X=2/%3VW$%9+Y<_98#5*+W%/GCF1,^?BIN9D
MGPZ ^R1E;_"B+!-8 PFYN4RC[22V9O!G8#@T"JPN"3J*-9%::+V "#S112+K
M6;631!'N(Y[W1)[1#)7663^(IU$OK@ NMW:9GT/L?<AN5(/,[U;2TG!4<*9M
MA'1%*^OM!PP96]^1PY;>/Q/J_%FO;A)&X['=+#K<]Y#[=)5E_S/2V_@GX'].
M_"4MFFO)/4/[63Z[#D)FZ]<(B_FC3E.]7V4'!0TH[],C3JY+B>%?3'*SK_>B
M>*LNRU[NRF&H_G[DQ_QV&SKX14.;$>)Y"E-(O4$2)W?&^J=6:)'YPA_D8@R[
M@ LNK+RO__FU[2*B' 67>!:9_H5<ER8WL'522PM=8[\N3 X!N/[QB 5E81N_
M4#\?5>X8_Z-KP<TLZB6\R&SC&EO&S2R/_\-TR-SDAG'(C1!0RWP6#C,SK>BG
M?)U&8V[82Q]^[GV#_)JMM'^P1ZVY31?]FB(]P@0]6J:CE%N=P9CGS#7?T!0\
M2Y+!,6#W_]7VW5%-->N[ 024*E*D!^E2I7<B*DVD]R[2A8!(#2T4Z1T4!)3>
MJR"]%^E-NO3>04(/$,(-^I7SG7M^]YZU[KI_9*WL[)GG+3-[YIV=>9\QGL=)
MO)-BG@UG-_Z:,F^E&!\9W1*C8&_B2)^]&]-!IYO%5@!Q59,UX&:$/:2#144$
M!3K_8)KT;'Q]T:\_/=OJ@C2[I<"0=T0AWT(8?N@>'HGOCEKA.:R7>/$I;$A_
M@H0EQ=#* GV;F*O2:?-9(FGL2$>4OS(=+YB?Z^%QM=UA+[.3ZNGAROH4'JJG
MW X"RA=MNC>'5.ZP7X;AMO(1BY>7=VS(LL07]<5B378JO^$S&MYXB@)-?3'R
MJS<^IM6$+!J'J-D()<6GKFSM3>NNQI*G;,L&,EDS3XL7URRS!)OFK+)\GZ#I
M:H>&W@NQ+_;4X=@W$JB^9=S#<=#&R&%Z'R]1_/,Y0]/\A[T=![LUOQ?A&GNV
M@BZI3S>MYW]U+NS8H250&.[Z5<*WX89#0\5U \6\YZ1+GA#;LMNGG<.^U:]A
MW^*["VGQ84(1"+%EN8BS$#)%=#&1!Y%M\T_HM2U,>TE75W_.WA:/^:Z==_Y]
M@_;5QBA_DY.!-\SQ,5!2'X%_$%&A2NXI;4:I8%P^_\S\?58 _WIUP&0DN=RA
MY3BY*WE)*"B ,KOKW=H(UVK9ETBPW:@ZI7/X(96-V](S+4TFF>7=@.[I^PXG
M%)+M__I08(=L+>!X.KPB-3T0:(Q[CCZG:,K7SA[Q)1!GB;?V,#E'-+1Z28)[
MV?)T/YS34Y6D[KU];I@-1I[!AE)--)W!>PIAQU@YU<-5HCBC?\*&;B[<1BB8
M6&9W797A^TWEI#!_K:KA??KF^X*"XT.18%(UQG-2%]\SI<=84:2>G ?,C<M0
M(IN[.INOV,^+$86.CO1,JSPAPC6J%/W)JPOUG+[W6#'BC,8WI%-/PI+$-\M2
M>1P^.>\_IB5B:0.27/EK:X7))JM^U&7*7IC6D5F?%U(5Z%?&O6/P]:N@_*Q@
M'H.=<OV3<@ZBHJ)2^CR\WGHIX57?'QYJYV4K8ATLGU'=D,N+[\4=UAS(WT,7
MX)]/-D RU/*/H?*F/Y&E_R*"$]PM>E=HF3(N\#LCKZ&P TC*B.K\/X^+C7J%
MCW_L,<0/]6K%KZC%?#8U#_>OQ)%G?*T9* =N]PT]T455J"DEX_9%B.4:VNA=
M X**UA5E=(I_ZMJ:QBKD6J!AK'K^H*..Z\0$.)XV4_)3E"8KUPT[<TK^!)9[
MY8CEA$@.G<9+1SDL3&Z\DM6\+=\I\]:9,&I:8>O>0+I5M:.!XNL]:Z9V&7IK
M1(6SC,KEZ;*.]TN>1,"@34Z4%ORI5TXK,7<@<LAA-: ZY7:T/ZNNJ98,A9JW
M5BMMT,AG@C*8U\G#Z?FCMIP+\J$D%:EU^B<DAPZ?Z#2[<H8C/SWB16@?L&O!
MK@%AN2.[1;;<Z5_ HK@?\8JJM=7GY/K*9PGN/%-9%5)Q#[<H$.JR)QQXF128
MFK4P9,-9^0TV^WRX@Z08LR9)[D/(6J?N\\B#GO"]DDC074^A,>>9L+5DQ3!5
M>^9IB9>RE/(\*7QK1>I7RPY=1H2DX:?&F'8-G.89.9D9^%SH=1K<^".%T;==
MWO42[ KN-H,$C^*.J'TT1IKXI D^F%LNX],OVQ.+0>Z3B4+C 9\JZW951FB%
M#.GM6&(CW3KDO 5:(6D]!5:2)(W-;L@^7%G.L4>^#@[TC&]6RSBCMV?>D[92
M'W74>CK"(JGT]\G (\]W]7,;+SEL.$<#WY"^Q:CP:9D%2@W8M33CEV:,90=.
M/OVH\Y32>)D\I#H2E$BF)(RC[OLCESH4L-K5Q4DV7@*MX.!BK I<MII?GE/A
M8,5#JM#5\I*1C=SK%?2M^&11GXH-+P>16R>X]F0;6<?J&59^JCH+P W2U (Y
M!&\N$J7<ICLN4B:R >)[BCEGR1=NGM[:UMK#;^P7??L\S,Z0)/"E<'A%+\\"
M9*58VOQ O?4A:8.+5G75J/&LS*O*2[1 ^?[6.4O (F]S LM02H'4NH\$92@J
M.%VRA)M>,F]H'.X/9 %?GW<TO4BU!#;\J)V=]X_JK6OD5JN:X+?AU.N7XRQ9
MDE^^ERX[W<[ !L&>_GC?ZH\=SNRI!X2AXF)+7ZEL+N92DM>CYD)6T5(W&Y77
M##$]50^LG97A^G77@-.J:P!_+WX3,G !HV\&.2@AMM'H9++%5BFB7Y;%T#^4
MC=+%QE/X&I#>I82:H&80-QM!BF$KR" :,>2E/:PT;+/TZ?8CI 5X-^8T",%I
M'P0\%MY:.)NY85.N;**&?E_)A2Z D:0'7B1>,L#^]BF&/4*XW@(!:--AM'D?
M)1T'NT,YZ-8*DAA?Z _ S!L\VAZ@EW728%R>7O9>8";F7%'F:A+6?,0Q?:E7
MU232@Q U70:X 7<'ZW*G&I[LK>/3I'!S@]X,^3?;-\TE=E5ZT4PWU,%.G:G5
M&R,A[&(4S>!*U S<?GCS2AT,W?B"B()K?2:-Z.&3G+%!C2-!JS?OXZ=1T9;)
M.1!6+,I:0Y'Z5XT728<_NGP%(<@ME+83&6&^_C<)$ZB+R%38[TR(T6L #6A)
MOT+3D6#]_J_$B5RD* JQ\H:401GAA-+5[B;GH>U2LQEQ? WH4H:K_HU1/'V3
MJO%J>X'A[/,UH [:5GSUEXG6J@H?92S_5%GU=,;X?!?$@"3-E6;W3?SSBN1O
MEU@/2[?T7X)+$:? F%__DOQI7<5FQJ*)P'C3RN70+WU8_E:SVJI@G::?^U^4
M_9T)D@J_,7@N(_)E;<#_9+%J_WV>X0EIO' *+ZE"[>$>@???V]^\C)>;4I,:
M)P_'0A *Z*WT428>(@]>]$4F#O6E>EH>%TZ&[EO3R[:7\Y8*KT:RVIUB]"W!
MC(-CYWLJ+FE TG65U8_JVWGBAN)6)5U<G)D<X^)/"FV6H!3Z1D_IMT?F]63I
M _'=AV?ER0R_F$]]PGKI,(NG392-8#F8"!1GI]\Y-,[^RM19G-NXTD$RD/SF
MU=/8-WC@AZ_>[-;08=-7.2MCPK>0]-MZG5$2'57)#OFZ<_50JX(A7F8MN>^+
MO@2S0O'M8KZMK5D,:2,(L96 FN:&,6=VYWH;FQK;CTHC5Y^S=%Q>?F&Q<INJ
M'>05WL47DSZH<+^JB,J7M[$J<TJ!S]^B(B<Q8VLRA;P#)<;X"$[2N"XU1^BM
MBGJ5E$$HI\*23<5=SLH>2JKK?WV^*ALOPS/82N*'6Z+$B]7QN;G#9A_32$Y
M4'17]'LHJ3T79NP@V51"[YKX8I-)R]#@(YX.@%7J;7A;Y[KTB(!%@$72^FK?
M:15.%&,Y#U> <F(M)1,U(D">8M^D@7VY^^3V3TZ$JB=#6-^/V'D^=O!=KT7M
M]3[.02_7TBH10=0DT=D'8AN2&S_MH!C#-9A;R.I49WCQLN5AB^%WHD\K>(0
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MBWG,DKJO@K;&<FF,BE@C:-6@J)C/J_HFH>@_N,<H@/A<'CEY(U7V?>K>#;@
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M9M;UV-7$<<&%?6?AZPW#;P/TK*64@4CQ>WZ/1Z+BVWH*;UO0T<0-#>QZ^S5
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M0\;A8?YWL@B'+@8*<O&) CA+N^KLK+$RQ/4ME[/P2:!^\O(!57#G&!UQ1&'
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M=\H\9G0?W_&RF]C9E9D7":Y+4?"4IY")B-$--A>/JH/R&#16GOFN^/&0AN\
MWV__'):3&:%B?S T\+DX?&.&E!-9ME2;H:.O\'E6B5DCAI)HO0H5BCX"N7'X
MQ&PZ[#RF9.FL$Z[3F1F\:X*8ZK>TQ2OR)PQ?I-D9>IXR]&VB+C?U*@[7$**U
M[M#8T-@E/-.]$DY].2EDX[!8?CI<%<&("7@U@!>!<^\^7=6;7IR,HYCH&FK-
M2R"1F]'$E%E911V;":M@V]Z[;9(R%D LSZ#(W@# 2@]>,F$%]KS4!6\D,L1D
MKGU[O=V?*DS.\20NM#'+ILI]=-8KG"?T;JK8&WDF7_(]OW=:TAU#@5J=I'4C
M9D2*UM1[%-6<:[(56:_AXM1D*I*51I/?:*E&2%?*OM;[?#IOY30,Y=UG,C@Z
MPB_G.<4>4\&VEG9TA(_*^JD5;W#(#=+*AN=-IQ_V7"W5XES)Y4#;P)D%\HPQ
M<QD/I;5YH$4<Y-%8[GDR0Z/AHQBY&>7\ ]Z36F-V8/"#Y%X_@1C+&)RB6DOC
M!(G'K)!B]_^.;EARZBK@_@^9-.7II:/.) =07/W&3*2[<]?K;?/MYN=1V-^_
M8\=W>1U0CH,Y]17J:V*MB<SBI;6^2:O0="C=>WR'L82DO-HHD(9; YYWZD*F
MKEO.'5-6RF7;VSMR>_+!>S+<0,[*'K3@C<BF,O]-J]9C_I:C/4*5@[C7TV;N
MV8W3NDK!HTJG$,NXGK"W-7/!6"L/NLD9O1T4"CR50N5(K$]WXP:+1KS>+\\I
MR-TR>_BJ'>==,_G"3'7FRPO*1U[X (A 9/'!?5T/+[41%@4WO'(2&VY.E@U:
M.4RD>0NF^8G%<LEKT;-OBH*$E?(6L;N5\6MCNMY[#NNQ14M(M="RNZ*U;X7W
MMF8O*$7.T@A9ZB8EF8=R;Q]?"6X9Z=A1V"6UFMK><J2"F$=.SA;4RZ\^$A81
M+G,L]'P\#-[GCI_=%AR=([+''VCJ(>[_*$WI7Y]CIDWG&R!#N@67#$Q(??H8
M[_$.95$X30O:1SQTCV@Q]3R4]2B]7Y*H_O8$0%6&,#T3Y6 T3=1:31>N^0GX
M5'-=ZTAR:VM+$9](5:&RN0[*)EA]IKRFP<.:/;TP!_I I7^9>YAV*R/!!NJ$
MU #;_TSM]6'\E7JD<9?='O1P:TM]\8(R7NX/Z!% 1CCP*>I[&GIF\I7QBAI*
M?N1+SZ:@XD?L_\!7>:^V=P,647PU>JZ"_J_W'@,NVW>TV=*T9B75)T=*4 CQ
MS$PDOQO@ >8?7P!_&H6FV'1P,:*>J.]PKFS\7/$&3O,]$TG]C=Z9OY0&_%.4
MUOL%9QNQFSN:F=QL->LY3\P5 BPJ/ZB1)B;>)JH':PM?9BTN K,A<]5AXCP>
MUJ;Y-M/84XQW/RCZS#+>_>DVZ@$ S/;1Y[7NCPIL&5Q0MM7"2H/L'LBM#N]-
M]H4L1<0^*K[7Y J6J+60_!8G)TMU#;AC^4YMR33JF55Q9A"Q^/9!=VC+FJX(
MYWN<=I9H#\J)\@-MOWV!0@5AV_4HE>8C,**64_>YWYLVJ1\\1GRI[0*--DN$
M>%,_.LRQ_*U7.Y,!5KZ,'BE7RAM:<5+#F8VAIQ)L\V(?/Y8_C]E[J6ST&4KY
MV('8K;TUWG%^QF!+#5]PF,A[E-&\871]@.(V^5K,<Q##V*)FO2&TS36IL=S
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MSO&VBU^!0XE6".W#^]6[[D2*NJ;@9%U]]Y\&U#]I,\?>@D2/BH66BJI&GWI
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M>IW>B%!5KOA>_[GA\/74_P)02P,$%     @ R4AN64A))^M8#P  *Q   !
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MS*X#,::5TI8/"U E?C=T&#CDH0-V!]!"FZ%\T:T/[6VTLM6T1(V6F]M3Z?B
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M+D SBT+@?H._X2H=@[QX#^,IE>?MS%]YC321'+!="N7"W@5Q7YX4Q"D 1V9
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MO.^MXJ50GCF6B:BVBG$(Z53;3;OZ<!&$S^:!H :$3$50!4?6IB2.OE>H.1U
MZ2!V0"YG#ZT17XKS$;CMH^LO07D2IBEQX];41Q@Z\(ZC$]$16RF'Z$!^PQL:
M(+#@$<AJ$9BLZ;O?.7UP<IR5^BAO8<1T#D=)H=K16HWH0*$]*E+YJ& 5W]$!
M7!;-_R*-?Q=,:74I522H6=>-P'FF?9H&JKNJ^]8_VW;/2;^*9H(R%TVN@!G@
M2A9%*_QF:C&:6LR>^HE9G5C:EA?W"H1C!_ESD6;VII<.V(C1@3W'Y389F&1_
M3ZY0GF4:GTM7EHHJ&QVX(0?9$1B@ [L5+<->2L$DCUTZH-XRE)/0Z*5&W/+>
M,.1[F9_BHJBF\O.6U24&,R;QW0D(:2>*UH+:0L6C**X51H2I_=GV%P4>[3_4
M"K2ZNLTKWD^*D;V4'O,.M?77']S+/RHK/TK99]MTI:#XC?6%^N'LOP+CXC=Z
M0VV,@]YT& M> _UC9K,[20[9Y^] 3425,%+(J]!$TO2,57R-V:G]F'EQE8,#
M=+'SQ!?$Y(G2X:!UEPEC'_.&*Q;9/%V=P5&M7D^]]\)'\_V..A!48OU> ZXZ
MF9J]1AGTM4&%P:,_K>BF?-<=+*2(B3>6[_7YA>KZ:EU6QO2OT[X>[M+"-A*Y
M0ICX35 Q7-I<,TFQJ_9^B)KA.INAA;8I5Z^+Z8F)N3EWN!.CT0]&!\JNX!,?
M5"#=H4OKQL$NY+HW<^C',Q\0DC#GI8<B0S]-[IJAQUZ=\PSIYAUMT#]?:'K4
M:'(ODT_;:6 ]&2[4GND(+!0[V73.S#K72DGD1W!+GIK:)9'/CL[9B[&HG=>;
M+EB4M'<D:?B<E'O4DX@YS:/V3:R.@(B^%\HIK'[).SJR&]!(,#O=(X'5'+)9
M-IZ_[[2D_,'!?!LI$:E:2RQ]$5H=Z)NVG#D>\"N#R5XMAJNE/[]_T25542&A
M6*2/]:X.MFM2TIW(..O?CD3M]"XW]+[5]3]_T^:=L6RJT63_18Y1+XKBQPA:
M7,]+Q":1#N K<42K2G*7L1#G$CK%-]@<I]]^C>0:4@7C5V-?:5,;5G.SR \Z
M]:U"_&9RL,QMZZO;>:7%X08?Z[4:WSMV/CWY\K)W84&9*.-6Y?7K9E]]^Y)_
M3\T]P!VU*)VHVEA\#T5^U+%JKXDG1+.@N^1\<,YQ>90^N QE4;)?(/!&[<MZ
MF-<2A^6]0 0?36*<<GFHJDIU5[%*>/3.&5CR6=ERYY#=FCK+NEL0B\;W4-5&
MXFDC)/.S,C&JLJG@JX,%_+NI>+<%?X=Y=-"L0Z37[/$\7NM'IXI":L]F:')A
M_%B6X.G:T10]<$RD])W9L8W<!3V=R/2L81;W?EG>ZE $QD2GN,_0Q6(Y@H+)
MFLC,[R'Q=CR@,1'FO!MQM2XR5ML'J5)V&3VB8/,U/5N$D&Z)E66+V>1[K8D/
M^FD]=(!EQ_6$7[*?Y2.M'%CY_#="=Y4<XT8&:_-RGG5Q^!N;@Z#3C[Z/<.85
M7VU_\-31JMK,V,1J14]P7BXUP'W'QMCHSV-@I?_\%U!+ P04    " #)2&Y9
M]\7W0\P&  !4+@  #0   '!T;E]E>#,Q,2YH=&WM6F%OVS80_2M<@&XM8"=Q
MTP"#[1E(F[0ST#9MF@_=O@RT=+*X4J)&4G:\7[]WI!P[B=<F31.GF[\$L7B\
M(Z5[]]Y1ZN>^T(-^3C(=]+WRF@:5+_^@L[U.9QMC_9UXL?]#NWUHDKJ@THO$
MDO24BMJI<BR.#E\=G+R1SI-MMP?]G>AK9-*9<'ZFZ9>MTZ./I^V#U\-7;[OB
MS]IYE<UZXN7QV].NZ.Q67GA5D!,E384UA2RW!OUJ/I6MVA^&OQ]%TSBM_?+@
MS?#U;]W+$WOBS<')JR&B[%9G/>'IS+>E5N.R:]4X]STX=MZ:<CPX^OCK\/GP
M5.QUMCO]G>9B?Z<:B&\>>K[AK<&/Y<A5O;N)DN"YD$60%V013B72*U,*DXD7
MN:),')U14GLU(7&<893L][S9191A2[R05HL/E2QE2R1A\S/A<^F[][E#+T>:
MYI%&QJ; @JMD GQT=WLKIF>F]-U5R=^;JM3G&-I]M(7]:%W)-(6;7[9VMSB0
MG4?)B7.ZV]FOSL) .A^(#IX]ZFTM;Y\#MIWZFT+4$+^=R4+I6??R"@IIQZKL
M[K+CQ291"=+5<29\UQ.IFRUZ4WV3T)WME6'O*-I0Y!+HL#11-$5M\[ERXGTM
M+6"E9^*$*F.] *1>&EL@@]KO&5SOI ;02G%*25X:;<:*7$L,RV1[<<_PQW[^
MR=W-<[JUUYBWJDQ16[I[=Q;FBM=UW; [SK"G]YK/SZ5#%B-?BYGX5)JIIG1,
MK9C6-B9S:GBV 9_#IT06RW(FZM+;FDL9&#Z0/;)<B@*_K)):9#+!)2M,H5"Z
M3+2[8E!20LY).V.30GXBQ%WRZ7 MQ6(04O.3Y1ALD"@+A0&S$M.Q$E11,<U5
MD@M7\Y_%_"E9:ISP!@KE-%0'JY&I\CDVZ"I*P@+9;X6EF13;Q+W&31G-EF_#
M^O-N ]2'!=2]AP%4$IDJ 05&U2+U6T IS#%LE\95F8&6HN939:+K%#X!KZ4\
M;P&:BJFL CH8V QXK1?(;4#C+H5&<4@5.VZQ1:UA +@:8"J$<V$]B72YR+29
MNCF6+8T5=+5$(,D7X[JQRM82)-U\,5=6N_XDVZ#R8:'RV;VB\O1""O_D&L0U
M#083C8E]5$CKH9"6 H  ",6M !)=D..V0+F<S=FL ,DRT?+O5+E$&U=C'M.O
M-3HBJ;(FH127G7@,X*0$)$9T')TEN2S') [ ;">UAD5G3[8[^X_I29C:V4_C
MK_A3<4=81@2S?\'TMP3L"#1>R[4#91<"90C$^[P,=UBPENY>S$C\X2;I?]R2
M_?S=MV2/Y9/[!.$A.;A#4@;Y]V7$M%B9)K)VUY_"$G%$R/XF4A2=IL8SK<%1
M$^4"\\&*RN"'CQ86G+G,NY9"+SB>J\X%)%H-)_.@ G]B+<YHE89#-%>/G$H5
MQ#+,HC(..J!D/[5CM1IJCPO2-K"D<83E>+ R[[F2?/-K+9G<L:FPA(7JQ8RH
MH9>E/_X;$1N"?S&?TO73QX9O'Q;?/AZM$>O7YJXKD+\^ZUT;^:@6$Y4RH*4S
M9: 5Z5 ,N$UEE$N;SC&'&J#D2&GE9RR$5X7E^A/@&9!W?DR[2NM'%7'6;*BJ
M;07DNR#<DP2,%A80&MXQE=#C&@4 (U1Q76$3-/,1Y*@_J@*1KS]K-S!_8#!/
M[A7F1Q.IZ\![C '*,G2<:H+L=2LZ1\CN:S!X_+FZC0QXQD2PKXO-ZLC4_M]C
M7T=CR'-KXDX\^_(1DQC->_Q0HBC> ZRGQ\[7GF$;2#XP2*;WR[PQYZ]BAX^#
MFTXPC%R"Y@V8EC6S29+:,C:6).H%?X5Q'E?X32:\.&Q4_!7?OT0'N73GPIN)
M+N"7TJ  PJ(;=IX)K3Z1;LZ>+]FW;K&/%6A=-+77;C<U97[S^N_+H?>_[KSG
MFY\IW/0D*+Q&3.>8:BUJ/U/1<HXO:(!)Y :*]TI_B45)=)?>6'<N+\,%."L*
MY3W12G(=&4A7'DD5UL33NVNOK=\W&7U%/=@</SW4XZ<#C68,#L/G-  L'Y$F
MBH#'1G6>'P--27YB&1F;LR D0UL9WI3.WY3<".7-F4T\5EY!;#+%1$?GO+:B
M(C1M*(P!;B1@*ZI8!PGKZ@(;Q0T)VVCH?N7;I(U"W2C4M9\-'4"(9A:,U@(L
M*- O@!5>_#<(;$6)J,J)T1-BG5C*<?/]@FT8FXI*FQEA=)J;2-/R KZ!QULJ
MW>VU/_CO&RGW\8[H$"G3%6_Q"(L1GF+G64L\W7WZ[.%\+7CI?MZ:_9\?GQP>
MG;2?'Y^>'K_!=JHS$=X^-)[W]N^,KW?<SM+GF6LOM7=<I98_1'UGP?\,H4"P
MG_D$][^ J*6X_-7WX!]02P,$%     @ R4AN64HX,\/H!@  >3    T   !P
M=&Y?97@S,3(N:'1M[5OO;]LV$/U7N #;6L!.XJ0!!MLUD#9I9Z!MUC38KR\#
M+9TLKI2HD90=[Z_?.U*.W<1;T[6)G<)?C$@D[TCJWKUWE-+/?:$'_9QD.NA[
MY34-*E_^09>'G8-=M/7WXLW^-^WVB4GJ@DHO$DO24RIJI\JQ.#UY>7S^6CI/
MMMT>]/>BK9%)9\+YF::G.Q>GOUZTCU\-7[[IBC]KYU4VZXD79V\NNJ*S7WGA
M54%.E#05UA2RW!GTJ_E0[M5^-_S]-':-P]HOCE\/7_W6O3ZP)UX?G[\<PLM^
M==D3GBY]6VHU+KM6C7/?@V'GK2G'@]-??QP^&UZ(P\[N07^ON=G?JP;BB[N>
M+WAG\%TY<E7O;KPD>"YDX>0Y6;A3B?3*E,)DXGFN*!,O5"G+1$DMSC*TDGW(
MBUUX&;;$.T]53J6XV!6_**U=2R1A"V;"Y])W[W.=7HXTS3V-C$V!"%?)!"CI
M[O=6#,],Z;NK(-";JM3G:-K_=@?KT;J2:0HS3W?V=]B1G7O)B2.[VSFJ+D-#
M.F^(!IY\V]M97CX[;#OU-P6OP7\[DX72L^[U&132CE79W6?#BT4B'Z2K_4QX
MUQ.IFR5Z4WT1UYW=E6[OR-M0Y')"PM)$T109SN?*B;>UM "7GHESJHSU L!Z
M86R!"&J_98C])#7@AA"D)"^--F-%",-AF>PN]@P_]K^?W-T\I\^V&N-6E2DR
M3/?PSMS<L+JN#;OC"#NXUWA^)AVB&/%:S,3[TDPUI6-JQ;"V,9A3PZ,-6!TV
M):)8EC-1E][6G,K \X'R$>52%+BRS"&93'#+"E,HI"X3^]WH4%)"SDD[XRZ%
M?$_PNV33X5Z*R<"EYB?+/KA#HBQT!KJ5&(Z9((N*::Z27+B:?Q;CIV2I,<(+
M*)33T!ZL2:;*YUB@JR@)$V2[%:9F4BP3>XU-&<V6MV']<;<%ZF8!]7 S@$HB
MNY)NB]!O :7HCF:[U*[*#+04E9\J$UVGL EX+<5Y"]!43&45T,' 9L!KO4!N
M QIWS3620ZK8<(M[U!H= %<#3 5W+LPGD2X7F393-\>RI;&"NI9P)/EFG#=F
MV5J"I)M/YL9LUQ]D6U1N%BJ?W"LJ+SX(X>]=@[BFP&"B,;&:"F$]%-)2 !
MH;@40* +<EP6*)=S=^Y6@&29:/DZ52[1QM48Q_1KC8Y(JJQ)*,5M)QX!."D!
MB1$=IY=)+LLQB6,PVWFMT:-S*-N=HT?T. SM'*7Q*EXJK@O+B&"V+YC^EH =
M@<9SN;6C[ -'&1SQ.J_#'3U82W?7'I$/&\+XX:IR(ZO+'QY\=?E(/K[/?')"
M#N: KZ!D/P[^%HOL1-;N]D-8[8X(0&X\1?UL:CS3&G0[42Z0.'I1&>SP*<F"
M_I<EA*50UH[G GJ![E8C+[A100I@+LYHE89305>/G$H5=#^Z19$?)$W)=FK'
MPCND41=4>B!\XPC3\1 8O.9*\N;76K).P:+"%!8"'B-B.;!<Q>"O$7%'2 F,
MIW3]3/BP\\[7)QT>C=:(]5O3\ W(WY[ ;XU\9(N)2AG0TIDRT(IT2 9<<3/*
MI4WGF$,.4'*DM/(SUO2KW'+^"? ,R+LZ=UY5MD1!=-DLJ*IM!>2[4(,D"1@M
M3"#4[F,J45IH) "T4,5YA;O4I8\@1_Y1%33)^J-V"_,-@WERKS _G4A=!]YC
M#%"6H7A6$T2O6U$$HX*X!8/'R]45<< S!H)]7:R[1Z;V_^[[-AI#7O4F/E3(
M/GY:)D;SXXJ0HBCN >;38^-KC[ M)#<,DNG],F^,^9O8X9/MIJ@-+=>@^0E,
MRYK9)$EM&1M+$O4#>X5Q'G?XU2RL."Q4_!5?)44#N717PIN)+N"7TJ  PJ0;
M=IX)K=Z3;H[1K_5O?<8ZMFA=2WVN*?/;5[\?=WWT_\[ZOO@K_D\]!0ROD--Y
M$FHMR)*Y>SDI+'B36?<32H0;!3DF)5&.>V/=E1X/-V"L*)3W1"O5R,A ZW-+
MJC G'OX5G-=M./RWQW.;>CQWK%&LPF#X?@KXY-/P1!'@UZCRJV.R*<GW++-C
M\1J$=BB[PTOQ^4NQ3P)U<Z85WR"L('Z98J"C*]Y?D0":,AV=@64$8"NJ? >)
M[^H""\6&A&4T<FCEB\.M)M@J^+6?G1U#J&<6!-8"+"BP+8 5OO%H$-B*$EJ5
M$Z,GQ#JZE./F4Q7;$#05E38S0NLT-Y&5Y0?X!AX_LQ+87?N#?]A(6=#GW<FW
M$X1,5[S!(RQ&>(J=)RUQL'_P9',^#+VVGY_-_L_.SD].S]O/SBXNSEYC.=6E
M"&]G&LN'1W?&UWMN[\;WN&M/N'><JVY^?WQZ24G-!W'B9U0%XB<+:<#H:OW;
MM]B!E&/;610/T -+WVE_#2A<\LO_&C#X!U!+ P04    " #)2&Y9S*F!:!\#
M  "7"0  #0   '!T;E]E>#,R,2YH=&W55FUO&CD0_BMSG%HE$@N[D)S:W>U*
M)"$I4A-:X*1>OU1F/;!NO;9K>Q.X7W_C)331G1JUIZ/2?4'@>7F>F7G&)J]\
M+8N\0L:+W LOL3!>?<3-<)#TR);W=X?Y+U%TH<NF1N6AM,@\<FB<4&L87UR-
M9M?,>;115.3]7:ZEYEMP?BOQ56<Q?K^(1F\F5S<I?&J<%ZMM!I?3FT4*26P\
M>%&C X5W8'7-5*?(S3XT>$7SR8?QSG47%EV.KB=O_DC_'IC!]6AV-2&4V&PR
M\+CQ$9-BK5(KUI7/*+'S5JMU,7[_>G(V6<!PT$OR_OUAWC<%_.?0^X([Q7.U
M="8[#$I)<T%+(.=H"4Z4S NM0*_@K16J%(9)&&^P;+RX19BNR /M@:F\;:QK
M&.G%:TA>P.^]>>^\!W,L6VK)\#0^,(&1@Q'7)DCU,9<]@Y?Q;Z%!OD*8,[MD
M"ETTW4C<PJCTP3*(X\&!*1Y2$P_*FW3AG%D)<\,4ZY(DT D>-IDI#N>5P-4_
MQ=%JATG2D8(%EI724J\%NBY,5-GK0H46EULH6[UMNZ&Q]18^*WTGD:^1#BKF
MV^:^:YBE:N469FBTI=8JN-2VIN*B=[#2MO4R:(7F@(K3N.9(4ZN7Q&(8=VD.
M@Y.GZ<!12/'\UQ>#09Q]S=W^3K)C6#62T$M=&TDA<"=\U6):_-((B^%2<P'@
M09M'[!B(6')ZQ(^_BH0Z9(4/&<:;LF)JC7NE)"^')VTS@Y]05%.]6\!2*\^$
MHI*(=S ^*IR)T!-#PPCXW>#!I 2*I%;0OI+!$"'7;0-70C%:9#JGG%RTV0,B
M>35R1U]3#UM8]W2W_L\7W0/*17B#4KC1MSNE)"<[I?S,ZCQ;2MPC+;7E] 8Z
MPTIZ%],X6]'P(R?^Q+1%OA/<5_0U?M:AM9'2,,[)\54G[H14=I^GPO!:I<FI
MV;0&OC><36<7XUET-ETLIM=4CMF TU+P^\S#TV?9;5C'DLE[UDOMO:ZSSN.&
MU,RNA4KCD+WO^H]NAE 3/?B\!?U6R$/YK2M]V.]C_X/4?OS".GKBJ3N&?UT<
M?80I_R1-M7^<BK\ 4$L#!!0    ( ,E(;EF?#ZMW, ,  /P)   -    <'1N
M7V5X,S(R+FAT;=56;6_;-A#^*S<7+1+ LF4[*5))%> D3F:@B5O;V[I]&6CQ
M;'&C2(ZD$GN_?D<I3H(5"X9B+K O@L1[>9Z[>T@J*WTE\ZQ$QO/,"R\Q-U[]
MBMO1<-@C6]9O%[/OHNA2%W6%RD-AD7GD4#NA-C"YO![/;YCS:*,HS_IMKI7F
M.W!^)_%]9SGYO(S&'Z;7MPG\5CLOUKL4KF:WRP0&L?'@184.%-Z#U153G3PS
M^]#@%2VFOTQ:US8LNAK?3#_\G/P],(6;\?QZ2BBQV:;@<>LC)L5&)59L2I]2
M8N>M5IM\\OG[Z?ET":-A;YCU'Q:SOLGA/X?>%]S)WZB5,^EA4 J:"UH"N4!+
M<*)@7F@%>@T?K5"%,$S"E5",7NEMMB8/M >F\K&VKF:D%Z]A< 8_]!:]BQXL
ML&BH#4:G\8$)C!V,N39!JL^Y[!F\B]^&!OD28<'LBBETT6PK<0?CP@?+,(Z'
M!Z9X2$T\*6_:A85'4Z*"90]^$E*Z+DRV6-1>W"'\2&(@G: 3G'AUX:(4N/Y2
M+L 4?[#-#%I2&.W^O2THC<FP!DLL2J6EW@@DF*DJ>ETHT>)J!T6CSETWC*':
MP>]*WTOD&Z2%DOEF%)]J9JDW<@=S--K2(!1<:5M1*Z)/L-:V\2)\H3F@XC3<
M!=*,JQ6Q&,5=FMKPY&4Z<!12O'EU-AS&Z6/NYGN0'L.ZEH1>Z,I("H%[X<L&
MT^(?M; 8CD 7 )Z4?,2.@8@-3H_X\:.DJ+M6^)!ALBU*IC:XU]7@W>BD:6;P
M$XIJJMKM6FCEF5!4$O$.QF>%,Q%Z8FA* ;\;/)B40)'4"AH2&0P1<MTF</TX
M/,K)19,]())7+5OZNIVA5N[E;OV?C\4GE,MP8R5PJ^]:I0Q.6J5\R^H\6TG<
M(ZVTY71C.L,*VD=)G*YI^)$3?V+2(-\+[DMZC5]W:-M(:1CGY/B^$W="*KO/
M4V*XVY+!J=DV!KXWG,_FEY-Y=#Y;+F<W5([9@M-2\(?,H[/7Z5W8C@63#ZR]
M-FGG>3<J9C=")7%(W7?]+PZ14!;](? &]Y\"GSK0N-+#_KL"OH[GH0^ZHQ<N
MU..O;@@]@CB^D12;O[/\+U!+ 0(4 Q0    ( ,E(;EG"V/JL?Q$  .B[   0
M              "  0    !P=&XM,C R-# Y,S N>'-D4$L! A0#%     @
MR4AN63_>^L+6#0  (IH  !0              ( !K1$  '!T;BTR,#(T,#DS
M,%]C86PN>&UL4$L! A0#%     @ R4AN61^VDC0C%@  83\! !0
M     ( !M1\  '!T;BTR,#(T,#DS,%]D968N>&UL4$L! A0#%     @ R4AN
M650T=$%Z1   YWX# !0              ( !"C8  '!T;BTR,#(T,#DS,%]L
M86(N>&UL4$L! A0#%     @ R4AN606WIX4!-   NL$" !0
M ( !MGH  '!T;BTR,#(T,#DS,%]P<F4N>&UL4$L! A0#%     @ R4AN64X3
MS[S&T   "&D)  L              ( !Z:X  '!T;E\Q,'$N:'1M4$L! A0#
M%     @ R4AN698%SL1$O0  G=,  !               ( !V'\! '!T;E\Q
M,'%I;6<Q-2YJ<&=02P$"% ,4    " #)2&Y92$DGZU@/   K$   $
M        @ %*/0( <'1N7S$P<6EM9S$W+FIP9U!+ 0(4 Q0    ( ,E(;EGW
MQ?=#S 8  %0N   -              "  =!, @!P=&Y?97@S,3$N:'1M4$L!
M A0#%     @ R4AN64HX,\/H!@  >3    T              ( !QU," '!T
M;E]E>#,Q,BYH=&U02P$"% ,4    " #)2&Y9S*F!:!\#  "7"0  #0
M        @ ':6@( <'1N7V5X,S(Q+FAT;5!+ 0(4 Q0    ( ,E(;EF?#ZMW
M, ,  /P)   -              "  21> @!P=&Y?97@S,C(N:'1M4$L%!@
0   ,  P YP(  ']A @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>ptn_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptn="http://ptn.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptn-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-12</endDate>
        </period>
    </context>
    <context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-10-20</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-10-04to2023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_OneToThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2017-11-01to2017-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="From2017-09-01to2017-09-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-06</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_ContigentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContigentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2024-09-30" id="ixv-6618">0000911216</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-07-01to2024-09-30" id="ixv-6619">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2024-09-30" id="ixv-6620">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2024-09-30" id="ixv-6621">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2024-09-30" id="ixv-6622">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-6623"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-6624"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-6625"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="ixv-6626"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="ixv-6627"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-6628"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-6629"
      unitRef="Shares">19548167</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-6630"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-6631"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-6632"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-6633"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="ixv-6634"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="ixv-6635"
      unitRef="USD">7781844</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-04to2023-10-31"
      decimals="0"
      id="ixv-6636"
      unitRef="USD">9109117</us-gaap:CostsAndExpenses>
    <dei:DocumentType contextRef="From2024-07-01to2024-09-30" id="ixv-7188">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-07-01to2024-09-30" id="ixv-7189">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2024-09-30" id="ixv-7190">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2024-09-30" id="ixv-7191">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2024-09-30" id="ixv-7192">001-15543</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2024-09-30" id="ixv-7193">PALATIN TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2024-09-30" id="ixv-7194">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-07-01to2024-09-30" id="ixv-7195">95-4078884</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2024-09-30" id="ixv-7196">4B Cedar Brook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2024-09-30" id="ixv-7197">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-07-01to2024-09-30" id="ixv-7198">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2024-09-30" id="ixv-7199">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-07-01to2024-09-30" id="ixv-7200">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-07-01to2024-09-30" id="ixv-7201">495&#x2011;2200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-07-01to2024-09-30" id="ixv-7202">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2024-09-30" id="ixv-7203">PTN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2024-09-30" id="ixv-7204">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2024-09-30" id="ixv-7205">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2024-09-30" id="ixv-7206">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2024-09-30" id="ixv-7207">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-07-01to2024-09-30" id="ixv-7208">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2024-09-30" id="ixv-7209">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-07-01to2024-09-30" id="ixv-7210">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-11-13"
      decimals="INF"
      id="ixv-7211"
      unitRef="Shares">19548167</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_289"
      unitRef="USD">2384214</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_288"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_297"
      unitRef="USD">228435</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_296"
      unitRef="USD">242272</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_299"
      unitRef="USD">2612649</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_298"
      unitRef="USD">9769668</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_301"
      unitRef="USD">307571</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_300"
      unitRef="USD">388361</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_303"
      unitRef="USD">438123</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_302"
      unitRef="USD">527321</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_304"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_305"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_307"
      unitRef="USD">3415259</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_306"
      unitRef="USD">10742266</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_309"
      unitRef="USD">3949028</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_308"
      unitRef="USD">4101929</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_311"
      unitRef="USD">4573292</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_310"
      unitRef="USD">4185046</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_313"
      unitRef="USD">319520</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_312"
      unitRef="USD">380542</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_315"
      unitRef="USD">18527</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_314"
      unitRef="USD">46014</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_317"
      unitRef="USD">1001350</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_316"
      unitRef="USD">944150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_319"
      unitRef="USD">9861717</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_318"
      unitRef="USD">9657681</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_321"
      unitRef="USD">132447</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_320"
      unitRef="USD">163782</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_325"
      unitRef="USD">1106700</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_324"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_329"
      unitRef="USD">11100864</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_328"
      unitRef="USD">10853763</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_350"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_351"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_362"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_336"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_337"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="fid_349"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_356"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_359"
      unitRef="Shares">19548167</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_358"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_339"
      unitRef="USD">195481</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_338"
      unitRef="USD">179266</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_341"
      unitRef="USD">441709073</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_340"
      unitRef="USD">441475747</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_343"
      unitRef="USD">-449590199</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_342"
      unitRef="USD">-441766550</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_345"
      unitRef="USD">-7685605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_344"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_347"
      unitRef="USD">3415259</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_346"
      unitRef="USD">10742266</us-gaap:LiabilitiesAndStockholdersEquity>
    <ptn:ProductRevenueNet
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2010"
      unitRef="USD">0</ptn:ProductRevenueNet>
    <ptn:ProductRevenueNet
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2011"
      unitRef="USD">2105977</ptn:ProductRevenueNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2013"
      unitRef="USD">5743754</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2014"
      unitRef="USD">5014630</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2015"
      unitRef="USD">2020931</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2016"
      unitRef="USD">3200244</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2017"
      unitRef="USD">7764685</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2018"
      unitRef="USD">8214874</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2019"
      unitRef="USD">-7764685</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2020"
      unitRef="USD">-6108897</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2022"
      unitRef="USD">78576</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2023"
      unitRef="USD">71630</us-gaap:InvestmentIncomeNet>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2024"
      unitRef="USD">-131600</ptn:ForeignCurrencyTransactionLossGain>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2025"
      unitRef="USD">159750</ptn:ForeignCurrencyTransactionLossGain>
    <us-gaap:InterestExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2026"
      unitRef="USD">5940</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2027"
      unitRef="USD">10882</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2028"
      unitRef="USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2029"
      unitRef="USD">682400</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2030"
      unitRef="USD">-58964</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2031"
      unitRef="USD">902898</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2032"
      unitRef="USD">-7823649</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2033"
      unitRef="USD">-5205999</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_2034"
      unitRef="USDPShares">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-01to2023-09-30"
      decimals="INF"
      id="fid_2035"
      unitRef="USDPShares">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2036"
      unitRef="Shares">19845106</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2037"
      unitRef="Shares">12170699</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2219"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2217"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2220"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2218"
      unitRef="Shares">17926640</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2221"
      unitRef="USD">179266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2222"
      unitRef="USD">441475747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2223"
      unitRef="USD">-441766550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2224"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2257"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2227"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2226"
      unitRef="Shares">232941</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2229"
      unitRef="USD">2329</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2230"
      unitRef="USD">346694</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2228"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2232"
      unitRef="USD">349023</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2231"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2235"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2234"
      unitRef="Shares">-54691</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2237"
      unitRef="USD">-547</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2238"
      unitRef="USD">-98935</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2236"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2240"
      unitRef="USD">-99482</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2239"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2243"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceShares
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2242"
      unitRef="Shares">1443277</ptn:SharesReleasedFromAbeyanceShares>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2245"
      unitRef="USD">14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2246"
      unitRef="USD">-14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2244"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2247"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2248"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2249"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2250"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2251"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2253"
      unitRef="USD">-7823649</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2254"
      unitRef="USD">-7823649</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2252"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2255"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2258"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2256"
      unitRef="Shares">19548167</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2259"
      unitRef="USD">195481</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2260"
      unitRef="USD">441709073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2261"
      unitRef="USD">-449590199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2262"
      unitRef="USD">-7685605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2311"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2263"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2266"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2264"
      unitRef="Shares">11656714</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2267"
      unitRef="USD">116567</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2268"
      unitRef="USD">409933959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2269"
      unitRef="USD">-412030437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_2270"
      unitRef="USD">-1979871</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2316"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2274"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2272"
      unitRef="Shares">98372</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2275"
      unitRef="USD">984</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2276"
      unitRef="USD">389352</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2277"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2278"
      unitRef="USD">390336</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2282"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2285"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2280"
      unitRef="Shares">-25467</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2283"
      unitRef="USD">-255</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2284"
      unitRef="USD">-56146</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2290"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2286"
      unitRef="USD">-56401</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2293"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2296"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2288"
      unitRef="Shares">217027</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2291"
      unitRef="USD">2170</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2292"
      unitRef="USD">529199</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2297"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2294"
      unitRef="USD">531369</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2298"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2312"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2313"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2314"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2299"
      unitRef="USD">-5205999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2300"
      unitRef="USD">-5205999</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_ptn_ContigentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2315"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2301"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2304"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2302"
      unitRef="Shares">11946646</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2305"
      unitRef="USD">119466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2306"
      unitRef="USD">410796364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2307"
      unitRef="USD">-417236436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2308"
      unitRef="USD">-6320566</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2164"
      unitRef="USD">-7823649</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2165"
      unitRef="USD">-5205999</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2167"
      unitRef="USD">80790</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2168"
      unitRef="USD">87357</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2169"
      unitRef="USD">89198</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2170"
      unitRef="USD">88563</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ptn:UnrealizedForeignCurrencyTransactionLossGain
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2171"
      unitRef="USD">131600</ptn:UnrealizedForeignCurrencyTransactionLossGain>
    <ptn:UnrealizedForeignCurrencyTransactionLossGain
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2172"
      unitRef="USD">-159750</ptn:UnrealizedForeignCurrencyTransactionLossGain>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2173"
      unitRef="USD">349023</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2174"
      unitRef="USD">390336</us-gaap:ShareBasedCompensation>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2175"
      unitRef="USD">0</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2176"
      unitRef="USD">-682400</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2178"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2179"
      unitRef="USD">1567260</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2180"
      unitRef="USD">13837</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2181"
      unitRef="USD">563548</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2182"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2183"
      unitRef="USD">-1072251</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2184"
      unitRef="USD">-152901</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2185"
      unitRef="USD">-2033887</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2186"
      unitRef="USD">388246</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2187"
      unitRef="USD">641212</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2188"
      unitRef="USD">-92357</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2189"
      unitRef="USD">-90382</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2190"
      unitRef="USD">-7016213</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2191"
      unitRef="USD">-5906393</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2193"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2194"
      unitRef="USD">2992890</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2195"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2196"
      unitRef="USD">2992890</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2198"
      unitRef="USD">99482</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2199"
      unitRef="USD">56401</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2200"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2201"
      unitRef="USD">531369</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2202"
      unitRef="USD">27487</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2203"
      unitRef="USD">26074</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2309"
      unitRef="USD">-126969</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2310"
      unitRef="USD">448894</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2206"
      unitRef="USD">-7143182</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2207"
      unitRef="USD">-2464609</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2208"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_2209"
      unitRef="USD">7989582</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2210"
      unitRef="USD">2384214</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2211"
      unitRef="USD">5524973</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2213"
      unitRef="USD">5940</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2214"
      unitRef="USD">10882</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1937">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(1) ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Nature of Business &lt;/em&gt;- Palatin Technologies, Inc. (&#x201c;Palatin&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#x2019;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Melanocortin Receptor System.&lt;/em&gt; The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company&#x2019;s prior commercial product, Vyleesi&#xae;, was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#x201c;HSDD&#x201d;) in premenopausal women.&#160;As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#x201c;Cosette&#x201d;) on December 19, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, and a co-formulation of bremelanotide with a phosphodiesterase type 5 inhibitor (&#x201c;PDE5i&#x201d;) for treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Business Risks and Liquidity &#x2013; &lt;/em&gt;The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of September 30, 2024 of $449,590,199 and a net loss for the three months ended September 30, 2024, of $7,823,649. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of September 30, 2024, the Company&#x2019;s cash and cash equivalents were $2,384,214 and current liabilities were $9,861,717. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#x2019;s MC1r and MC4r programs, and development of other portfolio products. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company follows the provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40,&#160;&lt;em&gt;Presentation of Financial Statements&#160;&#x2014;&#160;Going Concern&lt;/em&gt;, which requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#x2019;s ability to meet its obligations for the next year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Based on our available cash and cash equivalents as of September 30, 2024, management has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#x2019;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company may be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the first half of calendar year 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.&lt;em&gt; &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Concentrations &#x2013;&lt;/em&gt; Concentrations in the Company&#x2019;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and accounts receivable. The Company&#x2019;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ptn:RetainedEarningAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1444"
      unitRef="USD">449590199</ptn:RetainedEarningAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1445"
      unitRef="USD">-7823649</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1447"
      unitRef="USD">2384214</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1448"
      unitRef="USD">9861717</us-gaap:LiabilitiesCurrent>
    <ptn:SalesBasedMilestonePayments
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2162"
      unitRef="USD">159000000</ptn:SalesBasedMilestonePayments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1945">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(2) BASIS OF PRESENTATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three months ended September 30, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1938">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revision of Previously Issued Financial Statements&lt;/em&gt; - The Company has revised certain prior period amounts on the consolidated financial statements to correct a misstatement with respect to improperly classifying warrants as equity instead of as a warrant liability that is adjusted to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of ASC 815-40, &lt;em&gt;Contracts in Entity&#x2019;s Own Equity&lt;/em&gt;. As of September 30, 2023, The Company recorded an adjustment to record a liability for the warrants of $1,168,144 million , adjusted contingently redeemable warrants for $263,400, decreased additional paid-in capital for $5,619,090 and increased accumulated deficit for $4,187,546.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company also recorded a gain of $682,400 as a result in the change in fair value of the warrant liabilities for the three months ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has assessed the impact of improperly classifying the warrants within equity rather than as a warranty liability that is adjusted through charges or credits to the income statement to reflect changes in the fair value of the warrants, and determined the impact is not material, quantitatively or qualitatively, to any prior period impacted. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $1,974,575 and $9,089,113 in a money market account at September 30, 2024 and June 30, 2024, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligation were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three months ended September 30, 2023 were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;4,587,150&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"&gt;(2,481,173&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"&gt;2,105,977&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the three months ended September 30, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three ended September 30, 2024 and 2023 were 11,105,938 and 4,519,682, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of September 30, 2024, and 2023, respectively, due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1953">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <ptn:RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1989">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revision of Previously Issued Financial Statements&lt;/em&gt; - The Company has revised certain prior period amounts on the consolidated financial statements to correct a misstatement with respect to improperly classifying warrants as equity instead of as a warrant liability that is adjusted to the income statement each quarter to reflect changes in the fair value of the warrants, under the guidance of ASC 815-40, &lt;em&gt;Contracts in Entity&#x2019;s Own Equity&lt;/em&gt;. As of September 30, 2023, The Company recorded an adjustment to record a liability for the warrants of $1,168,144 million , adjusted contingently redeemable warrants for $263,400, decreased additional paid-in capital for $5,619,090 and increased accumulated deficit for $4,187,546.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company also recorded a gain of $682,400 as a result in the change in fair value of the warrant liabilities for the three months ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has assessed the impact of improperly classifying the warrants within equity rather than as a warranty liability that is adjusted through charges or credits to the income statement to reflect changes in the fair value of the warrants, and determined the impact is not material, quantitatively or qualitatively, to any prior period impacted. Accordingly, the Company will adjust prior periods as those financial statements are presented for comparative purposes in future filings.&lt;/p&gt;</ptn:RevisionOfPreviouslyIssuedFinancialStatementsPolicyTextBlock>
    <us-gaap:MarketRiskBenefitLiabilityAmount
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_29"
      unitRef="USD">1168144</us-gaap:MarketRiskBenefitLiabilityAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_30"
      unitRef="USD">263400</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_31"
      unitRef="USD">5619090</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CumulativeEarningsDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_32"
      unitRef="USD">4187546</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:UseOfEstimates contextRef="From2024-07-01to2024-09-30" id="fid_1954">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1955">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $1,974,575 and $9,089,113 in a money market account at September 30, 2024 and June 30, 2024, respectively. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ptn:MoneyMarketAccountsAndTreasuryBills
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_282"
      unitRef="USD">1974575</ptn:MoneyMarketAccountsAndTreasuryBills>
    <ptn:MoneyMarketAccountsAndTreasuryBills
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2040"
      unitRef="USD">9089113</ptn:MoneyMarketAccountsAndTreasuryBills>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-07-01to2024-09-30" id="fid_1957">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-07-01to2024-09-30" id="fid_1958">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1961">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1962">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1963">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1964">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) Identify the contract(s) with a customer; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to the performance obligations in the contract; and (5) Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligation were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three months ended September 30, 2023 were as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;4,587,150&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"&gt;(2,481,173&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"&gt;2,105,977&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <ptn:ScheduleOfSalesTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1971">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;4,587,150&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"&gt;(2,481,173&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"&gt;2,105,977&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfSalesTableTextBlock>
    <ptn:RevenuesGross
      contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember"
      decimals="0"
      id="fid_12"
      unitRef="USD">4587150</ptn:RevenuesGross>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember"
      decimals="0"
      id="fid_605"
      unitRef="USD">-2481173</ptn:ProductSalesAllowancesAndAccruals>
    <us-gaap:Revenues
      contextRef="From2024-07-01to2024-09-30_us-gaap_ProductMember"
      decimals="0"
      id="fid_264"
      unitRef="USD">2105977</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-07-01to2024-09-30" id="fid_1965">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ptn:AccruedLiabilitiesPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1966">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;</ptn:AccruedLiabilitiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-07-01to2024-09-30" id="fid_1967">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1968">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1969">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the three months ended September 30, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three ended September 30, 2024 and 2023 were 11,105,938 and 4,519,682, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of September 30, 2024, and 2023, respectively, due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_287"
      unitRef="Shares">11105938</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_1415"
      unitRef="Shares">4519682</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1416"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1970">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1939">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(4) NEW AND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update&#160;(&#x201c;ASU&#x201d;) 2023-07,&#160;Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <ptn:AssetPurchaseAgreementTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1940">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(5) ASSET PURCHASE AGREEMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#xae;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Under the terms of the Purchase Agreement, the Company sold certain assets (the &#x201c;Purchased Assets&#x201d;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of September 30, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#x201c;Korea&#x201d;) (see Note 8).&lt;/p&gt;</ptn:AssetPurchaseAgreementTextBlock>
    <us-gaap:AccountsReceivablePurchase
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1450"
      unitRef="USD">171000000</us-gaap:AccountsReceivablePurchase>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1452"
      unitRef="USD">9500000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:PaymentsForPurchaseOfOtherAssets1
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1449"
      unitRef="USD">2500000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
    <ptn:PaymentsToSalesBasedMilestonePayments
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1451"
      unitRef="USD">159000000</ptn:PaymentsToSalesBasedMilestonePayments>
    <ptn:ManufacturingSupplyAgreementsTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1988">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#x201c;Catalent&#x201d;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#x201c;Ypsomed&#x201d;), to manufacture the auto-injector device (the &#x201c;Ypsomed Agreement&#x201d;); and Lonza Ltd. (&#x201c;Lonza&#x201d;), to manufacture the active pharmaceutical ingredient peptide (the &#x201c;Lonza Agreement&#x201d;).&lt;/p&gt;</ptn:ManufacturingSupplyAgreementsTextBlock>
    <ptn:AgreementWithFosunTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1941">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(7) AGREEMENT WITH FOSUN&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun&#x201d;) for exclusive rights to commercialize Vyleesi in China (the &#x201c;Fosun License Agreement&#x201d;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.&lt;/p&gt;</ptn:AgreementWithFosunTextBlock>
    <us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1618"
      unitRef="USD">4500000</us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1619"
      unitRef="USD">5000000</us-gaap:PaymentsForRestructuring>
    <ptn:UpfrontPaymentOfLess
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1626"
      unitRef="USD">500000</ptn:UpfrontPaymentOfLess>
    <ptn:AgreementWithKwangdongTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1942">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(8) AGREEMENT WITH KWANGDONG&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#x201c;Kwangdong&#x201d;) for exclusive rights to commercialize Vyleesi in Korea (the &#x201c;Kwangdong License Agreement&#x201d;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea.&lt;/p&gt;</ptn:AgreementWithKwangdongTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_631"
      unitRef="USD">417500</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_633"
      unitRef="USD">500000</us-gaap:PaymentsForRestructuring>
    <ptn:taxexpenses
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_634"
      unitRef="USD">82500</ptn:taxexpenses>
    <us-gaap:PaymentsToAcquireReceivables
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_636"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1943">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Prepaid expenses&lt;strong&gt; &lt;/strong&gt;and other current assets consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,823&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,656&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,248&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;228,435&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,271&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1972">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;39,823&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,956&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;144,656&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,248&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;228,435&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,271&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_637"
      unitRef="USD">39823</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_575"
      unitRef="USD">23926</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_638"
      unitRef="USD">43956</ptn:PrepaidInsurancePremiums>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_577"
      unitRef="USD">71097</ptn:PrepaidInsurancePremiums>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_640"
      unitRef="USD">144656</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_581"
      unitRef="USD">147248</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_641"
      unitRef="USD">228435</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_583"
      unitRef="USD">242271</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1944">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(10) FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#x2019;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#x2019;s or liability&#x2019;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table provides the assets carried at fair value:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Carrying Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Quoted&#160;prices&#160;in &lt;br/&gt;active markets&lt;br/&gt;(Level 1)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Other quoted/observable inputs (Level 2)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Significant unobservable&#160;inputs&lt;br/&gt;(Level 3)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;September 30, 2024:&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,974,575&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,974,575&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;June 30, 2024:&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1973">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Carrying Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Quoted&#160;prices&#160;in &lt;br/&gt;active markets&lt;br/&gt;(Level 1)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Other quoted/observable inputs (Level 2)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Significant unobservable&#160;inputs&lt;br/&gt;(Level 3)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;September 30, 2024:&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,974,575&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,974,575&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;June 30, 2024:&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1460"
      unitRef="USD">1974575</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_1471"
      unitRef="USD">1974575</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_1461"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_1466"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2042"
      unitRef="USD">9089113</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_2041"
      unitRef="USD">9089113</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_2043"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_2044"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1948">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(11) ACCRUED EXPENSES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Accrued expenses&lt;strong&gt; &lt;/strong&gt;consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September&#160;30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,761,718&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;159,965&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;187,238&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;324,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;139,731&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,573,292&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1981">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September&#160;30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,761,718&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;159,965&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;187,238&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;324,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;139,731&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,573,292&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptn:CostClinicalStudy
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_661"
      unitRef="USD">3761718</ptn:CostClinicalStudy>
    <ptn:CostClinicalStudy
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_660"
      unitRef="USD">1509797</ptn:CostClinicalStudy>
    <ptn:OtherResearchRelatedExpenses
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_663"
      unitRef="USD">159965</ptn:OtherResearchRelatedExpenses>
    <ptn:OtherResearchRelatedExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_662"
      unitRef="USD">65972</ptn:OtherResearchRelatedExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_665"
      unitRef="USD">187238</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_664"
      unitRef="USD">284215</us-gaap:AccruedProfessionalFeesCurrent>
    <ptn:PersonalCost
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_667"
      unitRef="USD">0</ptn:PersonalCost>
    <ptn:PersonalCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_666"
      unitRef="USD">1771694</ptn:PersonalCost>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_669"
      unitRef="USD">324640</ptn:AccruedSellingExpenses>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_668"
      unitRef="USD">351485</ptn:AccruedSellingExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_671"
      unitRef="USD">139731</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_670"
      unitRef="USD">201883</us-gaap:OtherAccruedLiabilitiesCurrent>
    <ptn:TotaAcrruedLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_673"
      unitRef="USD">4573292</ptn:TotaAcrruedLiabilities>
    <ptn:TotaAcrruedLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_672"
      unitRef="USD">4185046</ptn:TotaAcrruedLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1949">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(12) COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Inventory Purchases &lt;/em&gt;- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#x201c;Catalent Agreement&#x201d;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of September 30, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Inventory purchase commitments&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,661,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,554,700&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,106,700&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2024, the Company has $1,001,350 and $1,106,700 accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Contingencies&lt;/em&gt; - The Company accounts for litigation losses in accordance with ASC 450-20, &lt;em&gt;Loss Contingencies&lt;/em&gt;. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#x2019;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1982">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Inventory purchase commitments&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,661,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,554,700&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,106,700&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_865"
      unitRef="USD">2661400</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-09-30_ptn_CurrentMember"
      decimals="0"
      id="fid_866"
      unitRef="USD">1554700</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-09-30_ptn_OneToThreeYearsMember"
      decimals="0"
      id="fid_867"
      unitRef="USD">1106700</us-gaap:AdvancesOnInventoryPurchases>
    <ptn:OtherLiabilitiesCurrents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_870"
      unitRef="USD">1001350</ptn:OtherLiabilitiesCurrents>
    <ptn:AccruedOtherLongTermLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_872"
      unitRef="USD">1106700</ptn:AccruedOtherLongTermLiabilities>
    <ptn:OtherLiabilitiesCurrents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_869"
      unitRef="USD">944150</ptn:OtherLiabilitiesCurrents>
    <ptn:AccruedOtherLongTermLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_871"
      unitRef="USD">1032300</ptn:AccruedOtherLongTermLiabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_1950">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(13) STOCKHOLDERS&#x2019; DEFICIENCY&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Series A Convertible Preferred Stock&lt;/em&gt; &#x2013;&#160;As of September 30, 2024, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of September 30, 2024, the Series A Conversion Price was $75.45, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.33 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of September 30, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Financing Transactions &#x2013; &lt;/em&gt;On January 29, 2024, the Company entered into a securities purchase agreement (the &#x201c;January 2024 Purchase Agreement&#x201d;) to sell in a registered direct offering (the &#x201c;January 2024 RD Offering&#x201d;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#x201c;January 2024 Private Warrants&#x201d;) to purchase up to 1,831,503 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;Private Offering&#x201d; and together with the January 2024 RD Offering, the &#x201c;January 2024 Offering&#x201d;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#x201c;2024 Placement Agent Warrants&#x201d;) to purchase up to 91,575 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Placement Agent Warrant Shares&#x201d;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On October 20, 2023, the Company entered into a securities purchase agreement (the &#x201c;October 2023 Purchase Agreement&#x201d;) with a certain institutional investor, to sell in a registered direct offering (the &#x201c;October 2023 RD Offering&#x201d;), an aggregate of (i) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounting for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of Company, therefore the placement agent warrants are classified out of permanent equity.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 12, 2023, the Company entered into a new equity distribution agreement (the &#x201c;2023 Equity Distribution Agreement&#x201d;) with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;), pursuant to which the Company may, from time to time, sell shares of the Company&#x2019;s common stock at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#x2019;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Proceeds raised under the 2023 Equity Distribution Agreement are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Cumulative from inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;No proceeds were raised under the 2023 Equity Distribution Agreement during the three months ended September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock Warrants&lt;/em&gt; - On June 20, 2024, the Company entered into a letter agreement (the &#x201c;Inducement Letter&#x201d;) with a holder (the &#x201c;Exercising Holder&#x201d;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#x201c;Existing Warrants&#x201d;). Pursuant to the Inducement Letter, the Exercising Holder agreed to exercise, for cash, Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#x2019;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the Existing Warrants by the Exercising Holder (the &#x201c;Warrant Inducement&#x201d;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the Exercising Holder.&#160;During the three months ended September 30, 2024, at the request of the Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of September 30, 2024, the Company had outstanding warrants for shares of common stock as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:39%;"&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;May 2022 Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;66,666 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 12.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;October 2022 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;90,909 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 6.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;October 2023 Private Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;943,396 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 2.12 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;April 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;October 2023 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;117,925 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 2.65 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;January 2024 Private Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,831,503 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 5.46 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;January 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;91,575 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 6.83 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;June 2024 Series A Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,727,273 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 1.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;June 2024 Series B Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,122,642 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 1.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="3" style="mso-ignore: colspan;"&gt;* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock Options &#x2013;&lt;/em&gt; For the three months ended September 30, 2024, and 2023, the Company recorded stock-based compensation related to stock options of $177,734 and $205,317. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A summary of stock option activity is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Term in Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7.92&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding - September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Exercisable at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;927,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.81&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.4&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Expected to vest at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,321,578&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.83&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9.1&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Stock options granted to the Company&#x2019;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Restricted Stock Units &#x2013; &lt;/em&gt;For the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation related to restricted stock units of $171,289 and $185,019, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A summary of restricted stock unit activity is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of September 30, 2024, due to a provision in the restricted stock unit agreements to delay delivery. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Time-based restricted stock units granted to the Company&#x2019;s executive officers, employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In connection with the vesting of restricted share units during the three months ended September 30, 2024, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_1653"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CashAvailableForDistributions
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1676"
      unitRef="USD">100</us-gaap:CashAvailableForDistributions>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_1664"
      unitRef="USDPShares">75.45</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare
      contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_1665"
      unitRef="USDPShares">1.33</us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare>
    <us-gaap:CashAvailableForDistributions
      contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_1666"
      unitRef="USD">100</us-gaap:CashAvailableForDistributions>
    <ptn:AggregateValue
      contextRef="From2024-07-01to2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_1663"
      unitRef="USD">403000</ptn:AggregateValue>
    <ptn:CashAvailableForDistributionsAdditional
      contextRef="AsOf2024-09-30_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_1667"
      unitRef="USD">100</ptn:CashAvailableForDistributionsAdditional>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2024-02-01to2024-02-29" id="fid_1651">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#x201c;January 2024 Private Warrants&#x201d;) to purchase up to 1,831,503 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;Private Offering&#x201d; and together with the January 2024 RD Offering, the &#x201c;January 2024 Offering&#x201d;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="fid_1636"
      unitRef="USDPShares">5.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2061"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-09-30_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2062"
      unitRef="USDPShares">6.825</us-gaap:SharesIssuedPricePerShare>
    <ptn:GrossProceeds
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1678"
      unitRef="USD">10000006</ptn:GrossProceeds>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1635"
      unitRef="USD">9224056</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-10-01to2023-10-20" id="fid_2065">) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_1637"
      unitRef="USDPShares">2.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_1640"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantShares
      contextRef="From2024-07-01to2024-09-30_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"
      decimals="0"
      id="fid_2069"
      unitRef="USD">1033491</ptn:PurchaseOfWarrantShares>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-01to2023-10-20"
      decimals="0"
      id="fid_1679"
      unitRef="USD">4573948</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-04-01to2023-04-12" id="fid_2071">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#x2019;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <ptn:ScheduleOfEquityDistributionAgreementTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_2105">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Cumulative from inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfEquityDistributionAgreementTableTextBlock>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1518"
      unitRef="Shares">217027</ptn:EquityGrossProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1516"
      unitRef="USD">547803</us-gaap:ProceedsFromOtherEquity>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2048"
      unitRef="Shares">721061</ptn:EquityNetProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2058"
      unitRef="USD">1744542</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1522"
      unitRef="USD">16434</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2054"
      unitRef="USD">52336</us-gaap:ProceedsFromFeesReceived>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1526"
      unitRef="USD">0</ptn:EquityExpensesProceeds>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2050"
      unitRef="USD">-126800</ptn:EquityExpensesProceeds>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1528"
      unitRef="Shares">217027</ptn:EquityNetProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1530"
      unitRef="USD">531369</ptn:EquityNetProceedsProceeds>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2060"
      unitRef="Shares">721061</ptn:EquityGrossProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2024-09-30_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2046"
      unitRef="USD">1565406</ptn:EquityNetProceedsProceeds>
    <ptn:WarrantsToPurchaseShares
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_1685"
      unitRef="Shares">3233277</ptn:WarrantsToPurchaseShares>
    <ptn:DescriptionOfExistingHolderPurchaseOfWarrants
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      id="fid_2078">(i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the Existing Warrants by the Exercising Holder (the &#x201c;Warrant Inducement&#x201d;)</ptn:DescriptionOfExistingHolderPurchaseOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-20_ptn_StockWarrantsMember"
      decimals="INF"
      id="fid_2076"
      unitRef="USDPShares">1.88</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantOfCommonStockSeriesA
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2077"
      unitRef="Shares">4849915</ptn:PurchaseOfWarrantOfCommonStockSeriesA>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_1687"
      unitRef="USD">6078561</us-gaap:ProceedsFromWarrantExercises>
    <ptn:ExercisingHolderReleasedShares
      contextRef="From2024-07-01to2024-09-30_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2080"
      unitRef="Shares">1443277</ptn:ExercisingHolderReleasedShares>
    <ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_2106">&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:39%;"&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 1.5pt solid;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;May 2022 Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;66,666 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 12.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;October 2022 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;90,909 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 6.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;October 2023 Private Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;943,396 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 2.12 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;April 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;October 2023 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;117,925 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 2.65 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;January 2024 Private Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,831,503 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 5.46 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;January 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;91,575 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 6.83 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;June 2024 Series A Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,727,273 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 1.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;June 2024 Series B Warrants&lt;/td&gt;&lt;td style="PADDING-RIGHT: 15px;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,122,642 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;$ 1.88 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="0"
      id="fid_1531"
      unitRef="Shares">66666</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      id="fid_1534"
      unitRef="USDPShares">12.50</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      id="fid_1537">May 11, 2026</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="0"
      id="fid_1533"
      unitRef="Shares">90909</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="INF"
      id="fid_1536"
      unitRef="USDPShares">6.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      id="fid_1539">October 31, 2027</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember"
      decimals="0"
      id="fid_1542"
      unitRef="Shares">943396</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember"
      decimals="INF"
      id="fid_1541"
      unitRef="USDPShares">2.12</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePrivateWarrantsMember"
      id="fid_1540">April 24, 2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="0"
      id="fid_1545"
      unitRef="Shares">117925</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_1544"
      unitRef="USDPShares">2.65</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      id="fid_1543">October 20, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="0"
      id="fid_1548"
      unitRef="Shares">1831503</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="INF"
      id="fid_1547"
      unitRef="USDPShares">5.46</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      id="fid_1546">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_1551"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_1550"
      unitRef="USDPShares">6.83</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      id="fid_1549">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember"
      decimals="0"
      id="fid_1532"
      unitRef="Shares">2727273</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember"
      decimals="INF"
      id="fid_1535"
      unitRef="USDPShares">1.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisAWarrantsMember"
      id="fid_1538">June 24, 2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="0"
      id="fid_1554"
      unitRef="Shares">2122642</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="INF"
      id="fid_1553"
      unitRef="USDPShares">1.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-09-30_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      id="fid_1552">June 24, 2029</ptn:LatestTerminationDate>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2081"
      unitRef="USD">177734</ptn:StockBasedCompensationToStockOptions>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2083"
      unitRef="USD">205317</ptn:StockBasedCompensationToStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_2107">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Term in Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7.92&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding - September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Exercisable at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;927,524&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.81&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.4&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Expected to vest at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,321,578&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.83&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9.1&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1555"
      unitRef="Shares">2263440</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1558"
      unitRef="USDPShares">6.11</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2024-07-01to2024-09-30" id="fid_1566">P8Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1559"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1560"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1561"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1586"
      unitRef="Shares">-14338</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1562"
      unitRef="USDPShares">7.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1588"
      unitRef="Shares">2249102</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1563"
      unitRef="USDPShares">6.12</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-07-01to2024-09-30" id="fid_1567">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1571"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1590"
      unitRef="Shares">927524</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A>
    <ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1564"
      unitRef="USDPShares">10.81</ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2024-09-30" id="fid_1568">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1572"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1591"
      unitRef="Shares">1321578</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice
      contextRef="From2024-07-01to2024-09-30"
      decimals="INF"
      id="fid_1565"
      unitRef="USDPShares">2.83</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2024-09-30" id="fid_1569">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1570"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2084"
      unitRef="Shares">418945</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2085"
      unitRef="Shares">88911</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2086"
      unitRef="Shares">95167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2089"
      unitRef="Shares">60566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2090"
      unitRef="Shares">238838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2092"
      unitRef="Shares">264945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2093"
      unitRef="USD">171289</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2094"
      unitRef="USD">185019</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-07-01to2024-09-30" id="fid_2109">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Outstanding at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_1603"
      unitRef="Shares">1374980</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <ptn:RestrictedStockVestedInPeriod
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1610"
      unitRef="Shares">-232941</ptn:RestrictedStockVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_1616"
      unitRef="Shares">2726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1613"
      unitRef="Shares">1139313</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <ptn:NumberOfOutstandingSharesOfRestrictedStockUnits
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2095"
      unitRef="Shares">279700</ptn:NumberOfOutstandingSharesOfRestrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2096"
      unitRef="Shares">274549</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2023-07-01to2023-09-30"
      decimals="0"
      id="fid_2097"
      unitRef="Shares">59842</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2099"
      unitRef="Shares">22343</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2100"
      unitRef="Shares">40707</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2101"
      unitRef="Shares">152432</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2098"
      unitRef="Shares">184443</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares
      contextRef="From2024-07-01to2024-09-30"
      decimals="0"
      id="fid_2104"
      unitRef="Shares">54691</ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
